MILLENIUM PHARMACEUTICALS, jetzt schägt sie zurück - 500 Beiträge pro Seite (Seite 2)

[Isabartels]

Kann jemand eine Bio Aktie finden, die heute noch schlechter gelaufen ist???????????????

[Boersenkrieger]

@blb

da hast du recht.. ich meide seit einiger zeit alles was mit biotech zu tun hat... ich habe mlnm anfangs im jahr 2000 gekauft und dann verbilligt so daß ich so ziemlich exakt bei derzeit -50% bin. celgene habe ich auch noch seit frühjahr 2000... alles mitgemacht -70% mal und dann +30%, derzeit auch noch etwa 15-20% im plus.

kaufe nur aktien die fundamental günstig sind, aber die beiden biotecs behalte ich noch ne weile und hoffe bei mlnm meinen einstandskurs wieder zu sehen. war mal im frühjahr 2004 bei nur -1,5% dann ging´s wieder bergab. meine aussage gilt eigentlich nicht speziell für mlnm sondern für die gesamte biotec-branche. ist einfach extrem riskant immer mit den einzelnen produkten und schwups gehn 40% in die binsen weil ein produkt nicht richtig funzt. es gibt auch werte mit hohen chancen und weniger risiken, ganz einfach weil sie ein kgv von 10-20 haben und ihre rekordzahlen quartal für quartal brechen mit wachstumsraten von 20-50% ... drum kram ich viel rum, damit ich auf der etwas sicheren seite bin.
wenn ich mlnm nichts mehr zutrauen würde wäre ich draussen. halte nach wie vor viel von dem wert und auch für die zukunft. naja hoffen wir mal bei mlnm auf bessere zeiten

[blb]

@Boersenkrieger: Würde dir raten, aktuell mehr aud Deutschland zu setzen. Medigene, GPC und Morphosys bieten selbst auf jetzigem Niveau noch tolles Kurspotenzial für die nächsten Jahre!

Grüße
blb

[Isabartels]

Könnte es sein, dass wir langsam eine beginnende Bodenbildung sehen?

[Isabartels]

Was ist das denn??????????????????????

26.01. 22:21:30 6,76 EUR 6,88 EUR
Letzte Kursänderung: 22:17:19

[Isabartels]

Spinnen die bei Lang&Schwarz?

Realtime-Kurse
Datum Zeit Bid Ask
26.01. 22:23:47 6,96 EUR 7,08 EUR
Letzte Kursänderung: 22:21:54

[Boersenkrieger]

@blb

da haste nicht ganz unrecht... naja morphosys wollte ich mal bei um die 20 hmmm da geht´s mir gerade ähnlich wie bei Solarworld und Linos... einfach etwas davongelaufen... aber klare sache vergleichsweise zu den amis sind die drei biotecs wirklich recht günstig und es sind vor allem auch top-unternehmen... ist eben nur die frage ob ich mir mal wieder nen biotec antun will

[Isabartels]

Millennium Reports Year End and Fourth Quarter 2004 Financial Results

- Product-Related Revenue Up, Net Loss Narrows -

CAMBRIDGE, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported consolidated financial results for the year and quarter ended December 31, 2004.

"For the second consecutive year, Millennium delivered on its promise to achieve its net loss target by growing product-related revenue and managing expenses," said Marsha Fanucci, chief financial officer and senior vice president. "Importantly, we achieved this target while investing in our marketed products and pipeline. Looking forward to 2005, we believe several key events, including the pending sNDA for VELCADE in second line multiple myeloma, increased penetration of INTEGRILIN into early use ACS and new business collaborations will result in continued revenue growth, the ability to achieve non-GAAP profitability in 2006 and sustainable growth."

2004 Year-End Results

* Net loss on a GAAP basis for 2004 decreased 48 percent to $252.3
million, or $0.83 per share, from $483.7 million, or $1.63 per share,
in 2003. Non-GAAP net loss(1) for 2004 decreased 26 percent to $180.8
million, or $0.59 per share, from $243.3 million or $0.82 per share, in
2003.

* Total revenue in 2004 increased to $448.2 million from $433.7 million
in 2003. Product-related revenue increased 43 percent from 2003.
Partially offsetting the increase in product-related revenue was an
anticipated decrease in strategic alliance revenue.

-- Net product sales of VELCADE® (bortezomib) for Injection in 2004
increased to $143.1 million from $59.6 million in 2003. VELCADE
was launched May 2003.

-- Co-promotion revenue, based upon worldwide sales of INTEGRILIN®
(eptifibatide) Injection, in 2004 increased to $206.3 million from
$184.3 million in 2003 due to higher net reimbursement of shared
expenses and increased U.S. ex-factory sales. U.S. ex-factory
sales, as provided by Schering-Plough Corporation, were $301.3
million in 2004 compared to $283.9 million in 2003.

-- Strategic alliance revenue in 2004 decreased to $98.9 million from
$189.7 million in 2003 as certain research and technology alliances
concluded in 2003.

* Research and development (R&D) expenses in 2004 decreased to $402.6
million from $488.5 million in 2003 as a result of savings from the
Company`s 2003 restructuring effort.

* Selling, general and administrative (SG&A) expenses in 2004 increased
to $196.6 million from $178.8 million as the Company enhanced its
commercial infrastructure to support VELCADE® (bortezomib) for
Injection and INTEGRILIN® (eptifibatide) Injection.

* As of December 31, 2004, the Company had $700.4 million in cash, cash
equivalents and marketable securities and $105.5 million outstanding
principal amount of convertible debt.

2004 Fourth Quarter Results

* Net loss on a GAAP basis for the fourth quarter of 2004 decreased 35
percent to $94.7 million, or $0.31 per share, from $146.4 million, or
$0.49 per share, for the fourth quarter of 2003. The improvement in
the 2004 period was primarily a result of decreased restructuring
charges, increased product-related revenue and reductions in R&D
expenses, offset in part by a decrease in strategic alliance revenue.
Non-GAAP net loss for the fourth quarter of 2004 decreased eight
percent to $84.7 million, or $0.28 per share, from $91.8 million or
$0.30 per share, for the fourth quarter of 2003.

* Total revenue for the fourth quarter of 2004 increased to $100.3
million from $85.4 million in the fourth quarter of 2003. The increase
in total revenue is due primarily to increased product-related revenue,
offset by lower strategic alliance revenue.

-- Net product sales of VELCADE in the fourth quarter of 2004
increased 42 percent to $40.8 million from $28.7 million in the
fourth quarter of 2003.

-- Co-promotion revenue, based upon worldwide sales of INTEGRILIN for
the fourth quarter of 2004 increased to $47.2 million from $32.4
million in the fourth quarter of 2003. U.S. ex-factory sales of
INTEGRILIN for the fourth quarter of 2004, as provided by Schering-
Plough Corporation, were $73.7 million compared to $39.7 million in
2003.

-- Strategic alliance revenue for the fourth quarter 2004 decreased to
$12.4 million from $24.2 million in the fourth quarter of 2003.
This decrease is due primarily to the timing of payments earned
under the Company`s VELCADE collaboration with Ortho Biotech, a
member of the Johnson & Johnson family of companies, and the
conclusion of the research phase of the Company`s alliance with
Bayer Healthcare AG.

* R&D expenses for the fourth quarter of 2004 decreased to $102.9 million
from $111.4 million for the fourth quarter of 2003. This decrease
reflects the financial benefits of the Company`s 2003 restructuring
effort, including reductions in personnel and personnel-related costs.

* SG&A expenses for the fourth quarter increased to $59.1 million from
$56.6 million for the fourth quarter of 2003. This increase is due
primarily to increased expenses in our commercial efforts necessary to
support our marketed products.

2005 Financial Guidance

The Company is reiterating its guidance for 2005, as provided at the JPMorgan 23rd Annual Healthcare conference on January 10, 2005:

* VELCADE U.S. product sales of $185 million to $195 million;

* INTEGRILIN U.S. ex-factory sales of $315 million to $330 million;

* Net loss on a GAAP basis better than $155 million and a non-GAAP net
loss better than $100 million with the difference between the GAAP and
non-GAAP net loss attributable primarily to amortization and
restructuring;(2) and

* Cash, cash equivalents, and marketable securities at the end of 2005
greater than $500 million.

Fourth Quarter Highlights

"VELCADE continues to show significant long-term growth potential with more than 250,000 patients falling within indications and lines of therapy where we have seen clinical responses: across the multiple myeloma treatment paradigm, second line mantle cell lymphoma, second line follicular and marginal zone lymphoma, second line bronchioloalveolar carcinoma (BAC), and second line non-small cell lung cancer," said Mark Levin, chief executive officer. "We will realize the product`s potential over time as we gain the necessary regulatory approvals and support compendia listing processes. INTEGRILIN also shows significant opportunity for growth within its labeled indication in the early use acute coronary syndrome treatment setting where 700,000 patients in the U.S. who, according to American College of Cardiology and American Heart Association (ACC/AHA) guidelines, would benefit from the use of a GP IIb-IIIa inhibitor prior to entering the catheterization lab but currently go untreated."

VELCADE® (bortezomib) for Injection Fourth Quarter Highlights

In December, the U.S. Food and Drug Administration (FDA) accepted for review the Company`s supplemental New Drug Application (sNDA) and granted Priority Review designation for VELCADE for the treatment of patients with multiple myeloma who have received at least one prior therapy, commonly referred to as second line. The submission was based on data from the phase III APEX study that compared VELCADE to a traditional multiple myeloma therapy, high-dose dexamethasone. In the trial, VELCADE demonstrated a statistically significant survival benefit. A patient population of approximately 11,000 in the U.S. could potentially benefit from a new second line treatment option such as VELCADE.

Also in December, Millennium and Johnson & Johnson Pharmaceutical Research & Development L.L.C (J&JPRD) supported the presentation of a number of front line studies of VELCADE in combination with chemotherapy at the 2004 46th Annual Meeting of the American Society of Hematology (ASH) in which overall response rates ranged from 73 percent to 95 percent with complete and near- complete response rates ranging from 17 percent to 29 percent. Adverse events were similar to those observed in other clinical trials with VELCADE and included gastrointestinal events, neuropathy, fatigue, and hematologic toxicities. One of these front line studies was the basis for the recently initiated phase III VISTA trial, a large, international registration-enabling clinical trial of multiple myeloma in the front line treatment setting.

Millennium and J&JPRD also supported three separate ongoing phase II clinical trials for non-Hodgkin`s lymphoma presented at ASH, in which the overall response rates with single-agent VELCADE in follicular lymphoma ranged from 18 percent to 60 percent, and in mantle cell lymphoma, from 39 percent to 50 percent. Adverse events observed were thrombocytopenia, fatigue, anemia and peripheral neuropathy.

In November, VELCADE received fast track status from the FDA for VELCADE in second line mantle cell lymphoma and was included in the National Comprehensive Cancer Network guidelines for the treatment of second line mantle cell lymphoma.

Millennium and J&JPRD are broadly investigating the use of VELCADE in several types of hematological and solid tumor cancers. To date, VELCADE has been approved and launched in more than 30 countries outside of the U.S. by Ortho Biotech and Janssen-Cilag who are responsible for commercialization of the product in Europe and the rest of the world.

INTEGRILIN® (eptifibatide) Injection Fourth Quarter Highlights

In November at the 2004 American Heart Association (AHA) meeting, Millennium presented data from the CLEAR Platelets (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) trial in which the addition of INTEGRILIN to a commonly used antiplatelet regimen provided superior platelet inhibition and prevention of heart muscle damage, also known as myocardial necrosis, associated with elective coronary stenting in the low- to-moderate risk study patients. In the study, patients receiving the combination of INTEGRILIN and clopidogrel had lower platelet reactivity over 24 hours compared to patients receiving clopidogrel alone (p<0.001). The combined INTEGRILIN and clopidogrel group also had a lower release of cardiac markers (p<0.05). No significant differences in bleeding were observed among groups.

At AHA, Millennium also presented results from the PROTECT trial, designed to compare INTEGRILIN to the direct thrombin inhibitor bivalirudin in high- risk patients undergoing percutaneous coronary intervention (PCI) using physiologic and clinical endpoints. On the physiologic primary endpoint of coronary flow reserve, a measure of epicardial coronary artery flow, the primary endpoint favored bivalirudin but was not statistically significant when imputed as pre-specified for abrupt closure, no reflow, and thrombotic bail-out during PCI. Only 18 out of 857 patients had a TIMI major or minor bleeding event and there were no fatal bleeds. INTEGRILIN showed a statistically significant (p=0.048, adjusted for baseline as pre-specified) improvement in myocardial perfusion (a measure of blood flow to the heart muscle) compared to bivalirudin. This improvement with INTEGRILIN was shown to be highly correlated to improved clinical outcomes including reductions in death, myocardial infarction and ischemia.

In November the Journal of the American Medical Association (JAMA) published results from the CRUSADE Quality Improvement Initiative, including the finding that an early invasive management strategy, as recommended in the ACC/AHA guidelines, is not utilized in the majority of high-risk patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS). According to the authors, an early invasive strategy only occurs in 50 percent of high-risk patients with non-ST-segment elevation myocardial infarctions (NSTEMI), and a two-to-three fold increase in death and myocardial infarction was observed in those patients who did not receive the recommended early invasive treatment as recommended in the ACC/AHA guidelines, which include the use of a GPIIb-IIIa inhibitor.

Research & Development Fourth Quarter Highlights

At ASH, Millennium presented data on MLN518, a small molecule receptor tyrosine kinase inhibitor, from a phase I/II trial of 25 evaluable patients with relapsed and/or refractory acute myelogenous leukemia (AML) with FLT3 mutation. Data presented showed single-agent anti-leukemic activity in seven patients including a patient with a complete remission with decreased platelets and two patients who achieved stable disease for more than 50 days. Toxicities were mild-to-moderate and included weakness, fatigue, QTc prolongation, nausea and vomiting. Based on these encouraging results, Millennium intends to continue development of the molecule and has plans to initiate a Company-sponsored phase I combination study in 2005.

In October, researchers from Millennium and Brigham and Women`s Hospital presented results from seven studies in rheumatoid arthritis (RA) that could pave the way for the development of more effective, less toxic therapies that are custom-designed for each patient based on his or her genetic makeup. The research, which was shared during the American College of Rheumatology meeting in San Antonio, Texas, offers new insight into genetic clues to better understand RA risk, underlying disease mechanisms, and response to treatment. The study findings, based on data from Millennium`s substantial patient registry, could one day help medical professionals predict who will develop RA, how severe their disease may become, which patients will respond best to which treatments, and how aggressively to treat them -- based on each patient`s unique genetic makeup.

In December, the Company announced the discovery of a panel of protein biomarkers that could play a role in the early detection, prognosis and monitoring of RA. The research, published in December`s Arthritis & Rheumatism in conjunction with an accompanying editorial, represents an important potential advance in the ability of clinicians to predict disease severity in patients with RA. The study was conducted as part of a collaborative research alliance between Millennium and Roche Diagnostics. The researchers have selected 33 of these potential biomarkers for further validation in the serum of patients with RA as well as healthy volunteers.

[Isabartels]

Vorbörslich mit 9,50$ jedenfalls leicht im Plus.

[Isabartels]

Waren die zahlen jetzt denn so schlecht???????????????

[Isabartels]

Wurde da die 9$Marke getestet???

[grafbibi]

http://members.fortunecity.com/findikli1/index.htm

[Isabartels]

Hä????????????

[Snake3000]

#511

Eines der kuriosesten Postings überhaupt!

[Isabartels]

#511
Alles okay mit Dir????????

[jm78]

[e-mail]
Investorenkontakt von Millennium

[jm78]

27.01.2005 19:27:
MILLENNIUM Pharma - Abverkauf läuft

MILLENNIUM Pharma (Nachrichten)(MLNM) : 9,13 $ (-3,38%)

Tageschart (log) seit April 2004 (1 Kerze = 1 Tag)

Diagnose: MILLENNIUM Pharma gehört mittelfristig zu den schwächsten Aktien im Nasdaq 100 und fällt heute auf ein neues Jahrestief ab. Der Kurs war während der Erholung seit August mehrfach im Bereich des bei aktuell 12,70$ liegenden EMA 200 gescheitert. Mit dem Rückfall unter die Unterstützung bei 11,47$ löste die Aktie ein neues Verkaufssignal aus und wird seit Anfang Januar verkauft.

Prognose: Der deutliche Rückfall unter die Unterstützung bei 9,69$ ist auch mittelfristig negativ zu werten. Es drohen damit weiter fallende Notierungen bis in den Unterstützungsbereich um 6,42$ auf mittelfristige Sicht.
Was ist da los frage ich mich ?
Vor ein paar Jahren gab es nur positive Prognosen.
Ist dieses Unternehmen nicht gut genug?
Sind die Analysten doof oder sind wir Anleger zu ungeduldig? Oder wird man nur mit Halbwahrheiten versorgt?

[Isabartels]

Als Mlnm Aktionär muss man zur Zeit schon sehr leidensfähig sein Aber es werde auch wieder bessere tage kommen. Die Aktie müsste völlig überverkauft sein!

[Isabartels]

Die zahlen heute und auch die Aussichten waren doch nicht schlecht oder??

[blb]

Wenn die 6$ kommen, lef ich nochmal ne Schippe drauf!
Zahlen waren nicht überragend, aber trotzdem solide!

Grüße
blb

PS: 700 Millionen $ Cash zum 31.12.!!!

[Isabartels]

An die 6$ glaube ich nicht. Ähnliche Aussagen gab es auch zu Schwarz Pharma und Morphosys. Und wir sehen ja wo die stehen!

[Boersenkrieger]

@jm78

die anleger sind zu geduldig... normal sollte man den wert rausschemissen... ich sehe mlnm als altsünde von mi von der ich mich nicht trennen kann.. wenn ich mir da meine 2004-investments anschaue... die gingen so ziemlich alle gen norden nur mlnm nicht... erinnert mich irgendwie an den kinderspruch "alle kinder schauen zum brennenden haus, nur klaus, der schaut raus" ...rechne auch mit ner gegenbewegung aber vielleicht kommt die ja erst bei 6,5 auf 9

[schakal23]

so ich bin wider dabei zu 7,20Euro von mir aus kan noch bis 6,50 runter gehen aber dann bis 9Euro minimum bei mlnm ist das üblich

und die zahlen sind auch nicht schlecht. aber wenn ich sehe wieviel die geld verbrenen oh gott die hätten mal zwei milliarden $ casch

[blb]

@Boersenkrieger: Geb dir vollkommen Recht, man müsste das Teil aktuell verkaufen. Ich denk aber nicht dran. Zum einen bin ich ziemlich hartnäckig, was mir bei Biotechaktien aber meist sehr geholfen hat, zum anderen ist MLNM wie meine PDLI und VRTX damals eine meiner Anfangssünden beim Aktienkauf gewesen. Hatte ziemlich in der Boomphase angefangen. Durch Nachkäufe hab ich aktuell aber einen schönen Kaufpreis, zwischendurch hab ich Teile auch schon mit schönem Gewinn verkauft. Da ich das Teil mittlerweile wohl so 4 Jahre halte (müsste nachschauen), seh ich auch nicht ein, warum ich "kurz" vor Erreichen neuer fundamentaler Rekorde fast auf Tiefststand verkaufen sollte! Ich seh schon die anderen hier mit dem Kopf schütteln, aber so bin ich nunmal. Das Ganze mit den Wucherpreisen 2000 wird mir auch nie wieder passieren, dafür hab ich in den letzten Jahren zuviel gelernt.

Trotz aller schlechter Vorzeichen, sollte man die Kirche im Dorf lassen. MLNM hat genug Cash, die Gewinnzone zu erreichen. Die Umsätze wachsen, der Gewinn wird reduziert.

Also, wer keinen langen Atem hat, steigt aus (und sollte meiner Meinung nach auch die Finger von Biotechaktien lassen)! Alle anderen warten eine MITTELFRISTIGE Bodenbildung ab, die sicher kommen wird und freuen sich in 2 Jahren über ne schöne Performance!

Grüße
blb

PS: Schaut euch nur mal den Chart von SEPR an! Ich hab sowohl den Absturz, als auch den Anstieg mitgemacht! Am Ende stand ein Plus von 150%! Gibts in dieser Form wohl nur bei Biotechs, deswegen mag ich die Branche auch so, slebst wenn ich mal richtig auf die Schnauze fallen sollte, was bei VRTX sicher passieren könnte...

[schakal23]

Trotz aller schlechter Vorzeichen, sollte man die Kirche im Dorf lassen. MLNM hat genug Cash, die Gewinnzone zu erreichen. Die Umsätze wachsen, der Gewinn wird reduziert.




du meinst den verlust

[Boersenkrieger]

@blb

hartnäckigkeit kann sic schon auszahlen wie bei meiner celegne da gings von -70% auf +30% die halte ich seit frühjahr 2000 und mit millennium hab ich auch noch in 2000 angefangen zu kaufen hatte dann mal bei 9 euro stark nachgekauft... 6.500 € investiert in das teil, im moment -51% ...sehe das auch so wie du... cash ist genug da, allerding sschien mir manchmal daß das management etwas merkwürdige entscheidungen trifft... einmal ahtten sie z.b. ein aussichtreiches prodkt einfach verkauft... puuh wie hieß das nochmal ? war glaub in 2001 oder 2002 keine ahnung mehr ...jtzt zu verkaufen wäre dumm, finde ich. und wenn´s schon auf 6,5 gehen sollte dann ist vielleicht genug schwung da für einen nachhaltigen anstieg. das wir zumindest mal wieder in den 18 $ bereich kommen längerfristig.

[Isabartels]

Also ich verkaufe auch nicht. habe blöderweise vor einigen tagen entnervt meine Imcl bei 29€ geschmissen; schlechte Analystenkommentare, kursverfall etc. Hätte ich doch noch einen tag durchgehalten. ging inerhalb von 3 tagen wieder auf knapp 32€!!!

[blb]

@schakal23: Ja vielen Dank für den Hinweis, ich hatte mich verschrieben!

Grüße
blb

[Isabartels]

sieht gerade so aus, als könnten heute ein paar Shorties gegrillt werden!

[Isabartels]

na also! Grillfest!!!

[Isabartels]

9,61$

[Isabartels]

Und raus zu 9,3€.hoffe später wieder billiger rein. glaube nicht, dass dieser Anstieg Bestand hat!

[schakal23]

#531

Und raus zu 9,3€.

du meinst zu 9.30$

oder irre ich mich. seid ihr alle schon hier einbißchen mitgenommen von den letzten runter rauschen die aktie

[Isabartels]

Sorry, meinte 7,€!!!!!!!!!!
gruss
Isa

[Isabartels]

Oh Mann, nochmal langsam 7,30 €!!!

[Isabartels]

28.01.2005 16:13:04 (SMITH BARNEY CITIGROUP)

Millennium Pharma. neues Kursziel


Die Analysten von Smith Barney Citigroup stufen die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) unverändert mit "hold" ein und senken das Kursziel von 13 auf 11 USD. Der Verlust je Aktie des vierten Quartals habe höher als angenommen gelegen. Die Guidance, die das Unternehmen bereits herausgegeben habe, sei ebenfalls aufgrund des möglicherweise niedrigen Velcade-Umsatzes enttäuschend gewesen. Aufgrund der nur moderaten Wachstumsperspektiven von Velcade sei das Ziel des Unternehmens, in 2006 die pro forma Profitabilität zu erreichen, in Frage zu stellen. Die Analysten würden nun erst in 2007 mit dem Erreichen der Gewinnzone rechnen. Angesichts der uninspirierenden Pipeline und den mangelnden Umsatzaussichten bedürfe es einer erheblichen Ausgabereduzierung, um die Profitabilität zu erreichen. Bis die Pipeline einen größeren Beitrag zum Wachstum liefere, bleibe man gegenüber dem Titel vorsichtig gestimmt. Vor diesem Hintergrund bleiben die Analysten von Smith Barney Citigroup bei ihrer Empfehlung die Aktie von Millennium Pharmaceuticals zu halten.
Quelle: AKTIENCHECK.DE

[Isabartels]

Bin mit der Kohle in PFE eingestiegen. Da kann ich besser schlafen und hole meine Verluste hoffentlich wieder rein!

[Isabartels]

Und der Anstieg von heute wird sofort wieder verkauft. Kein gutes zeichen, wo der Kurs doch so ausgebombt ist.

[Isabartels]

P.S
Nachdem das die ganzen letzten Tage so ging hatte ich mir geschworen den nächsten Anstieg zum Ausstieg zu nutzen!!

[jm78]

Hallo Börsenkrieger,
mir geht es ähnlich wie dir. ich habe wohl alle fehler gemacht die man so machen kann. Mal ehrlich, ich habe zu Anfang satt gewonnen und war mit dem was folgte total überfordert. Ich habe immer geglaubt schlimmer kann es nicht mehr kommen.Tja es kam immer Schlimmer und nun stehe ich da und traue mich ehrlich gesagt nicht mehr auch nur eine Aktie egal welche zu kaufen. In den guten Zeiten ging das Wort von der Aktienkultur um die von Amerika herüberschwappt. Mitlerweile glaube ich wieder an Sparbriefe und ähnliches und fühle mich (eigene doofheit)ausgenommen wie eine Weihnachtsgans.

[schakal23]

ich denke es werd sich um die 9$ ein boden bilden

[Boersenkrieger]

@jm78

naja ich habe einiges verzockt von 2000 (als blutiger anfänger) bis 2003 ...ich hab mir dann auch gedacht, entweder rückzug oder neuer angriff, also hab ich im sommer 2004 kurz nach dem augusttief bis dezember 11 neue werte gekauft die im schnitt recht gut gelaufen sind bis heute... jetzt hab ich mal 10%-15% verlust wieder abgebaut und mir geschworen alle verluste wieder reinzuholen.. aber ich mache nicht mehr den fehler das zu kaufen was gerade "in" ist sondern vergleiche eher kleinere einzelwerte miteinander und kaufe nach kgv´s, peg usw. ich streue breit weil ich nicht so extrem tief analysiere. aber es gilt eben was niedrig bewertet ist kann nicht tief fallen und dem ist auch so. das merke ich an schlechten tagen, da drückt´s meine werte dann nur leicht runter oder sie steigen trotzdem.
Orascom telecom war so ein beispiel kurs bei 12,60 gekauft nun schon 21,80... hatten ein kgv von etwa 10 und wachstumraten von 50-100% ...so ein wert kann einfach nicht fallen wenn sich fundamental nicht extrem viel ändert... er steigt oder bleibt gleich.. es sei denn es wird gefälscht wie sau aber davor kann man sich ja mit streuen schützen... eckert&ziegler, perficient, rofin sinar, headwaters... mal ehrlich da fühl ich mich einfach sicher.. man muss halt im netz rumstöbern.

linos hatte ich leider verpaßt die hatten nen super rebound geschafft und damit ein kgv von 6 ...danach mal 80% gestiegen, schade

man findet immer wieder gute werte aber man muss sie selber suchen..

und was man sich auch immer vor augen halten sollte:
der absturz nach 2000 ist einmalig in der geschichte was die high-tecs angeht, dagegen war die weltwirtschaftskrise 1929 ein glatter witz... sowas werden wir so schnell nicht wieder sehen.

aber man muss auf jeden fall interesse am schnüffeln haben. bunte bildchen und schöne kursziele vom aktionär bringen leider nichts... wobei immer auch sehr gute werte dabei sind/waren.

[schakal23]

@Boersenkrieger

also du meinst es lohnt sich nicht bei mlnm auf diesen niveu zu kaufen?

[Isabartels]

Immer das gleiche.Zu Anfang steigt sie an und man denkt schon die Wende ist da. anschliessend geht es dann sofort runter. Bin froh dass ich raus bin. Wenn die an einem solchen Tag wo fast alles steigt fällt, wann soll die denn steigen??????????
Kann mit meinen PFE wesentlich besser schlafen und muss nicht dauernd auf en Schirm starren!! bei 6€ steig ich wieder ein. So wie es aussieht werden wir die wohl auch sehen!!

[Isabartels]

Also ich glaube nicht, dass die in nächster Zeit gross steigen wird.
Die Phantasie ist irgendwie raus. So wie es aussieht wird velcade auch bei weiteren Zulassungen kein Blockbuster. Von der Pipeline her ist in naher Zukunft auch nichts zu erwarten. Insofern ist es schon fraglich, ob Mlnm 2006 schwarze Zahlen schreibt. ich glaube diese faktoren lasten derzeit auf dem kurs. Wenn ich noch investiert wäre, würde ich eher in Medx umschichten. Da ist deutlich mehr Phantasie drin und die Pipeline auch umfangreicher!!

[Boersenkrieger]

@schakal23

aus meiner sicht absolut nicht... die bewertung ist immer noch hoch und Velcade wird eben nicht so der hit...
wer bei biotecs einsteigt weil manche artikel was von möglichen blockbustern erzählen kann eigentlich auch gleich lotto spielen ...hab ich mir jedenfalls hinter die ohren geschrieben... der markt gibt genug günstige papiere her wo keine fantasie im kurs ist... MLNM wird noch weiter fallen

[blb]

@Isabartels: Naja, du gibst wohl die aktuelle Meinung der Analysten wider.. Das meiste dürfte aber jetzt schon mittlerweile im Kurs drin sein, wir kommen von 20$...

Und Velcade kann SEHR WOHL noch für andere Indikationen zugelassen werden! Ich würd mich von der schlechten Stimmung nicht anstecken lassen. Antizyklisches Handeln war noch nie verkehrt! Neukäufe bieten sich aktuell aber noch nicht an, entweder man hält sie und hat Sitzfleisch oder schmeißt sie raus und kauft sich nen anderen Wert.

MLNM ist zwar ne größere Position in meinem Depot, durch breite Streuung auf verschiedene Bios lässt sich das Risiko aber deutlich absenken!

Grüße an alle!
blb

[schakal23]

@Boersen

ich werde mein sl bei 6,30 machen fals die letzter boden nicht hält bei 6.45 dann bin ich raus sonst denke das wir bald ein boden bildung machen und dann richtung 9€ marschieren werden

[Isabartels]

blb
Na ja, es heisst immer, dass alles schon im Kurs drin ist und wenn es dann soweit ist, geht es doch noch weiter runter. Ich denke von der pipeline her ist vor 2008 nicht mit einem neuen Medikament zu rechnen. Und ob Velcade bis dahin die Profitablität sichert ist bei der Cash Burn Rate doch sehr zweifelhaft. Irgendwann kommt malweder ene Kapialerhöhung!
Gruss
Isa

[blb]

KE hlálte ich bei 700 Millionen $ Cash nicht für notwendig, Ende 2005 sollen es 500 Millionen sein!

Für alle, die shorten können (geht z.B. bei Etrade) bietet sich auch ein Straddle an. Ihr sichert euere Longpoisition einfach zusätzlich mit einem Short ab.

Grüße
blb

[Isabartels]

blb
Die 500Mio. Cash haben die doch in 2 jahren verballert!!!

[Snake3000]

Isa, Isa

Du bist wie die Fahne im Wind! Von einen auf den anderen Tag wird Millennium vom Pharmagiganten zur Bio-Klitsche.

Snake3000

[Isabartels]

Snake
Hast ja nicht ganz unrecht. Bin eben einfach nicht mehr so überzeugt. und dieser Kursverfall über Wochen; welcher andere Wert zeigt so eine Entwicklung. Keinerlei Gegenreaktion; wenn doch, wird sie sofort verkauft. Immerhin habe ich durch meinen Verkauf bei 7,3€ schon eine Menge Geld eingespart.
Und der kursverlauf war schon viel früher abzusehen. Warum soll man das aussitzen wenn man später viel billiger wieder rein kann.

[blb]

So ein Schmarrn, Isa!!! Die Guidance, Gewinne in 2006 steht ja noch. Und selbst wenn sie erst 2007 kommen, reicht die Kohle bis dahin!

Wie gesagt muss man es nicht aussitzen, es gibt bei weitem bessere Bios, aber einen Ritt auf der Rasierklinge haben wir hier auch nicht. MLNM ist kein 1-Produkt-Unternehmen!

Wünsche dir und allen anderen natürlich weiterhin viel Erfolg und möchte hier nochmal auf die deutschen Biotechs hinweisen. Wer ruhig schlafen will (was ich im übrigen auch tue), kauft sich noch ne MOR, MDG oder GPC...

Ich hab alle drei!

Grüße
blb

[Isabartels]

wird wahrscheinlich wieder ein super tag für Mlnm:

Realtime-Kurse
Datum Zeit Bid Ask
04.02. 15:23:09 6,75 EUR 6,85 EUR
Letzte Kursänderung: 15:17:58

[Isabartels]

Die trudelt immer weiter nach Süden. Wo mag die wohl hängen bleiben???

[jm78]

Hallo Isabartels, diese Frage stelle ich mir auch. Ich kann ehrlich gesagt den Niedergang der letzten Jahre nicht nachvollziehen. Schwarze Zahlen in 06 ??? Warum standen wir dann vor 04 bei 19$ und heute bei 9$? Ich habe ehrlich gesagt das Vertrauen in die MILM verloren. Ich kann die zusammenhänge nicht verstehen. Warum wird ausgerechnet diese Aktie so heruntergeprügelt? Tut mir leid aber ich habe leider auch mehr fragen als Antworten.
Aber Kopf hoch, irgendwann geht es wieder Berg auf.

Gruß JM78

[Boersenkrieger]

beim tief anfangs 2003 ...6,43 $ und das muß sich dann als boden erweisen sonst geht´s richtung 5 4 3 2 1

[Boersenkrieger]

das problem bei mlnm ist... sie sind einfach nicht billig... erst bei 1 $

[Isabartels]

Der kurs ist jetzt shon sehr reizvoll. muss mich echt beherschen. Das wird sonst bestimmt wieder ein Reinfall, weil der kurs bestimmt noch weiter runter geht. Nicht die kleinste Erholung erkennbar. Bei dem Börsenwert wird die ja langsam zum Übernahmekandidaten; ob so etwas dahinter steht???

[Isabartels]

welche Bio Aktie die noch keinen Gewinn macht ist denn billig??????????

[Isabartels]

Ich glaube so langsam ist die Chance höher als das Risiko. Habe mal bei 6,81€ gerade nachgekauft!!

[Snake3000]

Warum sollte Millennium viel zu teuer sein? Schaut euch die anderen US-Biotechs an.

PDLI 1,8
HGSI 1,5
MEDI 5,6

Die ersten beiden sind Fundamental keineswegs auf dem Niveau von MLNM (2,6 Mrd Mkt). Der Letztere spielt rein bilanziell in der gleichen Liga, hat aber im operativen Geschäft mehr zu bieten. Somit stellt sich für mich die Frage, ob wir den Boden derzeit gesehen haben. Weitere Unsicherheit liefern dann lediglich die externen Faktoren, wie der Wechselkurs, Euro-Dollar zurück auf 1,36, und die übermässig positive Marktbewegung der letzten Zeit (Dow-Jones 10700).

Isa viel Glück. Hätte nie gedacht, dass Medarex jemals (rein kurzbezogen) höher steht als Millennium. So kann´s gehen!

Schön Gruß

Snake3000

[blb]

Wenn man Kennzahlen wie z.B. das KUV anlegt, das bei Bios um die 8 im Schnitt beträgt, ist MLNM aktuell sicher nicht zu teuer. Meine Meinung ist, dass die Unsicherheit einfach den Kurs belastet. Warum war die Aktie bei 19$? Ganz einfach, man hatte sich von Velcade mehr versprochen und fallende Integrilin-Umsätze waren da auch noch kein Thema.

Jetzt einzusteigen halte ich wie schon öfter geschrieben für falsch. Das ist der Griff ins fallende Messer. Charttechnisch ist nach unten viel Platz!

Meine PDLI machen zur Zeit auch nciht grad Freude, heute minus 8%, wegen der Übernahme von EPS...

Naja, es kommen auch wieder andere Zeiten!
Solange keine Bodenbildung zumindest im Ansatz zu erkennen ist (wie z.B. der Doppelboden um die 10$ letztes Jahre), sollte man sich zurückhalten. Ich fürchte sogar, dass die Zahlen dieses Jahr vielleicht nochmal enttäuschen könnten!

MLNM hat sicherlich erstmal Vertrauen verspielt und ist dazu schon wieder mit der schlechteste Wert im Nasdaq100. Bei um die 6$ wär sie allerdings gerademal 2 Milliarden$ wert (hoff das stimmt), mit einem Cash Ende 2005 von 500 Millionen $ und über 500 Millionen $ Umsatz. Das ist für einen Biowert billig und nicht teuer!

Grüße an alle
blb

[Isabartels]

Snake

hielt ich auch immer für unmöglich, dass eine Medx mal höher steht. An 6$ kann ich nicht glauben, ist für mich unvorstellbar. Aber immerhin werden wir dann bald richtig günstige Kaufkurse bekommen. demnächst kommt doch wahrscheinlich eine erweiterte zulassung für velcade. Vielleicht stoppt das dann den aktuellen trend!!

gruss
Isa

[Isabartels]

Was noch auffällt, dass die anderen Bios wie Medx, die auch im Minus lagen, sich gegen Ende wieder erholt haben. mlnm jedoch hat auf Tagetief geschlossen wenn ich das richtig sehe!

[Boersenkrieger]

@blb
ich kann mich noch an zeiten erinnern da hatte Mlnm cash von 1,5 Mrd $ ...wenn das so weitergeht sind sie ende 2007 PLEITE... sie haben es nicht geschafft trotz cash cash cash eine bessere marktstellung zu erarbeiten. das erste hoffnungsvolle medikament wurde 2001 verkauft, dann die wenig sinn machende und viel zu teure COR-übernahme, Velcade bringt zu wenig... der nächste wirkstoff läßt auf sich warten... bislang muß ich sagen daß das unternehmen versagt hat. trotz bester voraussetzungen (patente, cash, plattformen). ...und nu noch 500 Mio übrig... MLNM hat nun schon 5 jahre enttäuscht und redet immer vom break even. ich vermute fast, daß die ihn nie erleben werden

[Snake3000]

@boersenkrieger

Nun mal langsam du alter Pessimist!

Von Anfang an wurde der Zielkorridor für den Break-Even auf das Jahr 2006 gelegt. Somit hat das Management noch zwei Geschäftsjahre, um die strategische Planung umzusetzen.
Nach deinen Grundsätzen müssten sämtliche Biotechs schon chapter 11 angemeldet haben.
Welcher andere Biotech-Wert besitzt derartige Geldreserven? Hierbei sind natürlich die absoluten Blue-Chips (Amgen-Biogen) ausgenommen. Bitte lass die Kirche im Dorf!

Gruß Snake3000

[Boersenkrieger]

@Snake3000
was soll den umsatz bringen ?
richtig, sie haben viel cash, aber vegleichsweise zu 2000-2001 dann doch einiges weniger und raus kam nicht besonders viel

ohne historie:
mlnm hat viel geld und viele patente und sie forschen an aussichtsreichen wirkstoffen. die bewertung ist vergleichsweise ok, wenn auch nicht billig

kann man immer so oder so sehen, der kurs macht mich eben pessimistisch und hoffentlich andere auch dann kann´s ja wieder hochgehen. ich rechne mal bis 6,4-6,5 runter (charttechnisch) und dann ist vielleicht wieder genug schwung da um wieder in den zweistelligen bereich zu laufen. bzw ich befürchte es... und wenn der widerstand dann nicht hält ...das einzige was einen downmove verhindern könnte wäre eine positive nachricht über was auch immer

[Isabartels]

das ist echt nicht mehr normal!!!

Berliner Freiverkehr 900625 1000 IND +6,710 +6,640

[7clever]

ja, heute wird`s spannend

seven

[Isabartels]

Ich finde diesen Kursverlauf unerklärlich. man meint, da müsste bald eine schlechte meldung kommen. keine Bio Aktie rast dermassen ungebremst gen Süden!!

[Isabartels]

Unfassbar!!!!!!!!!!!!!!

RLT 6,63 n.v. 16:51:06 Lang & Schwarz 16:51:06 n.v. 6,54 RLT

[Isabartels]

na ja, eine gewissheit gibt es immerhin. bei Null stoppt sie garantiert!!!!!

[7clever]

ist schwer auszumachen bei der Dynamik die MLNM an den Tag legt-beobachte erst seit $9

seven

[7clever]

ich glaube die stoppt auch bei NULL nicht- die rauscht als erste Biotechwaffe durch die Nasi

seven

[7clever]

sie entfernt sich deutlich von der Ideallinie...



seven

[Isabartels]

http://c.i4o.de/h_kl.html?PERIOD=4&ID_NOTATION=274079

[Isabartels]

na, sieht doch super aus. Vielleicht knacken wir ja heute schon die 8 $

[7clever]

was nur die $8 wenn solch dicke Vögel abstürtzen dann ...

seven

[7clever]

man könnte ja schonmal was weiches unterlegen, dann kann man sie vielleicht nochmal aufpeppeln

seven

[Isabartels]

dann?????

[Isabartels]

haben die Insolvenz angemeldet und ich habe es nicht mitbekommen??

[7clever]

MLNM




s
e
v
e
n

[Isabartels]

Ist echt die Frage, wann man es riskieren kann. Die scheint ja wirklich im freien Fall!!!

[7clever]

ja, $8.20 war mein Kaufziel?!
mich verunsichert nur, dass sie bei guter sowie schlechter Nasdaq fällt...

seven

[7clever]

ich fass jetzt rein, egal was kommt...
Man hat ja auch Verkaufziele- die hoffentlich etwas darüber liegen

seven

[7clever]

so erledigt, jetzt muss ich stark sein- und mach mir mal einen Kaffe

seven

[Isabartels]

Dann mach Dir aber einen starken Kaffee!!

[7clever]

ja, schluck

gibt immernoch einen ganz schönen sog nach unten.
Ich dachte mein Stützkauf würde mehr gewürdigt werden

seven

[7clever]

$8.15

[7clever]

gibt`s gute news? $8.10

[Isabartels]

8,08$

[7clever]

schade das war`s schon wieder für mich

War ne schöne unterhaltung zu meinem Kaffe- hatte ja keine Kuchen aber MLNM

auf ein nächstes mal

seven

[Isabartels]

Irgend was ist da faul. Der Kursverlauf stinkt!!!!

[Isabartels]

schon wieder raus??? Dann hättes Du Dir für den verlust lieber ein paar Kuchen kaufen sollen!

[7clever]

hab keine Lust, den Spinnern mehr in den Rachen zu schleudern

Die treiben das Spielchen noch eine Zeitlang. Die 7 ist wohl beschlossene Sache.

Das waren jetzt mal schnelle $500 Verlust
Das reicht für ne ganz schöne Torte mit Sahne
Oder 60 MLNM verbrannt...

seven

[7clever]

man kann genau sehen wo ich rausgeflogen bin

Isabartels jetzt bist du dran sie steigt



seven

[Isabartels]

Ich warte noch. Habe keine Lust mir die Finger zu verbrennen!!

[blb]

Leute, was macht ihr??!! Ihr werdet noch in Ruhe einsteigen können, also schaut euch die Sache weiter erstmal cool an...

Grüße
blb

[Isabartels]

seven,
da hättest Du deine 500$ Verlust sparen können wenn Du noch gewartet hättest!!

Blb
Klar wird noch gewartet!

[schakal23]

scheise ich bin doch etwas zu frühe eingestiegen

aber ich bin von mlnm uberzeugt das wegen bleibe ich erstmal drinn

ich habe zeit ich bin noch jung

und ich kann noch verbilligen

[jm78]

Es gibt einfach keine Nachrichten durch die der Verfall gerechtfertigt wäre. Erst verkaufen die Insieder und dann kommen die Nachrichten und die Erklärungen der Analystenarschlöcher. Immer die gleiche KACKE.

[7clever]

ich hätte wohl lieber mein Geld in Research gesteckt
Kann auch nicht`s finden screene schon seit letzter Woche...

seven

[amorphis]

wer etwas weitsicht hat...ein paar monate zeit hat....und sich von der allgemein schlechten stimmung um biotechs nicht einlullen lässt...der steigt JETZT ein...und streicht sich spätestens zum ende des jahres saubere 100% ein...

wer jeden tag auf die kurse guckt ist selber schuld!ähnliche chancen bieten sich derzeit bei pdli und medx!auf pdli lastet derzeit noch die übernahme...welche ich aber ziemlich positiv sehe!hat zwar einiges an cash gekostet...dem gegenüber steht aber ein dicker beitrag am umsatz!ach ja...imcl sollte man ebenso nicht ausser acht lassen!

[blb]

@amorphis: Geb dir Recht, die Bios sind allgemein schwach zur Zeit. Überlege auch bei PDLI nachzulegen, die Anleger haben hier noch überhaupt nicht gemerkt, was der EPS-Deal für die Firma bedeutet. Im Gegensatz zu MLNM kann man da aber auch charttechnische Unterstützungen ausmachen, weswegen ich von einem Kauf bei MLNM noch abrate. SEHR SPEKULATIV könnte man es bei 8$ versuche, allerdings nur auf Sicht von einigen Tagen und mit Ziel einer technischen Reaktion. Ob da mehr draus wird, wag ich aktuell zu bezweifeln.

MLNM ist trotz schwachem Umfeld ein Underperformer zur Zeit und war das auch schon 2004!

Grüße an alle!
blb

[liasis]

Die skala muss wohl bald nach unten erweitert werden!!!

[jm78]

Also Leidensgenossen,
Ich denke nicht in Wochen und habe 2000 € für Millennium über. Wo stehe ich eurer Meinung nach in einem Jahr?????

[Boersenkrieger]

@jm78
kauf dir doch lieber was sicheres wie World Gaming.
wir warten alle erstmal auf die 6,4-6,5 $ da ist der nächste widerstand und die sehen wir zu 99,9% ...nur eine heavy new könnte daran was ändern...
ob der widerstand dann hält ist ne andere frage. wenn er hält in einem jahr vielleicht 10 $ ansonsten evtl. 5 $

[blb]

Sollte natürlich "ESP-Deal" heißen. Sorry...

[7clever]

@Boersenkrieger time will tell

http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CI…

ich bleib dran...hab auch noch ein bisserl Geld über-
und wenn`s nix wird kauf ich mir Schokolade, man kann ja auch anders glücklich werden


seven

[schakal23]

morgen

was steht den da habe nichts verstanden

danke

[7clever]

sorry schakal23, lass dir das doch lieber
von Boersenkrieger erklären der weiss ja alles
Er wird dir auch ne einschätztung dazu geben können...

[ ] "eine heavy new"
[ ] "kein eine heavy new"

"wir warten alle erstmal auf die 6,4-6,5 $ da ist der nächste widerstand und die sehen wir zu 99,9% ...nur eine heavy new könnte daran was ändern"

seven

[7911793]

Also der Aktionär ist der Meinung, dass sie noch bis auf 5€ (ehemaliges Tief) fallen könnte. Dann sei aber ihrer Meinung nach, ein Ende der fallenden Kurse abzusehen. Glaube das allerdings nicht. Wenn sie deutlich unter 6€ fallen würde (5,50€) würde ich auch zuschlagen. Allerdings ist die Stimmung z.Z. absolut am Tiefpunkt angekommen. Man soll ja kaufen, wenn die Stimmung am Boden ist. Allerdings never catch a falling knife... .
Ich schaue mir die Sache noch ein bißchen an, wenn der Zug ohne mich abfährt, habe ich halt Pech gehabt. Bei unter sechs, könnte man auf Sicht von einem Jahr locker 100% einfahren, meiner Meinung nach.

[Isabartels]

Das Teil müsste doch dermassen überverkauft sein, dass man wenigstens mal eine ordentliche techn. Reaktion erwarten dürfte oder???????????

[Isabartels]

na, schon im Gange!!!Wäre heute besser mal rein.
Seven.
da hättest Du bei besseren Nerven heute ja richtig Gewinn gemacht!!!

[7clever]

ich sag nur nichts mehr ...

der Geniesser schweigt

seven

[Isabartels]

Ach so!!

[Isabartels]

Ist aber die Frage:
Trendwechsel oder techn. Reaktion
Ich bin für das zweite!!!

[7clever]

ich glaub du bist mir auch schonmal bei Karstadt über den Weg gelaufen...
Ich verkaufe sehr schnell, wenn es nicht so läuft, aber ich trade gerne
Hat sich immer ausgezahlt, dummerweise kommt jetzt das Weekend und ich bleib nie übers Weekend...

Ich bin sehr stur

seven

[Isabartels]

Karstadt kann sein. da war ich auch zu schnell raus!!!

[7clever]

@Isabartels
wenn`s nur ne techn. Reaktion ist, dann rettet mich das Weekend vor Verlusten.

Wenn nicht kann ich am Montag dem Kurs nachwinken

seven

[Isabartels]

ich glaube wir sehen nachher Gewinnmitnahmen. das vertrauen in Mlnm ist zur zeit einfach weg!!

[amorphis]

@wenn alle so denken wie du derzeit (über mlnm ) dann ist der boden erreicht!

bleibe bei meiner einschätzung von gestern...mlnm kommt wieder!und ich sage das jetzt nicht weil ich "besonders" viel von hätte...meine mlnm pos. ist viel zu klein...hätte ich derzeit jedoch gelder frei...würde ich mich langsam einkaufen!der markt neigt halt immer in schlechten phasen zu übertreiben...habe gestern mehrere beispiele gemacht bei denen es ähnlich abläuft!also wer 3-6 monate zeit hat...sollte wenigstens 50% einfahren!ist das nichts??????dafür bekommt ihr einen wert....der nach ner trendwende nur so schreit...total ausgebombt ist...vollgesogen mit schlechten erwartungen!ein kleiner positiver funken und schon explodiert das teil!auch wenn ihr mir das jetzt nicht glaubt...

[Isabartels]

Amorhies
ich teile durchaus Deine Einschätzung. denke nur es ist noch nicht soweit!!

[amorphis]

bei welchem niveau denkst du denn ist es soweit?nicht jedes ehemalige tief wird immer erreicht...und meine worte waren....ich würde mich langsam einkaufen!wenn ich eine fette position eingehen würde...dann verteil ich das geld auf sagen wir 3 käufe...ob jetzt der boden gefunden ist...oder ein $ tiefer...das interessiert keinen mehr...wenn mille ende des jahres 6,7,8,9 oder noch mehr dollars vom jetztigen niveau höher steht oder?!

[Boersenkrieger]

@amorphis

nachkaufen ist eigentlich ne sehr gute sache
wenn man -50% stehen hat und für´s gleiche geld ne zweite schippe draufpackt hat man nur noch -25% verlust... hab ich auch mal öfters gemacht. allerdings sollte man eben drauf achten daß die postion nicht zu sehr wächst
auf dem nieau könnte man eigentlich mal kaufen und bei 6,5 nochmal kaufen bei nem durchbruch auf 5 nochmal und dann hat man bei 10 $ schon ne super performance und ich denke die sehen wir wieder wenn der abwärtstrend mal gebrochen ist.

[amorphis]

@boersenkrieger...ich meinte damit nicht nachkaufen!halte eigtl nicht viel vom ewigen nachkaufen und verbilligen!und bei meinen 300 mlnm shares würd ich auch nie von nachkauf sprechen... was ich meinte...ist das jetzt das eingehen einer grösseren pos. mlnm keine schlechten aussichten hätte!und nen größeren einstieg würde ich nicht heute auf einen schlag machen...sondern den einstieg ein wenig streuen!so wars gemeint...

[blb]

Nach einem Kursverfall über Wochen, ja Monate, macht es keinen Sinn mittelfristig nach einem guten Tag einzusteigen. Zumindest einen Doppelboden oder sogar ein Higher Low sollte man abwarten. dann sit man auf der sicheren Seite!

Grüße an euch und schönes Wochenende!
blb

[Boersenkrieger]

@amorphis
ne größere position würde ich bei mlnm nicht aufbauen, da ist celgene interessanter z.b. ...es gibt viele andere wo man gutes potential hat und relativ wenig risiko

[7911793]

Nach dem Schlachtfest an Mlnm wird es so langsam Zeit einzusteigen. Zuvor hätte ich eine Frage:
Wieviele potentielle Medikamente sind momentan in der Pipeline und in welchem Stadium befinden sie sich?

[Isabartels]

Das sollte man aber wissen, wenn man glaubt es ist Zeit einzusteigen!!!

[amorphis]

@boersenkrieger....wann der genaue einstiegszeitpunkt ist...bzw wann wir die tiefsten kurse sehen kann keiner wissen...meine aussage war lediglich das ich ne größere position jetzt LANGSAM!in mehreren tranchen! eingehen würde!bei der nächsten länger andauernden bio-rally ist mlnm deutlich höher als jetzt!

[bonDiacomova]

an 7911793

der link zur pipline

http://www.mlnm.com/rd/pipeline/index.asp

[Pete the Rabbit]

Hallo MLNM Freunde,

bin letzten April (mit leichten Verlusten) raus aus MLNM zu 13,70. Jetzt bei halbierten Kursen juckt es doch, sich wieder einzudecken.

Andererseits, der Abwärtstrend scheint noch nicht vorbei.

Aber irgenwann könnte MLNM ein Übernahmekandidat werden.

Wie sind denn Eure Meinungen?

MfG
Pete

[Isabartels]

Unsere gute Mlnm nimmt heute auch wieder den Weg nach Süden!!!

[7clever]

ist schon komisch, wie man mit einfachen Regeln sein Kapital sichern und vermehren kann

Bez. sich nur auf Zockphasen:
--->
1. schon bei kleinen Verlusten raus
2. niemals übers Weekend halten auch bei Gewinn

seven clever traden

[7911793]

Vielen Dank bonDiacomova !!!

[Isabartels]

Was ist los, kann keine Meldung finden????


MILLENN PHARM EUR 6.67 6.77 0.34 5.37%

[blb]

Ja sie lebt noch???, sie lebt noch???, sie lebt noch???

Neue Analyse von Godmode:

Abwärtstrend voll intakt, Ziel wohl 6,X$, erst bei Abwärtstrendbruch über 11$ Kaufsignal...

Grüße
blb

[Isabartels]

Ich kaufe dann aber lieber bei 6,x $ als bei 11

[7clever]

Wenn es ab Heute $8.55 Richtung $11 geht
bleibt der Abwärtstrend trotzdem intakt!
Bei $11 gehts dann hoch

Genial


seven

[amorphis]

mein lieber mr. clever!ebenso einfach wie gewisse regeln zur kapitalerhaltung führen....ist es aber auch ersichtlich das bei jetztigen kursen bis zum bruch des abwärtstrends schon 30% zu verdienen sind!wer dann erstmal den trendbruch abwarten will...steigt aus...und kauft etwas höher zurück!ganz einfach!nach unten ist meiner meinung nach mittlerweile das risiko begrenzt...ob es derzeit nicht bessere bios gibt...sei mal dahin gestellt!

[7clever]

War nur ne Anspielung auf Godmode
Ich sags mal einfacher ausgedrückt, ich trade und solange es im vermeindlichen Godmode-Abwärtstrend für mich aufwärts geht- toll...

Berücksichtigen die Gesamtsituation nicht, machen irgendwelche Striche in den Chart... als hätte der nicht schon genug gelitten

seven

[amorphis]

ok...

[schakal23]

#639

es liest sich beängstiegend an wenn das zutrift dan habe ich 50% verlust aber dann werde ich nachlegen müssen

[blb]

7clever: Ich bin teilweise kritisch gegenüber Godmode, aber du vergleichst hier Äpfel mit Birnen. Es ging hier um die mittel- bis langfristige Einschätzung, nicht ob das Ding jetzt mal zwei Wochen von 8$ auf 9$ steigt. Da nimmt man ja auch dementsprechend andere Chartzeiträume und -einstellungen!

Schönen Abend!
blb

[7clever]

ich versteh nix von einstellungen an Charts
Bei MLNM kan ich ja auch nix schrauben...

Für mich ist ein Chart ne Vergangenheitsbewältigung...
Und ich sag es immer wieder solange Charttechniker mit Strichen arbeiten und dann gedehnte Worte brauchen um sich nur nicht festzulegen ... Neee das ist nix für mich.

Ich trade mit Gefühl, Verlust tut weh also raus Gewinn ist schön also realiseiren--- Wie haben wieder Weekend- und Cash ist gut

Hier was bisher geschah




seven

[Isabartels]

Millennium Announces Promising Findings from Novel Antibody-Chemotherapeutic MLN2704 Prostate Cancer Clinical Trial
- VELCADE(R) (bortezomib) for Injection prostate cancer data also presented -

ORLANDO, Fla., Feb 20, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced final results from a phase I clinical trial of MLN2704 in patients with advanced hormone-refractory prostate cancer. These results were presented at the 2005 Prostate Cancer Symposium taking place this week in Orlando, Fl.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The findings from this first in human MLN2704 single ascending dose trial indicated the molecule was well tolerated and produced sustained anti-tumor activity, including one patient who achieved a durable partial response in measurable disease for 11 months, as well as a sustained prostate specific antigen (PSA) decline of more than 50 percent. This patient received 14 doses prior to measurable disease progression at 47 weeks. MLN2704 is composed of a deimmunized monoclonal antibody (MLN591) directed at prostate specific membrane antigen (PSMA) conjugated to the chemotherapeutic agent DM1.

"We are encouraged by these findings with MLN2704 in prostate cancer, and we are continuing to assess the dose and schedule," said David Schenkein, M.D., senior vice president, clinical research, Millennium. "These results allow us to continue to pursue this important area of unmet medical need, and we are hopeful that further development can lead to new therapeutic options for patients with hormone-refractory prostate cancer."

Interim data from the Company`s ongoing multiple ascending dose trial evaluating MLN2704 in patients with prostate cancer has been accepted for presentation at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) scheduled for May 13-17 in Orlando, Fl.

Also presented at the meeting were results from two VELCADE studies in patients with progressive hormone-refractory prostate cancer: a phase I/II clinical trial of VELCADE in combination with docetaxel and a phase II study of VELCADE with and without steroids. The findings from the study evaluating VELCADE(R) (bortezomib) for Injection and 40mg docetaxel in combination weekly indicated the combination was well tolerated and showed promising activity. Specifically, in the higher VELCADE dose cohort, there were two partial responses in 18 patients with measurable disease and there were confirmed PSA declines of at least 50 percent in 36 percent of the 28 evaluable patients.

VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan.

"We are continuing to evaluate the data from the VELCADE trials in the prostate cancer population to better assess and understand the activity we have seen in these and past trials," said Dr. Schenkein. "We anticipate finalizing our evaluation and determining next steps in prostate cancer with VELCADE later this year in collaboration with our partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C."

MLN2704 in patients with advanced androgen independent metastatic prostate cancer; updated results

A single ascending dose phase I study of MLN2704, led by Howard I. Scher, M.D. at Memorial Sloan-Kettering, New York and Mario Eisenberger, M.D. at Johns Hopkins Oncology Center, Maryland enrolled 23 patients and examined the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics and immunogenicity of MLN2704. Patients received MLN2704 at doses ranging from 18 to 343mg/m2. Responses in patients with measurable disease were evaluated based on the RECIST (Response Evaluation Criteria In Solid Tumors) criteria and confirmed four to six weeks after the first documentation of a complete or partial response. In addition, anti-tumor activity was evaluated based on a sustained PSA decline of at least 50 percent confirmed by two separate measurements at least four weeks apart. Dose escalation continued if no dose- limiting toxicity was observed. Investigators reported the following results:

* Of 11 patients with measurable disease, one patient treated with a
264mg/m2 dose, achieved a durable partial response, including a PSA
decline of more than 50 percent . This patient received 14 doses prior
to measurable disease progression at 47 weeks;

* One additional patient, treated with a 343mg/m2 dose, achieved a PSA
decline of more than 50 percent that persisted for 24 weeks;

* Four patients achieved stable disease;

* Toxicities greater than grade three occurred in three patients
including an episode of uncomplicated febrile neutropenia with
lymphopenia and leukopenia, lymphopenia, and a transient grade three
elevation in hepatic transaminases. No grade four toxicities were
observed; and

* No immunogenicity was observed despite repeat dosing.

VELCADE(R) (bortezomib) for Injection in combination with docetaxel in patients with advanced androgen independent prostate cancer

A phase I/II study of VELCADE in combination with docetaxel, being led by Robert Dreicer, M.D., at the Cleveland Clinic Foundation, Cleveland, OH, examined the dose-limiting toxicities, maximum tolerated dose, and the effects on PSA levels of VELCADE and docetaxel, both given weekly for two out of three weeks, in patients with advanced androgen-independent prostate cancer. Two dose levels were expanded into phase II cohorts, one with VELCADE 1.3mg/m2 and docetaxel 40 mg/m2, the second with VELCADE 1.6mg/m2 and docetaxel 40 mg/m2. Anti-tumor responses in patients with measurable disease were evaluated based on the RECIST criteria and confirmed four to six weeks after the first documentation of a complete or partial response. In addition, anti-tumor activity was evaluated based on a sustained PSA decline of more than 50 percent confirmed by two separate measurements at least four weeks apart. Investigators reported the following results:

* In the cohort in which patients were treated with VELCADE 1.3mg/m2 and
docetaxel 40 mg/m2:

-- Of 25 evaluable patients, six patients (24 percent) achieved a
confirmed PSA decline of more than 50 percent of which four patients
achieved a confirmed PSA decline of at least 90 percent; and

-- 100 percent of the 13 patients with measurable disease achieved
either partial remission or stable disease, specifically three
achieved partial remission.

* In the cohort in which patients were treated with VELCADE 1.6mg/m2 and
docetaxel 40 mg/m2:

-- Of 28 evaluable patients, 10 (36 percent) had a PSA decline of more
than 50 percent;
-- 78 percent of 18 patients with measurable disease achieved partial
remission or stable disease, specifically two patients achieved
partial remission.

* Adverse events observed included fatigue, gastrointestinal events,
neuropathy, and hematologic toxicities.

VELCADE in combination with prednisone in patients with advanced androgen independent prostate cancer

A phase II study of VELCADE, led by Michael Morris M.D. and Howard I. Scher, M.D. at Memorial Sloan-Kettering, New York, NY enrolled 30 patients and examined the efficacy of VELCADE in patients with progressive androgen independent metastatic prostate cancer. Patients were treated in two groups, the first 12 patients receiving VELCADE 1.5mg/m2 twice weekly for two out of three weeks at induction with daily prednisone 10mg, and the next 18 patients receiving VELCADE 1.3mg/m2 on the same schedule at induction with prednisone 10mg upon progression. All patients received VELCADE 1.6 mg/m2 weekly as maintenance. Antitumor activity was evaluated based on imaging and measurement of PSA decline at six and twelve weeks. Investigators reported the following results from pooled cohorts:

* Of nine patients with measurable disease, two patients achieved stable
PSA and stable scans at 12 weeks;

* Two patients had a stable PSA at 12 weeks but progressed
radiographically;

* One patient in the higher dose group demonstrated a partial response on
scans but PSA continued to rise; and

* Side effects included hematologic, metabolic and hepatic side effects,
neuropathy, syncope, diarrhea and fatigue.

About Prostate Cancer

According to the American Cancer Society, this year approximately 230,110 new cases of prostate cancer will be diagnosed in the United States and approximately 29,900 men will die of this disease. The five-year survival rate of men with prostate cancer is 98 percent with this percentage jumping to 100 percent if the cancer is found before it metastasizes (spreads to another area of the body). Once the tumor spreads beyond the primary tumor, the five-year survival rate drops to 34 percent. Today there is a tremendous unmet medical need for treating the disease, particularly for end-stage or androgen-independent prostate cancer for which therapeutic options are limited. The exact cause of prostate cancer is not yet known; however, scientists have identified certain risk factors, including family history of the disease, age, diet and race.

About MLN2704

MLN2704 is composed of a deimmunized monoclonal antibody (MLN591) directed at prostate specific membrane antigen (PSMA) conjugated to the chemotherapeutic agent DM1. MLN2704 binds to PSMA, which is rapidly internalized into the cell delivering a lethal dose of chemotherapy directly to prostate cancer cells. Unlike the enzyme PSA which circulates in the blood, PSMA is a protein expressed on the cell surface of virtually all prostate cancer cells and its abundance on the cell surface increases as the disease progresses and becomes refractory to hormonal therapy. PSMA has little expression in normal tissues.

In April 2001, Millennium entered into an agreement with BZL Biologics, L.L.C., for the joint development and commercialization of antibody-based therapeutics targeting PSMA. Millennium currently has exclusive development and worldwide marketing rights to these products.

To develop MLN2704, Millennium conjugates the chemotherapeutic agent DM1 -- licensed from ImmunoGen, Inc. (Nasdaq: IMGN) -- to the MLN591 antibody, which targets PSMA. DM1 was developed by ImmunoGen specifically for antibody-directed delivery to tumor cells.

In December 2003, MLN-2704 was granted "Fast Track" status by FDA and has been selected for the Continuous Marketing Application Pilot 2 program. This latter innovative program is designed to facilitate scientific exchange and speed approval time.

About VELCADE(R) (bortezomib) for Injection

VELCADE is approved for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The effectiveness of VELCADE is based on response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in survival.

VELCADE(R) (bortezomib) for Injection is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, orthostatic hypotension, congestive heart failure, gastrointestinal adverse events, thrombocytopenia, and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 228 patients who were treated with VELCADE 1.3 mg/m2/dose in phase II studies, the most commonly reported adverse events were asthenic conditions (65%), nausea (64%), diarrhea (51%), decreased appetite including anorexia (43%), constipation (43%), thrombocytopenia (43%), peripheral neuropathy (37%), pyrexia (36%), vomiting (36%), and anemia (32%). Fourteen percent of patients experienced at least one episode of Grade 4 toxicity, with the most common toxicities being thrombocytopenia (3%) and neutropenia (3%). A total of 113 (50%) of the 228 patients experienced Serious Adverse Events (SAEs) during studies. The most commonly reported SAEs included pyrexia (7%), pneumonia (7%), diarrhea (6%), vomiting (5%), dehydration (5%), and nausea (4%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-(866)-VELCADE (1-866-835-2233).

[schakal23]

die letzten anstieg wegen diese news?

mal sehen was passiert nächste woche

[jm78]

Hallo isabartels,
leider verstehe ich englisch nicht so gut. Könntest du die Essens vielleicht übersetzen?

Gruß und vielen Dank

JM78

[niki69]

Hi, so geht´s mir auch. Wäre nett, wenn jemand mal zumindest grob schreiben könnte, was die Nachricht beinhaltet. DANKE

[jm78]

Hallo ihr alle,
steht ihr alle unter Schock? Hat es euch umgehauen oder hat es euch einfach nur die Sprache verschlagen was da in den letzten wochen bei MILLE passiert?
Ehrlich gesagt verstehe ich die Reaktion am Markt nicht.
Klar, MILLE ist zu einer Schweineaktie verkommen die ihres Gleichen sucht aber das Kursziel ist VORLÄUFIG von 13 auf10$ gesengt worden also selbst bei den Pessimisten sind noch 20% nach oben und kurzfristig drin. Also ich verstehe das alles nicht oder läuft man mit MILLE aus welchen Gründen auch immer in eine Katastrophe? Also Leute Wer ist bereit mich zu trösten und mich aufzumuntern?

Gruß
JM78

[7911793]

Servus Leute,

ich bin zwar kein Milleaktionär und auch kein Englischheld, aber ich versuche mal die ersten beide Absätze, die ich gelesen habe kurz wiederzugeben:

Es handelt sich um ein Medikament, dass gegen Prostakrebs eingesetzt werden soll. Es hat soeben die Klinische Phase 1 durchlaufen und wurde postiv getestet! Getestet wurde es 47 Wochen (grob 11 Monate), in denen 14 Injektionen (besser vielleicht Dosen) dem Testpatienten verabreicht wurden. Diese Ergebnisse seien ermutigend, um zukünftige Tumoraktivitäten zu bekämpfen. Zukünftig werde die Dosis und Verabreichungsdauer verifiziert. Mit Hilfe dieses Wirkstoffes soll ein neues Verfahren für die Chemotherapie, im Bereich Prostatakrebs, entwickelt werden. Das Management ist zuversichtlich, dass auch die weiteren Ergebnisse positiv verlaufen werden.

So jetzt mal ganz grob. Wie gesagt, ich bin auch kein Englischheld, obwohl man das als Student schon können sollte, also keine Garantie!!!


Mich wundert auch, dass die Mille wieder gefallen ist. Zum einen ist die Pipeline nicht schlecht, und zum anderen auch noch dieses positive Ergebnis. Hatte eigentlich gedacht, dass sie bei der nächsten positiven Meldung sprichwörtlich explodiert. Aber was nicht ist, kann ja noch werden. Ich bin leider voll investiert und meine United Internet Aktien laufen gut. Möchte Mille um die 6€ kaufen, weil ich der Meinung bin, dass damit gutes Geld auf Sicht von 6-12 Monaten zu verdienen ist. Wahrscheinlich sind die Leute durch Biogen Idec und Elan etwas geschockt, und schicken deshalb alle Bioaktien in den Keller. Anders kann ich mir das nicht erklären. Die letzten Zahlen waren auch nicht so schlecht. Von daher, kann es nur aufwärts gehen. Gut trades euch allen!

[jm78]

@7911793
vielen dank und viel glück für dich.
Gruß
JM78

[bonDiacomova]

bon dia

Der Medikamentenhersteller Millennium Pharma (900625) Inc. (MLNM) gab nachbörslich bekannt, eine Meilensteinzahlung in Höhe von 40 Mio. Dollar im Rahmen einer Zusammenarbeit mit der GlaxoSmithKline Group und Johnson & Johnson Pharmaceutical Research and Development zu erhalten. Nachbörslich legte die Aktie 0,96 % auf 8,42 Dollar zu.

-----------

Millenium Pharma erhält $40 Millionen

Der Medikamentenhersteller Millennium Pharmaceuticals Inc. verkündete in der Nachbörse in den USA, eine Meilensteinzahlung in Höhe von $40 Millionen im Rahmen einer Zusammenarbeit mit der GlaxoSmithKline Group und Johnson & Johnson Pharmaceutical Research and Development, einer Tochter von Johnson & Johnson, zu erhalten. GlaxoSmithKline werde demnach an Millennium insgesamt $19.9 Millionen für den Erhalt der Vermarktungszulassung für das Integrilin-Injektions-Präparat zahlen. J&J wird zwei Zahlungen in Höhe von $10 Millionen für das Erreichen einer Umsatzmarke bei dem Medikament Velcade außerhalb der USA leisten.

-------------


Millennium Achieves Milestone Payments of Approximately $40 Million

CAMBRIDGE, Mass., March 7 /PRNewswire-FirstCall

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced it will receive licensing fees and milestone payments based on the success of collaborations with the GlaxoSmithKline Group (GSK) and Johnson & Johnson Pharmaceutical Research and Development L.L.C. (J&JPRD) totaling approximately $40 million. Marsha Fanucci, chief financial officer and senior vice president, Millennium, will discuss these milestones in more detail in the Company`s presentation at the SG Cowen & Co. 25th Annual Health Care Conference on March 17, 2005 which will be webcast and accessible through the Millennium website at http://www.millennium.com.

---> http://biz.yahoo.com/prnews/050307/nem042_1.html

[Isabartels]

Und warum dann das:

MILLENN PHARM EUR 6.13 6.23 -0.12 -1.92%

[Isabartels]

MILLENN PHARM EUR 6.09 6.19 -0.16 -2.56%

[mountainbiker]

Tja, das waren ja noch schöne Kurse! Jetzt sind wir schon unter 6! Was ist denn das für eine Scheiß-AKtie???

[7911793]

Eine Abstufung von JP Morgan von overweight auf neutral belastet anscheinend die Aktie. Ein Kursziel geben die Analysten nicht an.

[7clever]

ja, das wars wohlerstmal...
Aber vielleicht trade ich mal wieder
Hoffe, dass ich nicht zu früh reinfasse!

seven

[blb]

Typisch Analysten. MLNM fällt von 20 auf 8 und dann stufen sie sie ab...

[Boersenkrieger]

mille verbrennt einfach geld und es kommt nichts raus... seit 5 jahren... celgene zeigt es wie es geht... millennium hat wohl keine chance gegen celgenes technologie zu bestehen, vielleicht haben sie einfach pfeiffen als wissenschaftler kann ja auch sein die milles

[Boersenkrieger]

Celgene To Pressue Millennium Pharma In Late 2005
03.08.05, 11:40 AM ET


Tear Sheet | Chart | News



J.P. Morgan Securities downgraded Millennium Pharmaceuticals (nasdaq: MLNM - news - people ) to "neutral" from "overweight" based on "a more tepid intermediate and long-term outlook for Velcade," given "overwhelmingly positive" late-stage clinical data for blood-cancer treatment Revlimid, made by Celgene (nasdaq: CELG - news - people ). "With market leadership in the third line setting for multiple myeloma (MM) and Thalomid continuing to gain momentum in the first-line setting, Velcade growth in second-line MM remains a key driver for Millennium. However, combined with highly positive phase III data, convenient dosing and hematology/oncology`s desire to `put their best foot forward`, we expect Revlimid to pressure Millennium`s Velcade franchise in the MM arena beginning in late 2005," said J.P. Morgan. "In our view, these overwhelmingly positive results for Revlimid negatively alter the outlook for Velcade in both the second- and third-line MM settings, the key drivers of growth for this franchise in the near-to-medium term. The earlier-than-expected data release coupled with the highly statistically significant positive efficacy data, in our view, puts greater competitive pressure on Velcade`s growth prospects." The research firm narrowed its 2005 projected loss to 34 cents from 44 cents, however, given the company`s recent announcement of $39.9 million in milestone payments from Johnson & Johnson (nyse: JNJ - news - people ) and GlaxoSmithKline (nyse: GSK - news - people ).

[jm78]

Aus dem Hause von JP Morgan kommt eine Herunterstufung für die Aktie des Biotech-Unternehmens Millennium Pharmaceuticals. Das Rating ist von „overweight“ auf „neutral“ verringert worden. Die Herunterstufung geschieht wegen des zu erwartenden negativen Einflusses, den Celgenes Revlimid auf das Medikament Velcade haben werde. Das Konkurrenzmittel weise eine höhere Sicherheit und ein besseres Wirkungsprofil auf. Für das laufende Jahr haben die Experten die Ergebnisschätzung von minus 10 auf minus 16 Cent je Aktie reduziert.
( aa )

Ich lach mich tot.
Die gleichen Leute die die Mille noch vor wochen angepriesen haben schimpfen jetzt wie die Rohrspatzen.
Jungs, ihr habt genau so wenig Ahnung von der Materie wie ich. aber is doch egal is doch nur Geld.
Gruß euch allen
jm78

[blb]

Du bringst es auf den Punkt, wennse wieder bei 10$ steht stufen sie wieder herauf. Mich ärgert nur, dass dadurch die Nachricht mit den 40 Millionen $ total verpufft ist. Tolles Timing!

Gute Nacht!
blb

[js200]

Millennium initiates Velcade retreatment trial

Friday , March 11, 2005 10:39 ET

Mar 11, 2005 (Datamonitor via COMTEX) --Millennium Pharmaceuticals has initiated a phase IV clinical trial of its Johnson & Johnson co-developed drug Velcade in multiple myeloma patients who have previously responded to the treatment and relapsed following a treatment-free remission.

The trial, named EVEREST, is a multi-center clinical trial that will assess the efficacy of retreatment with Velcade (bortezomib) for injection in terms of best confirmed M-protein response.

The trial will be conducted at approximately 80 sites in North America and will enroll up to approximately 120 patients. Eligible patients need to have tolerated 1.0 or 1.3mg/m2 doses of Velcade alone or in combination with dexamethasone (Merck & Co`s Decadron), and have had a reduction of M-protein of 50% or more that has lasted at least six months with a treatment-free interval of at least four months.

"Velcade has proven efficacy in patients with relapsed and refractory myeloma, with responses lasting approximately one year," said Dr David Schenkein, senior vice president of clinical research at Millennium. "There is no known mechanism of resistance to Velcade, and no new cumulative toxicity with extended therapy, so we are optimistic about the benefits of retreatment which would allow patients to receive multiple lines of therapy with Velcade."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon

Copyright (C) 2005 Datamonitor. All rights reserved

[js200]

03/14/2005 (12:20 ET) US Financial Network: Advanced Viral Research Corp. initiates its Phase II clinical trial and Genetech extends its technology licensing with Abgenix - M2 Communications
03/14/2005 (08:15 ET) StreetInsider Alert for MLNM - Street Insider
03/14/2005 (08:01 ET) Millennium Announces Senior Executive Appointments --Expands Key Leadership Roles and Promotes Senior Leaders From Within-- - PR Newswire
03/11/2005 (10:39 ET) Millennium initiates Velcade retreatment trial - Datamonitor
03/10/2005 (16:01 ET) SG Cowen & Co. 25th Annual Healthcare Conference to Webcast Millennium Presentation - PR Newswire

[schakal23]

17.03.2005 21:27
Blocktrade bei Corning, Millennium und Siebel
Blocktrades geben Hinweise auf institutionelle Tätigkeit.

Anbei die Aktien, bei denen es im heutigen Handel zu mindestens einem Blocktrade von über 500.000 Aktien gekommen.




mlnm stehet mit 1,056.000 aber steht nicht ob kauf oder verkauf aber wir habe mit plus geschlossen

[js200]

03/16/2005 (16:22 ET) MLNM: Drops -2.17%; Vol +84%; Last 90 Min of Trading - Knobias
03/16/2005 (08:47 ET) Wall Street News Alert: Aggressive Traders Alert! March 16, 2005 - M2 Communications
03/14/2005 (16:22 ET) MLNM: Jumps +3.42%; Vol +105%; Last 90 Min of Trading - Knobias
03/14/2005 (12:20 ET) US Financial Network: Advanced Viral Research Corp. initiates its Phase II clinical trial and Genetech extends its technology licensing with Abgenix - M2 Communications
03/14/2005 (08:15 ET) StreetInsider Alert for MLNM - Street Insider

[schakal23]

na da krabelt sich jemand langsam wider hoch

[blb]

Könnte langsam ein Boden werden, ich würde aber die nächsten Zahlen abwarten!

Euch allen schöne Feiertage!

Grüße
blb

[jm78]

Hallo Bib,wann kommen eigentlich die neusten Zahlen?
Gruß
JM78

[leonide]

Hallo,
die neusten Zahlen sind mir ziemlich schnuppe ...,
Boden gefunden wäre gut ...,
habe mich zwischenzeitlich für meine Verhältnisse bis über beide Ohren mit Milles eingedeckt.
Nehme jetzt meine Schlaftablette und melde mich in 1 -2 Jahren wieder, falls es einen interessiert.
Nur dass es dann nicht heißt, so früh und viel eingedeckt, kann ja jeder behaupten ... !
Wenn es nicht klappt, seid bitte freundlich zu dem Penner unter der Brücke, könnt ja ich sein.
Bis dahin oder lieber nicht
leonide

[js200]

Lehman Brothers Eighth Annual Global Healthcare Conference to Webcast Millennium Presentation
via COMTEX

March 24, 2005

CAMBRIDGE, Mass., March 24, 2005 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the Lehman Brothers Eighth Annual Global Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium management will provide an overview of the Company and upcoming corporate events. The presentation will be delivered at 3:45 p.m. EST on Thursday, March 31, 2005 from the Loews Miami Beach Hotel in Miami, FL. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

[phone]

SOURCE Millennium Pharmaceuticals, Inc.

Kyle Kuvalanka of Millennium Pharmaceuticals, 617-761-4734 http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[js200]

FDA Grants Full Approval for VELCADE(R) (Bortezomib) for Injection; Claims Include Survival Advantage and Use in Second-Line Multiple Myeloma
via COMTEX

March 25, 2005

-- Doubles number of patients who could benefit from VELCADE --

CAMBRIDGE, Mass., March 25, 2005 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the U.S. Food and Drug Administration (FDA) approved the Company`s supplemental New Drug Application (sNDA) for VELCADE. This approval expands the label to include the treatment of patients with multiple myeloma (MM) who have received at least one prior therapy. VELCADE is the only drug therapy that has demonstrated a significant survival advantage as compared to a standard therapy in relapsed MM. Initial accelerated approval for relapsed and refractory MM was granted in May 2003. VELCADE is now fully approved in relapsed MM.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The approval was based on data from the randomized phase III APEX study that compared single-agent VELCADE to a traditional MM therapy, high-dose dexamethasone. The study demonstrated a significant survival advantage with VELCADE (p<0.05*) in patients who had received one to three prior therapies. Importantly, this pronounced survival advantage was also observed in the second-line MM patients. The safety profile of VELCADE remained consistent with previous phase II findings. This indication doubles the number of U.S. patients who could potentially benefit from VELCADE to approximately 22,000.

"We are thrilled that more patients will have access to VELCADE earlier in their treatment where VELCADE has shown a significant improvement over a standard therapy in improving survival and delaying disease progression," said David Schenkein, M.D., senior vice president, clinical research at Millennium. "Millennium is committed to making a difference in patients` lives and will continue, in partnership with Johnson & Johnson Pharmaceutical Research and Development L.L.C., to explore extensively the benefits of VELCADE across the multiple myeloma treatment paradigm as well as in other hematologic and solid tumors."

*Precise p-value cannot be rendered.

The approval of this supplementary filing comes approximately 22 months after the initial FDA approval of VELCADE(R) (bortezomib) for Injection. VELCADE, the first of a new class of medicines called proteasome inhibitors, is the first treatment in more than a decade to be approved for patients with multiple myeloma, a cancer of the blood.

APEX Study Results

The sNDA submission was based primarily upon the results of the phase III APEX study, which compared VELCADE to high-dose dexamethasone. The APEX trial enrolled 669 patients with relapsed multiple myeloma (patients had received one to three prior therapies) at 93 centers in North America, Europe and Israel. This study was conducted under the direction of Paul Richardson, M.D., clinical director, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute. The APEX trial was halted one year early after an independent data monitoring committee concluded the findings of a pre-specified interim analysis showed a statistically significant improvement in time-to-disease progression in favor of VELCADE.

In the overall study population, VELCADE was superior to high-dose dexamethasone based on time to progression (p<0.0001), overall survival (p<0.05*) and response rate (p<0.0001). Additional findings include the following:

-- Overall, 40 percent fewer patients died in the VELCADE arm relative to the dexamethasone arm; -- Overall response rate of 38 percent with VELCADE, with a median duration of response of 8.0 months compared with a response rate of 18 percent, with a median duration of response of 5.6 months for dexamethasone; -- Six percent of VELCADE patients had a complete response and 7 percent had a near complete response as compared to less than one percent each with dexamethasone; and -- After a median of 8.3 months of follow-up, improvement in median time to progression was 78 percent with VELCADE relative to dexamethasone.
Among the 251 second-line multiple myeloma patients (those who had only one prior therapy), VELCADE was superior based on time to progression (p=0.0019), response rate (p=0.0035) and overall survival (p<0.05*). Additional findings include the following:

-- Overall, 55 percent fewer patients died in the VELCADE arm relative to the dexamethasone arm; -- Overall response rate with VELCADE was 45 percent (median duration of response was 8.1 months) compared with 26 percent for dexamethasone (median duration of response 6.2 months); and -- Six percent of VELCADE patients had a complete response and 6 percent had a near complete response as compared to two percent each with dexamethasone.
Adverse events on the VELCADE arm were predominantly grade one or two, were similar to those previously observed in other trials and were considered manageable by the investigators.

-- The most commonly reported adverse events were asthenic conditions, diarrhea, nausea, constipation, peripheral neuropathy, vomiting, pyrexia, thrombocytopenia, psychiatric disorders and anorexia and appetite decreased; and -- The most commonly reported serious adverse events were pyrexia, diarrhea, dyspnea, pneumonia and vomiting. *Precise p-value cannot be rendered. About VELCADE(R) (bortezomib) for Injection
VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE 1.3 mg/m2 dose in the phase III APEX study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%) and anorexia and appetite decreased (34%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%) and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea and pneumonia (4%) and vomiting (3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery, development of products and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contacts:

Adriana Jenkins (Media) Kyle Kuvalanka (Investor Relations) 617-761-6996 617-761-4734

SOURCE Millennium Pharmaceuticals, Inc.

Adriana Jenkins (Media), [phone], or Kyle Kuvalanka (Investor Relations), [phone], both of Millennium http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[ch76xxxx]

[js200]

Millennium to Discuss Full Approval of VELCADE(R) (bortezomib) for Injection in Second-Line Multiple Myeloma
via COMTEX

March 28, 2005

- Significant survival advantage and next steps for VELCADE are among highlights of presentation at Citigroup Smith Barney Healthcare Conference -

CAMBRIDGE, Mass., March 28, 2005 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that the Company will be focusing on the recent full approval of VELCADE in relapsed refractory multiple myeloma (MM) at the upcoming Citigroup Smith Barney Healthcare Conference. Management will discuss the significant survival advantage that was demonstrated in a phase III study comparing VELCADE to a standard therapy, the results of which led to the expanded label in the treatment of patients with MM who have received at least one prior therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The U.S. Food and Drug Administration (FDA) approved the Company`s supplemental New Drug Application (sNDA) for VELCADE on March 25, 2005, less than two years after the initial accelerated approval for relapsed and refractory MM was granted. VELCADE is the only drug therapy that has demonstrated a significant survival advantage as compared to a standard therapy in relapsed MM. This indication doubles the number of U.S. patients who could potentially benefit from VELCADE to approximately 22,000.

"The new label recognizes the benefits of VELCADE in earlier lines of therapy for MM patients, and we believe ongoing studies will continue to build evidence for its potential use in the front line setting," said Mark Levin, chief executive officer, Millennium. "The approval further demonstrates the success of the Company`s strategy to rapidly advance drugs from pipeline to market, and then expand the indications to benefit more patients."

Millennium management will present at 3:55 p.m. EST on Tuesday, March 29, 2005, from The Mayflower Hotel in Washington, DC. The event will be webcast live and will be archived for 30 days. It can be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com.

VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan.

To date, approximately 12,000 patients have been treated with VELCADE. VELCADE is currently approved in more than 40 countries around the world, for treatment of multiple myeloma (MM) patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.

About VELCADE(R) (bortezomib) for Injection

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE 1.3 mg/m2 dose in the phase III APEX study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%) and anorexia and appetite decreased (34%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%) and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea and pneumonia (4%) and vomiting (3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, co- promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery, development of products and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contacts:

Adriana Jenkins (Media) Kyle Kuvalanka (Investor Relations)

617-761-6996 617-761-4734

SOURCE Millennium Pharmaceuticals, Inc.

Adriana Jenkins, [phone], or Kyle Kuvalanka, [phone] both of Millennium Pharmaceuticals, Inc. http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[Boersenkrieger]

na das müßte doch mal nen kleinen schub bringen

[js200]

CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference to Webcast Millennium Presentation
via COMTEX

March 28, 2005

CAMBRIDGE, Mass., March 28, 2005 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference will be webcast live and may be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium management will provide an overview of the Company and upcoming corporate events. The presentation will be delivered at 4:15 p.m. EDT on Monday, April 4, 2005 from The Millennium Broadway Hotel in New York City. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

[phone]

SOURCE Millennium Pharmaceuticals, Inc.

Kyle Kuvalanka of Millennium Pharmaceuticals, Inc., [phone] http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[blb]

Die Frage der Fragen: Ist das jetzt der Boden?

[schakal23]

ich denke schon

[Isabartels]

Hier die Einschätzung von Biotech.Experte.


01.04.2005 - 19:49
MILLENNIUM Pharma rutscht ab

MILLENNIUM Pharma (MLNM) : 8,17 $ (-2,96%)

Aktueller Tageschart (log) seit Juni 2004 (1 Kerze = 1 Tag).

Kurz-Kommentierung: MILLENNIUM Pharma gerät heute im intraday schwachen Marktumfeld wieder deutlicher unter Druck. Nach dem Einbruch unter die 9,69 $ wurde der Kurs bis auf 7,70 $ abverkauft und konnte sich mit dem Biotechsektor in den Vorwochen stabilisieren. Unterhalb des EMA 50 (blau) bei 8,90 $ dreht der Kurs wieder nach unten ab und kippt intraday aus dem kurzfristigen Aufwärtstrend. Kurzfristig droht damit zumindest ein nochmaliger Test der 7,70 $, eine Bodenbildung ist hier mittelfristig noch nicht erfolgt. Ein Rückfall auf ein neues Tief wäre negativ zu werten und setzt weiteres Downpotenzial bis 6,24 $ mittelfristig frei. Das charttechnische Setup hellt sich kurzfristig auf, wenn der Kurs die bei 8,60 $ liegende kurzfristige Abwärtstrendlinie auf Schlussbasis nach oben durchbrechen kann.

[Isabartels]

Key Data on VELCADE(R) (Bortezomib) for Injection in Front-Line Studies and Beyond at the International Multiple Myeloma Workshop

-- Over 20 presentations and posters, including results from multiple

frontline studies --

CAMBRIDGE, Mass., April 8 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that positive results from studies of VELCADE(R), an approved treatment for patients with multiple myeloma (MM) who have had at least one prior therapy, will be featured at the 10th Annual International Multiple Myeloma Workshop in Sydney, Australia, April 10-15, 2005. Highlights include:

* Front-line results from phase I/II studies of VELCADE alone or in
combination with dexamethasone; pegylated liposomal doxorubicin;
melphalan/prednisone; and dexamethasone/doxorubicin.
* Second-line results from a phase III multi-center trial comparing
VELCADE to high-dose dexamethasone, with clinical outcomes reported by
type of prior therapy.
* Results of phase I/II studies in relapsed and/or refractory patients
investigating VELCADE in combination with melphalan; dexamethasone,
pegylated liposomal doxorubicin/thalidomide, and lenalidomide, as well
as a single agent in high risk patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

[hevchen]

hallo, gibt es neuigkeiten???

[Snake3000]

Positive Test-Resultate für Velcade lassen den Kurs ein wenig explodieren!

Millennium Shows Positive Velcade Data
Wednesday April 13, 12:44 pm ET
Millennium Pharmaceuticals Reports Data Showing Velcade As Front-Line Blood Cancer Treatment

CAMBRIDGE, Mass. (AP) -- Millennium Pharmaceuticals Inc., which focuses on treatments for cancer, inflammatory diseases and cardiovascular disorders, said Wednesday that a series of clinical studies of its cancer treatment Velcade showed positive results as a front-line treatment.

ADVERTISEMENT
Velcade is an injectable treatment for patients suffering from multiple myeloma -- a type of bone marrow cancer that affects white blood cells called plasma cells.

In a series of mid-stage clinical trials, investigators reported that multiple myeloma patients treated with Velcade, adriamycin, and dexamethasone following a stem cell transplant had a near complete response rate of 57 percent. In another group treated with Velcade and liposomal doxorubicin, 12 of 15 multiple myeloma patients showed partial responses to the treatment.

As a second-line treatment, Velcade was compared with high-dose dexamethasone in a late-stage clinical trial. Velcade showed a 45 percent response rate with a 13 percent complete and near complete response rate. Patients who had received one prior therapy showed a longer duration response and significantly higher survival rates, Millennium said. Survival rates showed that the probability of death with dexamethasone was about 2.6 times that of Velcade therapy.

For relapsed or unresponsive patients with multiple myeloma, Velcade, when combined with other cancer therapies such as liposomal doxorubicin/thalidomide, melphalan and lenalidomide, showed response rates of more than 60 percent, Millennium said.

"These front-line data suggest Velcade may offer a new option for patients with multiple myeloma who have not yet been treated," said David Schenkein, Millennium senior vice president of clinical research, in a statement. "While Velcade is the only single agent to demonstrate a statistical survival advantage in relapsed patients, the benefits in combination with other therapies confirm our belief that Velcade-based therapies can become the new standard of care in multiple myeloma."

Multiple myeloma is the second most common type of blood cancer, primarily affecting elderly patients. In the United States, more than 40,000 people suffer from multiple myeloma, with more than 14,000 new cases diagnosed each year.

Millennium reported Velcade sales of about $143.1 million in 2004. The drug is approved in the United States for multiple myeloma patients who have received at least one prior therapy.

Shares of Millennium rose 21 cents to $8.52 in afternoon trading on the Nasdaq.

8.91$

Schön Gruß
Snake3000

[Snake3000]

VELCADE(R) (bortezomib) for Injection Phase II Clinical Trial Initiated in Lung Cancer
Monday April 25, 8:01 am ET
- -
- Company-sponsored trial in patients with either brochioloalveolar carcinoma (BAC) or adenocarcinoma with BAC features reinforces commitment to strategic development --

CAMBRIDGE, Mass., April 25 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of PEAK (Prospective Evaluation of bortezomib in Adenocarcinoma with bronchioalveolar features as a Keystone of therapy). This is a multicenter phase II clinical trial of VELCADE in patients with either advanced BAC or adenocarcinoma with BAC features that have progressed on or after receiving one to two lines of chemotherapy, one of which must have been an epidermal growth factor receptor tyrosine kinase inhibitor (EGRF TKI). The open-label study will assess efficacy in terms of tumor response rate measured by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.

ADVERTISEMENT
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"Millennium, and our partner Johnson and Johnson, are committed to investigating VELCADE as a therapy for lung cancer and this trial is an integral component of our global development plan," said David Schenkein, M.D., senior vice president, clinical research, Millennium. "In reviewing previous VELCADE experiences, we saw several dramatic single-agent responses in patients with BAC and we are eager to explore the potential of VELCADE so that we may be able to offer new options for patients in need."

VELCADE is approved in the U.S. for the treatment of patients who have received at least one prior therapy. Millennium and Johnson & Johnson continue to investigate VELCADE globally in phase I, II and III clinical trials in both hematologic and solid tumors, including frontline MM, non-Hodgkin`s lymphoma and lung, prostate and ovarian cancers.

About BAC

Patients with BAC or adenocarcinoma with BAC features comprise a 30,000- patient group representing approximately 20% of the overall non-small cell lung population. These patients tend to have a unique histology and have typically responded poorly to cytotoxic drugs used for non-small cell lung cancer. Data suggest that the incidence of BAC is increasing, notably in younger non-smoking women. Despite reports of prolonged survival, BAC remains incurable with the vast majority of patients dying of respiratory failure or pneumonia within five years of diagnosis.

About VELCADE® (bortezomib) for Injection

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE 1.3 mg/m2 dose in the phase III APEX study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%) and anorexia and appetite decreased (34%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%) and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea and pneumonia (4%) and vomiting (3%).

VELCADE is being co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for Japan. VELCADE is approved in more than 40 countries worldwide including the U.S., European Union members, and a number of countries within Latin America and South-East Asia such as Argentina, China, Korea, Singapore and Thailand.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, co- promotes INTEGRILIN® (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s discovery and development of products. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

[Boersenkrieger]

na endlich mal wieder die 9 vorne... hofentlich bleibt das so bis handelsende.. dann können wir so langsam mal wieder mit zweistelligen kursen rechnen

[blb]

Ja, sieht langsam besser aus. Ich halt mich mit nem Zukauf allerdings weiter zurück...
Quartalszahlen kommen ja auch bald!

Grüße
blb

[Boersenkrieger]

7.70 war der tiefstkurs... jetzt sind wir wieder ein stückchen weg... glaube das war der boden. aber nachkaufen tu ich da auch nicht und zwar nie mehr... ich lasse meine -50% position einfach mal laufen und hoffe sie irgendwann noch mit gewinn raushauen zu können. mal sehen.

[schakal23]

25.04.2005 18:15
MILLENNIUM Pharma - Erholung besitzt noch Potenz...
MILLENNIUM Pharma (Nachrichten)(MLNM): 9,14$ (+3,27%)

Aktueller Wochenchart (log) seit Mai 2002 (1 Kerze = 1 Woche).

Diagnose: MILLENNIUM Pharma steht nach einer Erholung seit Anfang 2004 wieder stark unter Druck und fiel in den Vormonaten auch unter die wichtige Unterstützung bei 9,69 $ zurück. Bei 7,70 $ konnte sich die Aktie stabilisiere und aus dem steilen kurzfristigen Abwärtstrend bei derzeit 8,20 $ nach oben ausbrechen. Die Erholung setzt sich in dieser Woche fort und wird bei 9,69 $ auf einen wichtigen widerstand treffen. Verstärkend wirkt die in diesen Bereich fallende mittelfristig maßgebende Abwärtstrendlinie.

Prognose: Die Erholung kann kurzfristig noch bis in den Bereich 9,69-10,13 $ fortgesetzt werden, hier ist ein Rückfall wahrscheinlich. Erst ein Ausbruch über den bei 10,13 $ derzeit auch liegenden Abwärtstrend auf Schlussbasis generiert ein neues mittelfristiges Kaufsignal. Darunter bleibt das mittelfristig bärische Szenario zunächst intakt.


na wollen wir hoffen das die die 10,13$marke durch brechen

[Boersenkrieger]

na immer diese charttechniker.... unterstützungen halten nicht mehr in dieser zeit, weder nach oben noch nach unten... meist ist ein widerstand nach 1-2 tagen durchbrochen. die zeiten ändern sich eben in dieser schnellebigen zeit

[schakal23]

Millennium Pharmaceuticals, Inc. | MLNM
Last Sale:
$ 9.18 Net Change:
0.33 3.73% Share Volume:
6,274,135

die letze stunde über 3,5 million schars

[schakal23]

was ist los heute 3.5% in minus?

[Isabartels]

heute gabs zahlen!!

[Isabartels]

Millennium Reports First Quarter VELCADE® (bortezomib) for Injection Sales Up 51%, R&D Expenses Down 11% Compared to First Quarter 2004
VELCADE approval in second-line multiple myeloma and clinical trial data demonstrate strength of products and pipeline for continued Company growth

CAMBRIDGE, Mass., April 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported consolidated financial results for the quarter ended March 31, 2005 and confirmed financial guidance for 2005.

"Millennium continues to establish a track record for achieving its financial goals by growing revenue and managing expenses," said Marsha Fanucci, chief financial officer and senior vice president of corporate strategy. "Millennium is balancing its 2006 non-GAAP profitability(1) goal with continued investment in its products and pipeline to create sustainable growth for shareholders."

2005 First Quarter Results

* Net loss on a GAAP basis for the first quarter of 2005 was $36.4 million, or $0.12 per share, compared to $40.6 million, or $0.13 per share, for the first quarter of 2004. Non-GAAP net loss for the first quarter of 2005 was $26.8 million, or $0.09 per share, compared to $20.6 million, or $0.07 per share, for the first quarter of 2004.

* Total revenue for the first quarter of 2005 increased 34 percent to $123.7 million from $92.6 million in the first quarter of 2004.

* Net product sales of VELCADE in the first quarter of 2005 increased 51 percent to $44.8 million from $29.6 million in the first quarter of 2004.

* Co-promotion revenue for INTEGRILIN® (eptifibatide) Injection decreased 10 percent to $42.8 million from $47.8 million in the first quarter of 2004. While co-promotion revenue declined, U.S. ex- factory sales of INTEGRILIN for the first quarter of 2005, as provided by the Company`s collaborator, Schering-Plough Corporation, increased five percent to $71.4 million from $67.7 million in the first quarter of 2004. The decline in co-promotion revenue is due to a decrease in net expense reimbursement due from Schering-Plough to Millennium.

* Strategic alliance revenue for the first quarter of 2005 increased to $36.1 million from $15.1 million in the same quarter a year earlier. The increase is due primarily to milestone payments earned for the successful achievement of sales thresholds of VELCADE® (bortezomib) for Injection under the Company`s collaboration with Ortho Biotech Products, L.P., a member of the Johnson & Johnson Family of Companies.

* Research & Development expenses for the first quarter of 2005 were reduced 11 percent to $86.2 million from $96.3 million in the first quarter of 2004. This decrease reflects the completion of the Company`s phase III APEX trial for VELCADE in 2004, as well as continued resource management.

* Selling, General & Administrative expenses for the first quarter of 2005 increased 15 percent to $51.6 million from $44.8 million for the first quarter of 2004. This increase is the result of sales and marketing spend associated with preparation for the launch of VELCADE in an expanded label and the re-branding of INTEGRILIN launched at the American College of Cardiology (ACC) Annual Scientific Sessions in March.

* Other income, net for the first quarter of 2005 decreased to $1.9 million from $43.7 million in the first quarter of 2004. This difference reflects the final $40.0 million gain which was recognized in the first quarter of 2004 related to the Company`s sale of its equity interest in Campath® (alemtuzumab) humanized monoclonal antibody.

* As of March 31, 2005, the Company had approximately $576.0 million of cash, cash equivalents and marketable securities. In January 2005, the Company paid $49.3 million to Schering-Plough for advances made to COR Therapeutics, Inc. prior to the merger of Millennium and COR. This cash balance does not reflect approximately $40.0 million the Company expects to receive in the second quarter of 2005 from Ortho Biotech and GlaxoSmithKline relating to milestones achieved. In addition, as of March 31, 2005, the Company had $105.5 million outstanding principal amount of convertible debt.

2005 Financial Guidance

The Company is reiterating its full-year financial guidance initially outlined in January 2005:

* VELCADE U.S. net products sales are expected to be in the range $185 million to $195 million.

* INTEGRILIN U.S. ex-factory sales, as reported by Schering-Plough, are expected to be in the range of $315 million to $330 million.

* Net loss on a GAAP basis is expected to be less than $155 million and on a non-GAAP basis is expected to be less than $100 million.

* Cash, cash equivalents, and marketable securities are expected to be greater than $500 million.

First Quarter 2005 Highlights

"Millennium continued to build momentum around its products and pipeline this quarter," said Mark Levin, chief executive officer. "We expect that the approval of VELCADE in second-line multiple myeloma will continue to fuel top- line growth of the Company while allowing physicians to increase familiarity with and confidence in the drug in an earlier line of therapy. In addition, clinical results of MLN2704 highlight the progress of our pipeline with the molecule indicating early clinical efficacy and safety in prostate cancer patients."

VELCADE® (bortezomib) for Injection Highlights

The U.S. Food and Drug Administration approved the Company`s supplemental New Drug Application for VELCADE. The approval expanded the original VELCADE label to include the treatment of multiple myeloma (MM) patients who have received at least one prior therapy. VELCADE is the only drug therapy that has demonstrated a significant survival advantage as compared to a standard therapy in relapsed MM. The new indication significantly increases the number of U.S. patients who potentially could benefit from VELCADE. Earlier today, Ortho Biotech announced that the European Commission approved the use of VELCADE as monotherapy for MM patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

In April, the Company and its research collaborator, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced the presentation of clinical results from a series of investigator initiated trials of VELCADE in the front-line MM setting at the 10th Annual International Myeloma Workshop (IMW) in Sydney, Australia. Highlights of the data presented include overall response rates in the range of 67 percent to 95 percent and complete and near complete responses in the range of 13 percent to 32 percent. Toxicities in these studies were similar to those observed in other studies with VELCADE.

Positive interim results from the front-line trials have led to three large, phase III registration-enabling trials in

[Isabartels]

28.04.2005 - 19:38
CSFB zu Millennium Pharma



Credit Suisse First Boston haben heute die Titel von Millennium Pharmaceuticals mit "hold" bestätigt. Das Kursziel wurde von 14 auf 12 Dollar zurückgenommen.

Wie der zuständige Analyst ausführte, habe der Quartalsverlust des Biotech-Unternehmens niedriger gelegen, als von CSFB erwartet worden war. Millennium habe höhere Meilenstein-Zahlungen von Johnson & Johnson für sein Krebs-Medikament Velcade erhalten. Zudem wurden die Ausgaben für Forschung und Entwicklung gesenkt.

Es sei viel darüber spekuliert worden, ob Millennium 2006 die Gewinnschwelle erreiche. Viel wichtiger sei jedoch, wie das langfristige Wachstum aussehen werde. Hier gehe man davon aus, dass der Gewinn des Unternehmens 2008 lediglich bei 13 Cents pro Aktie liegen werde. 2006 werde sich Millennium darum bemühen, weitere Gelegenheiten zu Zulassungsanträgen und Lizenzierungs-Abkommen zu nutzen. Dies könne aber vorerst auf Kosten der Gewinnentwicklung gehen.

[Isabartels]

28.04.2005 - 19:35
Millennium Pharma: Verlust leicht verringert



Millennium Pharmaceuticals hat den Verlust im ersten Quartal auf 36,4 Millionen Dollar oder 12 Cents pro Aktie verringern können. Im Vorjahr war ein Minus von 40,6 Millionen Dollar eingefahren worden. Ohne Sondereffekte lag der Verlust bei 9 Cents pro Aktie, während man am Markt durchschnittlich mit 10 Cents gerechnet hatte. Die Umsätze kletterten, dank höher als erwarteter Erlöse durch das Krebsmedikament Velcade, um 34 Prozent auf 123,7 Millionen Dollar.

An der Nasdaq rutschen Millennium Pharmaceuticals aktuell dennoch um 4,29 Prozent auf 8,70 Dollar ab.

[aalerich]

zu den Zahlen folgendes Fazit der Konsensschätzung :

Ergebnis : -11 Cent / in line
Umsätze : erw. 129 mio / erreicht 123 mio. - also verfehlt
Ausblick eher verhalten - nicht überzeugend
bissel schade

[blb]

Meinungen zu den Zahlen?

Waren zwar über den Erwartungen, scheinbar enttäuscht jedoch der Ausblick! Hoff mal der Boden um die 8$ hält!

Grüße
blb

[Isabartels]

Wenn man mal die Pipeline anschaut und die cash Position + cash burn, dann werden die irgendwann wieder eine kapitalerhöhung brauchen. meine meinung jedenfalls!

[js200]

Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented
via COMTEX

May 14, 2005

Results support broad development program and underscore strength of oncology pipeline

ORLANDO, Fla., May 14, 2005 /PRNewswire-FirstCall via COMTEX/ --

Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced positive results from studies of VELCADE in lymphoma and lung cancer at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place this week in Orlando, Florida. Data for MLN2704, the Company`s drug candidate for prostate cancer, were also presented. Results included:

* In relapsed patients with mantle cell lymphoma (MCL), interim results of a multicenter phase II study of single-agent VELCADE showed median survival had not been reached after 10.5 months of follow-up, and demonstrated an overall response rate of 42 percent; * In non-small cell lung cancer (NSCLC), final data from the single-agent arm of the multicenter phase II trial of VELCADE with or without docetaxel showed a response rate and overall survival comparable to approved agents for use in second-line lung cancer; and * In patients with late-stage, hormone-refractory prostate cancer, interim phase I/II results of MLN2704 showed four of six patients receiving a high dose achieved a reduction in prostate specific antigen, including two with a greater than 50 percent reduction. (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
"These data demonstrate the growth potential of VELCADE and the strength of the Company`s development programs in several areas including non-Hodgkin`s lymphoma," said David Schenkein, M.D., senior vice president, clinical research, Millennium. "The early mantle cell data is consistent with results from four previously presented trials and is particularly exciting considering that these were heavily pre-treated patients and the toxicities were predictable and manageable."

VELCADE is approved in the U.S. for the treatment of patients who have received at least one prior therapy. Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) continue to investigate VELCADE globally in phase I, II and III clinical trials in both hematologic and solid tumors, including front-line MM, non-Hodgkin`s lymphoma and lung, prostate and ovarian cancers.

VELCADE(R) (bortezomib) for Injection in Relapsed MCL (ASCO Abstract 6563)

The second-stage interim analysis of the PINNACLE phase II study led by Richard Fisher, M.D., University of Rochester, and presented by Andre Goy, M.D., Hackensack University Medical Center, Hackensack, NJ, showed the median survival for patients had not been reached at 10.5 months of follow up. Preliminary results from 48 evaluable patients included:

* Overall response rate of 42 percent with a complete and unconfirmed complete response rate of eight percent; * Median duration of response was 6.2 months and median time to progression was 4.3 months; * Patients received 1.3 mg/m(2) of VELCADE for a median of 4.5 cycles; and * Adverse events were similar to those observed in other clinical trials and toxicities were found to be predictable and manageable and included fatigue, peripheral neuropathy and gastrointestinal events.
Millennium was granted fast track status by the FDA for VELCADE in MCL in November 2004. In June, the Company will be presenting additional data from other lymphoma trials at the 9th International Conference on Malignant Lymphoma in Lugano, Switzerland.

VELCADE in Second-Line NSCLC (ASCO Abstract 7034)

Data from a multicenter phase II study, led by Joan Schiller, M.D., University of Wisconsin Comprehensive Cancer Center, and presented by Michael Fanucchi, M.D., Winship Cancer Institute, Emory University, Atlanta, GA, were reported. Investigator-assessed responses included:

Single agent results (n=75) * Median survival of 7.4 months and one-year survival of 39 percent; * Approximately eight percent achieved a partial response, and disease control rate (stable disease or better) was 29 percent; and * Median time to progression of 1.5 months. Combination with docetaxel results (n=80) * Median survival of 7.8 months and one-year survival of 33 percent; * Approximately nine percent achieved a partial response and disease control rate was 54 percent; and * Median time to progression of 4 months.
Patients in the study received 1.5 mg/m(2) of VELCADE as a single agent biweekly or 1.3 mg/m(2) of VELCADE biweekly plus 75mg/m(2) of docetaxel on day one of every three weeks. Patients received a median of two cycles. Toxicities were manageable and adverse events were similar to those observed in other clinical trials of VELCADE such as gastrointestinal symptoms, fatigue and peripheral neuropathy.

Millennium and J&JPRD remain committed to further development and plan to commence randomized, phase II trials of VELCADE in combination with Tarceva (erlotinib) and Alimta (pemetrexed), two new therapies in the treatment of NSCLC. The companies also recently announced the initiation of the phase II PEAK trial in brochioloalveolar carcinoma.

MLN2704 in Late-stage Hormone Refractory Prostate Cancer (ASCO Abstract 4615)

Preliminary data from an ongoing multicenter, open label phase I/II clinical trial led by Howard Scher, M.D., Memorial Sloan-Kettering Cancer Center, and presented by Matthew Milowsky, M.D., Weill Medical College of Cornell University, were reported. Responses were evaluated based on a sustained 50 percent prostate specific antigen (PSA) decline and by measurable disease (RECIST criteria). Investigators reported the following results:

* Four of six patients receiving MLN2704 at 330mg/m(2) achieved a greater than 25 percent reduction in PSA, two of which achieved a greater than 50 percent reduction; * In the study overall (n=29), three patients achieved a decrease of PSA greater than 50 percent that was sustained 10 weeks in one patient and greater than 31 weeks in another patient. Five additional patients achieved a decrease of PSA between 25 and 50 percent that was sustained between four and 13 weeks; * Of the seven patients with measurable disease, four achieved stable disease by RECIST criteria; and * Toxicities have been generally low-grade (Grade 1 and 2) and manageable, including neutropenia, neuropathy, fatigue and gastrointestinal symptoms; the only dose limiting toxicity was increased serum alanine transaminase.
"MLN2704 is a conjugated monoclonal antibody that shows activity in prostate cancer tumors in a novel way," said Howard Scher, M.D., Chief of Genitourinary Oncology at Memorial Sloan-Kettering Cancer Center in New York, and the study`s lead investigator. "We are continuing with early phase I/II trials to assess the optimal dose and schedule of MLN2704."

About VELCADE(R) (bortezomib) for Injection

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE in a phase III study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%), anorexia and appetite decreased (34%), parasthesia (27%), dysesthesia (27%), anemia and headache (26%), and cough (21%). 14% of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%), and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea, pneumonia (4%), and vomiting (3%).

VELCADE(R) (bortezomib) for Injection is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 46 countries worldwide, including the U.S., European Union and a number of countries within Latin America and South-East Asia.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About MLN2704

MLN2704 is composed of a deimmunized monoclonal antibody (MLN591) directed at prostate specific membrane antigen (PSMA) conjugated to the chemotherapeutic agent DM1. MLN2704 binds to PSMA, which is rapidly internalized into the cell delivering a lethal dose of chemotherapy directly to prostate cancer cells. Unlike the enzyme PSA which circulates in the blood, PSMA is a protein expressed on the cell surface of virtually all prostate cancer cells and its abundance on the cell surface increases as the disease progresses and becomes refractory to hormonal therapy. PSMA has little expression in normal tissues.

In April 2001, Millennium entered into an agreement with BZL Biologics, L.L.C., for the joint development and commercialization of antibody-based therapeutics targeting PSMA, including both chemotherapeutic agent conjugated and radio-labeled products. These products include MLN2704 and MLN591RL. Millennium currently has exclusive development and worldwide marketing rights to these products. To develop MLN2704, Millennium conjugates the chemotherapeutic agent DM1 -- licensed from ImmunoGen, Inc. -- to the MLN591 antibody, which targets PSMA. DM1 was developed by ImmunoGen specifically for antibody-directed delivery to tumor cells.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery and development of products and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE(R) (bortezomib) for Injection and INTEGRILIN(R) (eptifibide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editor`s Note: This release is available under the Media section on the Company`s website at http://www.millennium.com.

ASCO Abstracts: 6563, 7034, 4615 Contacts: Theresa McNeely (media) Kyle Kuvalanka (investor) [phone] [phone]

SOURCE Millennium Pharmaceuticals, Inc.

Theresa McNeely, media, [phone], or Kyle Kuvalanka, investor, [phone], both of Millennium Pharmaceuticals, Inc. http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

[schakal23]

malsehen wie die kurs heute auf diese nachricht in usa reagiert

[Snake3000]

Eine spitzen Reaktion (kopfschüttel)

[schakal23]

mensch warum reagiert so den kurs ? ist doch keine schlechte nachricht

hat der markt mehr erwartet?

[jm78]

Lieber Schakal 23,
das Problem ist, dass Mille jegliches Vertrauen verspielt hat. Guck dir den Chart der letzten Jahre an und du weißt warum. Hier helfen nur noch gute Zahlen und ein positiver Ausblick aber wie gesagt, darauf vertraut bei denen keiner mehr.

Trotz dem Kopf hoch und viel Glück

Gruß
JM78

[schakal23]

man ist das langweillig hier gewordendie aktie will sich garnicht bewegen

[jm78]

lieber schakal23,
wenn die mille aktie mal wieder etwas steigt und das wird bestimmt irgendwann so sein, werden wir wieder viel betrieb in diesem forum haben. dann werden etliche schwachmaten wieder tipps geben und uns wissen lassen wie clever sie all die monate ja sogar jahre waren. viele schämen sich für den kack den sie hier so erzählt haben.
viele sind ratlos und warten nur auf bessere zeiten.
halte durch und bleib am ball.

gruß
JM78

[schakal23]

du hast recht .ich werde noch drin bleiben aber wie lange weiss ich noch nicht.bei diesen kurs bin ich fast gar nicht in minus "noch" gott sei dank

[mountainbiker]

Jetzt hängt die schon wieder bei 8 $. Und das nach der Nasdaq Rally der letzten Wochen...

[blb]

Selbst nach den News heute im Minus! Der Kursverlauf ist wirklich eine einzige Enttäuschung. Da verlier selbst ich langsam die Geduld...

Positiv ist, das ich wenigstens noch nicht nachgekauft habe. Hab dem Braten nicht getraut...

Grüße
blb

[schakal23]

langsam verlieren alle die hoffnung es müss was positives hier sonst sehen wier wider die 5 euro marke

[schakal23]

was ist los heute?

schlissen wir über die 8$ marke

[schakal23]

doch nicht gehalten knap da drunter

[schakal23]

Symbol Last
Sale Change
Net / % Share
Volume Market
MLNM $ 8.10 0.14 1.76% 3,639,971 NASDAQ-NM

na wier sagtes den heute doch über 8$ geschlossen und hohe vollumen

[Isabartels]

New England Journal of Medicine Publishes Studies of VELCADE® (bortezomib) for Injection in Multiple Myeloma and MLN02 in Ulcerative Colitis
VELCADE demonstrated survival advantage in relapsed multiple myeloma patients; MLN02 showed statistical significance in achieving remissions in ulcerative colitis

CAMBRIDGE, Mass., June 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the publication of results from two clinical trials in this week`s New England Journal of Medicine. The first publication reports results from the phase III APEX study which showed VELCADE was superior in survival, time to disease progression, and response rates compared to standard of care, high-dose dexamethasone, in patients with relapsed multiple myeloma (MM). Results from a second study, published in the same issue, detail findings from a randomized phase II trial of the investigational drug MLN02 in patients with ulcerative colitis that demonstrated statistically significant improvements in remission rates in patients compared to placebo, the trial`s primary endpoint.

"We are delighted to have two studies published simultaneously in the prestigious New England Journal of Medicine," said Bob Tepper, president, research and development, Millennium. "We believe it is a testament to the potential of VELCADE to change the treatment paradigm in multiple myeloma. The MLN02 study results demonstrate the importance of this first-in-class drug as a potential novel treatment for ulcerative colitis patients and exemplify the quality of our R&D pipeline."

The APEX study was halted at interim analysis in December 2003 at the recommendation of an independent Data Monitoring Committee due to significant prolongation of time to disease progression and significantly improved overall survival. Based on these study findings, the U.S. Food and Drug Administration approved a supplemental New Drug Application in March 2005 for VELCADE use in MM patients who have received at least one prior therapy. To date, more than 24,000 patients have been treated with VELCADE in more than 50 countries. Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) are currently investigating the potential benefit of VELCADE for the treatment of MM patients in the front-line setting in multiple phase III registration trials for MM. Millennium and J&JPRD are assessing VELCADE globally in other hematologic and solid tumors including non-Hodgkin`s lymphoma and lung, prostate and ovarian cancers.

VELCADE® (bortezomib) For Injection APEX Trial Confirms Survival Benefit

The APEX trial was conducted at 93 centers in North American, Europe and Israel and enrolled 669 MM patients who had received one to three prior therapies and randomized them to either treatment with single agent VELCADE or high-dose dexamethasone. Results from 627 evaluable patients (315 treated with VELCADE and 312 treated with dexamethasone) after a median 8.3 months follow- up included:

* Statistically significant survival advantage for patients treated in the single agent VELCADE arm which was maintained even though 44 percent of patients crossed over to receive VELCADE after experiencing progressive disease on the dexamethasone arm;

* One-year survival rate with VELCADE was 80 percent compared to 66 percent with dexamethasone;

* Complete plus partial response rate with VELCADE was 38 percent compared to 18 percent with dexamethasone;

* Statistically significant higher complete and near complete responses (13 versus two percent) were also found with VELCADE; and

* Median time to progression was improved by 78 percent (6.2 months on VELCADE versus 3.5 months for dexamethasone).

"The study results highlight the advantage of VELCADE in extending the survival of relapsed multiple myeloma patients," said Dr. Paul Richardson, M.D., Dana Farber Cancer Institute and author of the paper. "Also exciting are the recent results of investigations of VELCADE based regimens in the front- line setting that have suggested the potential of VELCADE to improve the quality of responses when received earlier in treatment."

A prospective analysis was conducted in patients who had received only one prior therapy (38 percent of the overall patients in the study) which also demonstrated significantly improved outcomes. Importantly, results showed that outcomes improved when VELCADE was given to patients in earlier lines of therapy. Results included:

* Patients treated with VELCADE versus dexamethasone demonstrated statistically improved survival;

* Forty-five percent of patients achieved a complete or partial response with VELCADE compared to 26 percent for dexamethasone; and

* Median time to progression was also significantly improved (7.0 months on VELCADE versus 5.6 months for dexamethasone).

Adverse events reported in patients treated with VELCADE were as previously reported and included gastrointestinal events, fatigue, neuropathy, pyrexia and hematologic toxicities. Patients treated with dexamethasone reported predictable adverse events including fatigue, insomnia, anemia and diarrhea. The duration of treatment each patient received, rate of serious adverse events and rate of discontinuation due to an adverse event were similar in both treatment groups.

MLN02 Phase II Study Results Show Statistical Improvement Across All Endpoints

Also published in this week`s New England Journal of Medicine were results from a double-blind, multicenter phase II trial of the Company`s investigational drug MLN02 in patients with ulcerative colitis. A total of 181 patients with moderately active ulcerative colitis were randomized to receive either a 0.5 mg/kg dose of MLN02, a 2.0 mg/kg dose of MLN02 or placebo at days one and 29. The primary outcome was clinical remission at week six, as defined as a score of zero or one on the Ulcerative Colitis Clinical Score (UCCS) and a score of zero or one on the Modified Baron Score (MBS) with no evidence of rectal bleeding at the study`s conclusion. Key findings included:

* Clinical remission was achieved in 33 percent of the patients receiving 0.5 mg/kg of MLN02 and 32 percent of the patients receiving 2.0 mg/kg of MLN02 versus 14 percent in those who had received placebo. These remission rates are statistically significant;

* Endoscopic remission was achieved in 28 percent of patients receiving 0.5 mg/kg of MLN02 and 12 percent of patients receiving 2.0 mg/kg of MLN02, compared to eight percent of those who received placebo. An endoscopic remission is defined as a MBS of zero;

* Statistically significant clinical response was achieved in 66 percent of patients (0.5 mg/kg) and 53 percent (2.0 mg/kg) in the treatment groups, compared to 33 percent of those who received placebo. Clinical response is defined as an improvement of three or more points on the UCCS from baseline; and

* The drug was generally well tolerated. Serious adverse events were comparable in the three treatment groups and were mainly related to exacerbations of underlying ulcerative colitis, which occurred in 15 percent of patients in the two treatment groups, compared to 10 percent in the placebo group. An infusion reaction occurred in one MLN02 treated patient who developed hives and mild angioedema.

"These data provide additional clinical validation to the benefits of inhibiting cell trafficking in treating chronic inflammatory diseases," said Nancy Simonian, M.D., senior vice president, clinical development, regulatory and medical affairs, Millennium. "MLN02 is particularly exciting because it selectively inhibits cell trafficking to the GI tract and not to other organs which may reduce the risk of infections. We are currently working on a commercially scalable cell line and hope to initiate new studies in 2006."

About VELCADE® (bortezomib) for Injection

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE in a phase III study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%), anorexia and appetite decreased (34%), parasthesia (27%), dysesthesia (27%), anemia and headache (26%), and cough (21%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%), and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea, pneumonia (4%), and vomiting (3%).

VELCADE® (bortezomib) for Injection is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD). Millennium is responsible for commercialization of VELCADE in the U.S.; Ortho Biotech and Janssen-Cilag are responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 50 countries worldwide, including the U.S., European Union and a number of countries within Latin America and South-East Asia. VELCADE is also approved in the European Union as a second-line treatment. It is indicated as a monotherapy for use in patients with progressive MM who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation. Millennium and J&JPRD continue to investigate VELCADE globally in phase I, II and III clinical trials in both hematologic and solid tumors, including front-line MM, non-Hodgkin`s lymphoma and lung, prostate and ovarian cancers.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About MLN02

MLN02 is an investigational, novel monoclonal antibody that binds to alpha 4 beta 7, a T-cell integrin (a cell surface protein). In laboratory studies, the mechanism of action has shown to prevent the migration of T-cells specifically to the GI tract. Increased T-cell trafficking is believed to play a role in the pathogenesis of inflammatory bowel disease (IBD), including conditions such as ulcerative colitis and Crohn`s disease.

[Isabartels]

Und warum schmiert dr Kurs ab???????????????

[Lobster333]

Wo schmiert der Kurs ab???
In meinem Chart geht die Kurve schön nach oben.

Gruß
Lobster

[schakal23]

hallo

kann jemand bitte sagen was das ganze ungefehr heist?

danke
vielleicht lege ich noch par nach

[mobilepro]

hab mir gestern auch mlnm aktien gekauft !

der ceo mark levin gab im jahr 2000 ein interv.
wo er sagte das sein unternehmensziel ist im jahr 2010
unter den 10 grössten pharmawerten aufzusteigen und
einen boersenwert von 100 millarden dollar,bis dahin
haben wir dann reichlich potential!

das enspricht einer vervierzigfachung des aktienkurses

[Snake3000]

Nachbörslich schon auf 8,85$

Diese Nachricht hat uns diesen wunderbaren Kursanstieg beschert!

Millennium Gets Two Positive Reports
Thursday June 16, 2:08 pm ET
Millennium Pharma Gets Studies Published in New England Journal of Medicine for Velcade, MLN02

CAMBRIDGE, Mass. (AP) -- Millennium Pharmaceuticals Inc. said Thursday that two of its studies showing favorable results for its Velcade cancer treatment and an investigational bowel inflammation treatment have been published in the New England Journal of Medicine.

ADVERTISEMENT
In a clinical trial following 669 patients with multiple myeloma, a cancer of the bone marrow, researchers found that 80 percent of patients given Velcade were alive after a year compared with the 66 percent of patients given high doses of dexamethasone, a steroid often used in cancer treatments. Patients in the trial had received one to three other treatments for the disease.

The study also found that 38 percent given Velcade responded completely or partially to the treatment compared with 18 percent in the dexamethasone group. The company said Velcade slowed progression of the disease by 78 percent, with the disease progressing after 6.2 months in Velcade patients compared with 3.5 months in dexamethasone patients.

The company halted the trial prematurely in December 2003 after it was found that Velcade outperformed the control group.

The articles follow a publication last week of a Velcade study in a British medical journal showing that up to 95 percent of previously untreated multiple myeloma patients responded favorably to the treatment when taken alone or with other medications.

The second study concerned Millennium`s experimental ulcerative colitis treatment MLN02. The mid-stage study found that up to 33 percent of patients receiving MLN02 achieved remission of the disease compared with 14 percent in the placebo group. Also, up to 66 percent of patients in the MLN02 group responded to the treatment versus 33 percent who responded to placebo.

MLN02 is an antibody that binds to cell surface proteins that prevent cells believed to cause the disease from migrating to the gastrointestinal tract.

Bin mal gespannt, was morgen noch so geht!

Schön Gruß

Snake3000

[Snake3000]

Nachtrag:

Kann mir vorstellen, dass jetzt einige institutionelle Adressen sich wieder eindecken müssen. (short squeeze) Der Kurs scheint eine gewisse Dynamik zu entwickeln.

Gute Nacht

[Snake3000]

NB: 9,30$

[Boersenkrieger]

Wow ! NB 9,37 $

die erste porion MLNM liegt bei mir nun schon 5 jahre im depot ...nachgekauft bis heuer -50% depotstand... na ich werd doch nicht mal wieder ins plus gleiten in den nächsten jahren
war ja bislang alles sehr enttäuschend für dieses patent- und plattformmonster dem eine glorreiche zukunft zugesprochen wurde... aber wer weiß vielleicht gibt´s ja doch noch mal nen ver40facher

allerdings... wenn ich die news so einschätze mal... schöne news aber auch keine überragenden oder ? ...wobei ok... +10 bis +15% sind da wohl schon gerechtfertigt

[amorphis]

@mobilepro... lol lol lol ein zitat aus dem jahre 2000...mehr ist da nicht zu sagen!

[mobilepro]

ja timming ist an der boerse alles !


eigentlich bin ich mehr in pennystocks
aber die mlnm story überzeugt mir!

miv therapeutics psivida und starpharma gte und mobl
sind meine favoriten!

[schakal23]

schön zu sehen wie mlnm ab geht aber ich will nicht bis 2010 warten

danke für die übersätzug

[blb]

Sieht nach Doppelboden aus, wenn wir die 9$ nachhaltig knacken!



Grüße
blb

[Nerven_wie_stahl]

geiles teil heute
besser gehts net,vorgestern eingestiegenfast perfekt

[jm78]

hi schakal23,
denk doch bitte mal an (ich glaube mein letztes) posting . IST DAS NICHT WITZIG ALTER JUNGE

[schakal23]

@jm78

du hast recht mein gott das ding geht ja richtig ab schon lange nicht so ein vollumen an ein tag gesehn bei mlnm

die frage ist bis wo geht die reise hin bis 10 ?euro

[schakal23]

last sale

mlnl 9,41 13.8% 53,103,557 Nasdac

[bonDiacomova]

Symbol: MLNM
Last Trade: 9.56 Jun 17

After Hours Change: 0.15 (1.59%)

Today`s Change: 1.29 (15.60%)

Bid: 9.58
Ask: 9.60

[Knaller51]

[blb]

Der gestrige Kursanstieg passt endlich mal zum Threadtitel!

Bin mal gespannt wie es weitergeht!

Grüße und schönes Wochenende an alle!
blb

[Boersenkrieger]

@mobilepro... lol lol lol ein zitat aus dem jahre 2000...mehr ist da nicht zu sagen!

na warte mal ab wir sind nicht mehr im jahr 2000... die die an der börse groß kasse machen steigen ein bevor ES losgeht und ES könnte wieder losgehen... leider haben wir allerdigns probleme mit dem öl... deswegen ist es schwer zu sagen wo lang es gehen wird

[schakal23]

ich bin gespant auf heute. wenn wir in plus schliessen denn ist das ein gute zeichen dann marschieren wir auf die 10€

[schakal23]

bis jetzt sieht super aus mal sehen bis zum scluss was übrig bleibt

[schakal23]

man verdammt immer wider nach par porzenete fangen alle an gewinn mit zunehemen. mal sehen was bleibt übrig heute ich habe gedacht diese woche knacken wir die 10$ marke

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/21/2005 (14:20 ET) MLNM: Volume Spike; 42% > 20-adsv, Stock -6.46% - Knobias



06/21/2005 (09:48 ET) EARLY MKT: Upgraded Semis Lift Tech Sector - Knobias



06/21/2005 (06:14 ET) MLNM: mentioned in today`s Wall Street Journal - Knobias



06/20/2005 (13:38 ET) MARKET: Oil Moves Back to $59, Stocks Drift Lower - Knobias



06/20/2005 (10:38 ET) MARKET: $59 Crude Oil Weighing on Broad Market - Knobias



06/20/2005 (10:25 ET) MLNM: Volume Spike; 5% > 20-adsv, Stock +4.14% - Knobias



06/20/2005 (10:07 ET) Traders Celebrate 14th Straight Month of 100% Profitability With "Stock Alerts" - Market Wire



06/20/2005 (06:24 ET) MLNM: mentioned in today`s Wall Street Journal - Knobias



06/17/2005 (22:30 ET) Millennium jumps on positive view of drug news - UPDATE 1 - AFX News - Europe



06/17/2005 (21:39 ET) Millennium jumps on TV plug, drug news - AFX News - Europe



06/17/2005 (19:46 ET) Big Movers in the Stock Market - Associated Press Online



06/17/2005 (18:04 ET) Big Movers in the Stock Market - Associated Press Online



06/17/2005 (17:19 ET) Millennium jumps on positive view of drug news - UPDATE 1 - AFX News - UK



06/17/2005 (16:59 ET) Millennium jumps on positive view of drug news - UPDATE 1 - Xinhua News Agency - Financial Network



06/17/2005 (16:28 ET) Millennium jumps on TV plug, drug news - AFX News - UK



06/17/2005 (16:27 ET) MARKET: Indices Finish Higher as Oil Closes at Record Highs - Knobias



06/17/2005 (15:17 ET) Millennium jumps on TV plug, drug news - Xinhua News Agency - Financial Network



06/17/2005 (14:06 ET) Big Movers in the Stock Market - Associated Press Online



06/17/2005 (11:05 ET) WallStreetGrapevine: "Stocks on the Rise" - M2 Communications



06/17/2005 (10:27 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



06/17/2005 (10:23 ET) MLNM: New Form 3 Filed, Beneficial Ownership Initial Filing - Edgar



06/17/2005 (09:50 ET) MLNM: Volume Spike; 58% > 20-adsv, Stock +12.21% - Knobias



06/17/2005 (09:10 ET) MARKET: Stocks Poised for a Strong Open - Knobias



06/17/2005 (08:45 ET) MLNM: Filed New Form 8-K, Material Event Disclosure - Edgar



06/17/2005 (08:01 ET) Millennium Announces Appointment to Board of Directors - PR Newswire

[jm78]

Was soll das? Erneut ein Beitrag den nur der Autor und 3 Eingeweihte verstehen.

[schakal23]

die 9$ hält auch nicht mal sehen wie sieht aus auf schluss basis

[Presler]

[posting]17.012.025 von schakal23 am 27.06.05 17:48:07[/posting]weiss jemand wann neue Produkte von Millennium auf den Markt kommen ? Den "fairen Wert" sieht Goldman Sachs ja bei 7,5$, frage mich nur,nach was die bewerten?

[mobilepro]

2007 bis 2009 will mlnm bis zu drei substanzen
pro jahr auf dem markt bringen !

[blb]

@mobilepro: Ist doch viel zu viel, haste da ne Quelle? Der Fokus liegt zur Zeit ganz klar auf Velcade in den verschiedenen Indikationen. Wo sollen bei der Pipeline bitte 3 Medikamente pro Jahr herkommen?

Hammermeldung heute!
Neuer CEO, ne Frau! Vielleicht bringts ja was...

Millennium Announces New CEO
WEDNESDAY, JUNE 29, 2005 7:01 AM
- PR Newswire

CAMBRIDGE, Mass., June 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (MLNM) today announced that Deborah Dunsire, M.D., an accomplished pharmaceutical executive and head of Novartis Pharmaceuticals Corporation`s North American Oncology Operations, has been named as the new president and chief executive officer of Millennium. Dr. Dunsire will also be elected to the Company`s Board of Directors. She plans to assume her duties by August 1, 2005. Dr. Dunsire will succeed Mr. Mark Levin, co-founder and CEO since the Company`s inception. Mr. Kenneth Weg, a member of the Board of Directors since 2001, will become the new non-executive chairman. Mr. Levin will remain an active member of the Board.


"Deborah has an impressive track record in building and motivating multi- functional organizations to deliver significant revenues and sustainable growth, two key goals for Millennium," said Mr. Weg. "Her depth of experience and proven leadership in the pharmaceutical industry and repeated success in commercializing products will enable Millennium to optimize the potential of its novel therapies and capitalize on the Company`s strengths in innovative drug discovery and development."

Dr. Dunsire has nearly 20 years of experience in the commercial, operational, clinical and scientific aspects of a world-leading pharmaceutical business. She led the Novartis U.S. Oncology Business in a competitive market, achieving more than 25 percent compounded annual growth rate over the last eight years. While at Novartis, Dr. Dunsire also played a critical role in the broad development and successful launch of a number of products including Zometa, Femara and Gleevec, and evaluated and implemented key business development initiatives. She was also responsible for managing the merger and significant growth of the combined Sandoz Pharmaceuticals and Ciba- Geigy oncology businesses.

"Millennium is poised for continued growth and I`m excited to be joining at such a pivotal point in the Company`s development," said Dr. Dunsire. "Widely recognized for scientific leadership, entrepreneurial culture and visionary management, Millennium can command a strong commercial presence and leverage its robust product pipeline. I look forward to building on the Company`s rich legacy and track record in bringing breakthrough medicines to patients, while fulfilling its goal of non-GAAP profitability in 2006 and long-term growth."

Dr. Dunsire has served on the U.S. pharmaceutical executive committee at Novartis, was a designated member of the corporate executive group, and a member of the operating committee charged with defining corporate strategy, managing operations and assessing executive performance.

Earlier in her career, Dr. Dunsire was a clinical researcher responsible for the implementation of global phase II and phase III studies across multiple therapeutic areas such as immunology, endocrinology, neurology, dermatology, oncology and transplantation. She has also been a practicing physician.

"Deborah shares an unwavering commitment to making a difference in patients` lives, the Company`s mission since day one," said Mark Levin. "She is dedicated to building a leading biopharmaceutical company and has the commercial and business experience to make it happen for our stockholders, employees, partners and patients."

Acknowledging the exceptional contributions of Mark Levin, Mr. Weg stated, "Mark has been one of the great visionaries in the biotech industry and his passion for the business, amazing energy and ability to motivate people at Millennium has been no less than remarkable. I would like to express the Board`s sincerest appreciation for Mark`s dedication to the Company over the past 12 years, his commitment to patients to deliver breakthrough medicines, and his promise to build value for shareholders."

Mr. Weg has had more than 30 years of experience in the pharmaceutical industry including significant leadership roles at Merck & Co., Inc. and Bristol-Myers Squibb Company (BMS). At BMS he was elected to the Board of Directors in 1995 and became vice chairman in 1999. He also served as president, Worldwide Medicines Group; president, Pharmaceuticals Group; and president of Pharmaceutical Operations. Currently, Ken is chairman of Clearview Projects, a consulting firm which provides partnering and transactional services to biopharmaceutical companies and academic institutions.

Conference Call Information

In conjunction with this news release, Millennium will host a live webcast of its conference call today, Wednesday, June 29, 2005 at 8:00 AM ET. This webcast can be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

This press release contains "forward-looking statements," including statements about the Company`s growth, discovery and development of products and financial results. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward- looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contacts:

Theresa McNeely (media) Kyle Kuvalanka (investors)
[phone] [phone]


SOURCE Millennium Pharmaceuticals, Inc.

Theresa McNeely (media), [phone], or Kyle Kuvalanka (investors),
[phone] both of Millennium


http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.

[blb]

Pipeline:

[mobilepro]

bis zu 3 substanzen das ist schon möglich

10 sind in der klinischen phase
4 in der vorklinischen!

VELCADE FÜR VERSCHIEDEN INDIKATIONEN PROSTATA LUNGENKREBS
ODER LIEG ICH DA FALSCH

[covino02]

...und es geht weiter nach oben.

MLNM USD

12:01:46.107 B 600 9.6400
12:01:46.038 B 400 9.6400
12:01:35.363 S 100 9.6300
12:01:31.437 B 100 9.6400
12:01:31.437 B 100 9.6400
12:01:31.328 B 100 9.6400
12:01:31.328 B 100 9.6400
12:01:31.293 B 100 9.6400
12:01:31.293 B 700 9.6400
12:01:31.117 B 300 9.6400

wann fällt die 10$ ??

[covino02]

akt: 9,67 usd

[schakal23]

oh man was war los gestern vielleicht wegeb diesen hier




Millennium Pharma. underperform
30.06.2005 08:46:17
Rating-Update:
Die Analysten von Friedman, Billings, Ramsey & Co stufen die Aktie von Millennium Pharmaceuticals (ISIN US5999021034/ WKN 900625) unverändert mit "underperform" ein.

Analyse-Datum: 30.06.2005

[covino02]

...dies werden die letzten kurse um die 9,70usd sein.

spätestens nächste woche fällt die 10usd.

also - nochmal letzte gelegenheit zu einstelligen kursen zuzugreifen.

viele grüße
covino

[covino02]

gesagt - passiert:

mlnm:

10:23:38.245 S 100 9.8000
10:23:38.245 S 200 9.8000
10:23:37.231 B 600 9.8000
10:23:37.079 B 400 9.8000
10:23:36.713 B 200 9.7900
10:23:36.713 B 100 9.7900
10:23:36.713 B 162 9.7900

[schakal23]

man es macht kein spass ein tag steigen die da hat man sich noch nicht gefreut da fallen die wider

[Boersenkrieger]

ja... weil der CEO zurückgetreten ist.. schade gerade jetzt wo es fundamental wieder besser aussah... das schadet dem kurs immer, es sei denn der CEO wird als pfeiffe angesehen

[blb]

Falsch Boersenkrieger, nach der Ankündigung, dass ein neuer CEO kommt, stieg die Aktie um 8%. Man war vom alten CEO alles andere als überzeugt, da z.B. das Erreichen der Gewinnschwelle zigmal nahc hinten verschoben wurde.

Grüße
blb

[jm78]

Rating-Update:

Die Analysten von Friedman, Billings, Ramsey&Co stufen die Aktie von Millennium Pharmaceuticals (Nachrichten) (ISIN US5999021034/ WKN 900625) unverändert mit "underperform" ein.

Analyse-Datum: 30.06.2005

[covino02]

heute ausbruch aus der w-formation ??

[schakal23]

könnte hin hauen

[Snake3000]

Ausbruch erst ab 10$. Wird heute nichts mehr. Aber trotzdem gute Wochenperformance!

[schakal23]

hats nicht gereicht. hoffentlich das am montag nicht die wider fällt

[schakal23]

gut gehalten heute mal sehen wie die rest der woche den aussieht

[schakal23]

MLNM
Millennium Pharmaceuticals, Inc. NASDAQ-NM




Back to Headlines | Previous Story



Millennium Initiates Phase II Clinical Trial in Patients With Multiple Sclerosis



- MLN1202 Novel Molecule Believed to be First CCR2 Antagonist Studied in MS -

CAMBRIDGE, Mass., July 11 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a multicenter phase II clinical trial of MLN1202 in approximately 40 patients with relapsing-remitting multiple sclerosis (MS), the most common form of the disease. MLN1202, a novel humanized monoclonal antibody, is designed to block CCR2 chemokine receptors and prevent the infiltration of immune cells into inflammatory sites. The CCR2 chemokine pathway is believed to play a central role in a number of inflammatory conditions, including MS.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

This proof-of-concept study will assess the safety and tolerability of the molecule and determine the effect of MLN1202 on disease activity by magnetic resonance imaging (MRI). Study participants will receive multiple doses of MLN1202 in two dosing regimens over the course of four months. The study will be conducted at sites in Canada and Europe.

"MLN1202 is designed to specifically target the CCR2 receptors found primarily on monocytes and macrophages -- versus all leukocytes -- which may be beneficial in lowering the risk of systemic immune suppression," said Nancy Simonian, M.D., senior vice president, clinical, regulatory and medical affairs, Millennium. "MS remains a significant area of unmet medical need and we are hopeful that the novel mechanism of action of MLN1202 could provide patients with a new treatment option."

About MLN1202

MLN1202 specifically targets CCR2 chemokine receptors found on the surface of a specific subset of leukocyte: macrophages and monocytes. A number of published preclinical studies suggest that chemokine receptors -- such as CCR2 -- play an important role in the inflammatory response, particularly the trafficking of monocytes and macrophages in both normal and pathological states. The expression of these chemokines and their receptors is increased during the acute phase of MS in humans as well as in animal models of MS. As a result, chemokines have become an emerging focus for research into novel therapeutics for MS.

Currently, Millennium is evaluating MLN1202 in a multi-center phase II clinical trial involving approximately 30 patients with rheumatoid arthritis. The first three cohorts have been fully enrolled and MLN1202 appears to be well tolerated with favorable pharmacokinetic and pharmacodynamic profiles. A fourth cohort has been added with data anticipated in 2006. Additional studies of MLN1202 are planned in atherosclerosis and scleroderma.

For more information about MLN1202 clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at [phone] or [phone].

About Multiple Sclerosis (MS)

MS is characterized pathologically by the destruction of myelin sheath tissue, which surround nerve fibers in the central nervous system. It is believed that this tissue damage in the brain and spinal cord of MS patients is caused by an inflammatory response.

More than two million people worldwide are estimated to suffer from multiple sclerosis, which is the leading cause of neurological disability in young adults.(1) MS is the most common inflammatory and neurodegenerative disorder of the central nervous system, including the brain, spinal cord and optic nerves.(2) It is usually diagnosed between age 20 and 40 and is twice as common in women as men.(1)

MS can have a significant impact on patients` social activities, employment and overall quality of life. MS typically presents in relapsing forms. Relapsing-remitting MS is the most common form of the disease. These patients suffer acute attacks (relapses) of neurological dysfunction followed by complete or incomplete remission in function. Over time, the majority of patients develop progressive neurological disability. Patients can experience symptoms ranging from fatigue, tingling, numbness and blurred vision to poor muscle control with partial or complete paralysis, speech or mental impairment.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, cardiovascular, and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products.

References

(1) Multiple Sclerosis International Federation ( http://www.msif.org/en/ms_the_disease/quick_facts.html ).

(2) Multiple Sclerosis International Federation ( http://www.msif.org/en/ms_the_disease/index.html ).

(3) Multiple Sclerosis International Federation ( http://www.msif.org/en/ms_the_disease/types_of_ms.html ).

Editor`s Note: This release is available on the Media section of the Millennium website at http://www.millennium.com

[schakal23]

hoffe ich das wir morgen die 10$marke knacken können ich habe das ganze ein übersätzt mit mein softwar aber ich stelle liebe die garnicht drinn

aber es lest sich gut an kann jemand vielleich was mehr darüber sagen die haben ein neuen versuch gestartet CCR2?

[schakal23]

wann brechen wir die 10$

[schakal23]

heute könneten wir die 10$ brechen es fängt gut an

[Knaller51]

los ab über die 10 Dollar spring

[covino02]

...und immer wieder vereinzelt diese riesigen kauforders - spätestens mitte nächster woche sollten wir die 10usd von oben sehen !!

mlnm - strong buy

[jm78]

Los jetzt ab über die 10 $ hopp.

[Knaller51]

packen wir heute die 10 dollar ich hoffe es

[schakal23]

da hat jemand ein ganze menge gekauft für 10 wir waren schon da aber leider par minuten nur vielleicht kriegen wir noch hin heute sieht nicht schlecht aus

[Knaller51]

der abwärtstrennt ist hinter uns

[Knaller51]

ab in den norden

[Knaller51]

Bullenfalle??????

[schakal23]

handell vollumen werden immer besser ich glaube nächster woche ziel 12$

[blb]

Sieht gut aus, das Dreieck wird nach oben aufgelöst!
Das Gap vom Januar dürfte bald zu sein.



Grüße
blb

[schakal23]

über 4,5 millionen gehandelte stück in zwei stunden

ich glaube wir sehen die 12 diesen woche

[schakal23]

hoffentlich bleiben wir heute über 10$

[schakal23]

was nun hat die 10 gehalten oder wenn genau 10 ist das einbißchen anders das ja ein kunst heute genau am 10 zu schliesen

[schakal23]

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940




1. Name and Address of Reporting Person *

FRIEL ROBERT F 2. Issuer Name and Ticker or Trading Symbol

MILLENNIUM PHARMACEUTICALS INC [ MLNM ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Last) (First) (Middle)

45 WILLIAM STREET 3. Date of Earliest Transaction (MM/DD/YYYY)

7/15/2005
(Street)

WELLESLEY, MA 02481
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $9.94 7/15/2005 A 11667 (1) 7/15/2015 Common stock 11667 $0 11667 D


Explanation of Responses:
( 1) Becomes exercisable for 1/48th of the number of shares subject to the option monthly beginning 07/15/2005.

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
FRIEL ROBERT F
45 WILLIAM STREET
WELLESLEY, MA 02481 X



Signatures

Joel S. Goldberg 7/19/2005
** Signature of Reporting Person Date



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.




--------------------------------------------------------------------------------
End of Filing

© 2005 | EDGAR Online, Inc.

[schakal23]

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940



1. Name and Address of Reporting Person *
Dunsire Deborah
2. Date of Event Requiring Statement (MM/DD/YYYY)
7/18/2005
3. Issuer Name and Ticker or Trading Symbol
MILLENNIUM PHARMACEUTICALS INC [MLNM]

(Last) (First) (Middle)
MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__ X __ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
President and CEO /

(Street)
CAMBRIDGE, MA 02139


(City) (State) (Zip) 5. If Amendment, Date Original Filed (MM/DD/YYYY)



6. Individual or Joint/Group Filing (Check Applicable Line)
_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 2. Amount of Securities Beneficially Owned
(Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
No securities are beneficially owned

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Dunsire Deborah
MILLENNIUM PHARMACEUTICALS, INC.
40 LANDSDOWNE STREET
CAMBRIDGE, MA 02139 X
President and CEO

Signatures

Joel S. Goldberg, Attorney-In-Fact 7/19/2005
** Signature of Reporting Person Date



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.


POWER OF ATTORNEY

I hereby appoint LAURIE B. KEATING, BRUCE LEICHER, JOEL S. GOLDBERG and JEAN L. ERNST, each of them acting singly, my true and lawful attorney-in-fact with full power of substitution, for me and in my name, to sign on my behalf any and all forms required to be filed pursuant to federal securities laws by virtue my position with and my ownership of securities in MILLENNIUM PHARMACEUTICALS, INC. and its affiliated companies, as may be required or appropriate, from time to time, and to file the same with the Securities and Exchange Commission. I grant to each attorney-in-fact full power and authority to do and perform everything requisite and necessary to be done, as fully as I could do in person. I verify and confirm all that each attorney-in-fact, or his or her substitute, may lawfully do or cause to be done by virtue of this Power of Attorney.

This Power of Attorney will continue in effect until I revoke it in writing to the above-named attorneys-in-fact, and each attorney-in-fact is entitled to rely on this Power of Attorney until he or she receives written revocation from me.

Date: July 8, 2005 /s/ DEBORAH DUNSIRE
Deborah Dunsire

[schakal23]

also leute die erste filling habe ich verstanden da ist inseider kauf


Stock option (right to buy) $9.94 7/15/2005 A 11667 (1) 7/15/2015 Common stock 11667 $0 11667 D

die zweite ist irgend ein vollmacht an die anwälte

also wenn dier 11667 st kauft für 9.94$ da sehen wir noch mindesten die 15$ noch wenn nicht mehr was sagt ihr dazu?

[schakal23]

schon über 4 million stück 15$ wir kommen

[Boersenkrieger]

na... sie fangen sich ja so richtig heute

[schakal23]

oh man da kommt bestimmt was auf uns zu oder das waren die beide filling von gestern?

[blb]

Hauptsache wir sehn die einstelligen Kurse nicht mehr! ZIEEEEEEEEEEEEH!

Grüße
blb

[covino02]

was habe ich letzte woche gesagt??

die 10usd fällt - jetzt in grossen schritten auf die 15usd !!

[miristegal]

Na endlich.
MLNM bewegt sich doch.
Allen Investierten VIEEELLL Glück und mir naturlich auch.

MFG

[blb]

So, das Januar-Gap ist zu!

[schakal23]

wie sieht eigentlich jetzt chart teschinich aus bis 18 is doch alles frei oder kann jemand was dazu sagen?

[schakal23]

noch eins jungs diese woche schiessen wir hoch




FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940




1. Name and Address of Reporting Person *

Dunsire Deborah 2. Issuer Name and Ticker or Trading Symbol

MILLENNIUM PHARMACEUTICALS INC [ MLNM ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director _____ 10% Owner
__ X __ Officer (give title below) _____ Other (specify below)
President and CEO
(Last) (First) (Middle)

MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET 3. Date of Earliest Transaction (MM/DD/YYYY)

7/18/2005
(Street)

CAMBRIDGE, MA 02139
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 7/18/2005 A (1) 200000 A $0 200000 D

Common stock 7/18/2005 A (1) 200000 A $0 400000 D


Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common stock $10.00 7/18/2005 A 150000 (2) 7/18/2015 Common stock 150000 $0 150000 D


Explanation of Responses:
( 1) Reflects a grant of restricted stock under the 2000 Stock Incentive Plan which vests under the terms of the employment offer letter and the Restricted Stock Agreement between the Company and Dr. Dunsire. If Dr. Dunsire remains an employee of the Company, 20% of the shares will vest on 07/18/2007, 30% will vest on 07/18/2008 and 50% will vest on 07/18/2009. If Dr. Dunsire`s employment with the Company terminates, other vesting provisions may apply as specified in the agreements.
( 2) Becomes exercisable for 1/4 of the total number of shares subject to the option on 07/18/2006 and for 1/48th of the total number of shares subject to the option monthly beginning 08/18/2006.

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Dunsire Deborah
MILLENNIUM PHARMACEUTICALS, INC.
40 LANDSDOWNE STREET
CAMBRIDGE, MA 02139 X
President and CEO

Signatures

Joel S. Goldberg, Attorney-In-Fact 7/20/2005
** Signature of Reporting Person Date



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.




--------------------------------------------------------------------------------
End of Filing

© 2005 | EDGAR Online, Inc.

[schakal23]

Symbol Last
Sale Change
Net / % Share
Volume Market
MLNM $ 10.59 0.71 7.19% 18,233,613 NASDAQ

über 18 million st

[aalerich]

der Ausbruch aus der bullischen Keilformation war ja
wie aus dem Lehrbuch.
Aber für weitere gute Kurse brauchen wir auch ein vernünf-
tiges Qergebnis.
Wann kommt das eigentlich ?

[covino02]

heute noch GRÜN !!!

[hevchen]

Q2 2005 Millennium Pharmaceuticals Earnings Release
Date: July 28th, 2005

hoffe der Umsatz und gewinn steigt stark, dann ist der Anstieg der letzten tagen mehr als gerechtfertigt und dann könnten wir noch sehr viel höhere kurse sehen..

gruss

hevchen

[blb]

Gewinn ist gut, des dauert noch a bisserl!

Grüße
blb

[mmfriend]

Heute technische Reaktion oder Vorwegnahme schlechter
Unternehmensdaten II Q.? Weitere Kursverluste möglich
wenn Widerstände 10,12-10,69 fallen. Dieses stark volatile
Papier ist unberechnebar. Schade nach der Permormance der
Vortage :O

[Snake3000]

Diese NAchricht kam nachbörslich.

Schering-Plough to Acquire From Millennium Exclusive U.S. Marketing Rights for INTEGRILIN(R) (eptifibatide) Injection
Friday July 22, 4:01 pm ET
- Millennium to receive upfront payment and royalties on U.S. market-leading CV drug -

KENILWORTH, N.J. and CAMBRIDGE, Mass., July 22 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP - News) and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced an agreement to restructure their collaboration for cardiovascular drug INTEGRILIN to optimize the growth potential of this U.S. market-leading GP IIb-IIIa inhibitor. Under the new relationship, Schering-Plough will acquire exclusive development and commercialization rights to INTEGRILIN in the U.S. Schering-Plough and Millennium have been co- promoting INTEGRILIN in the United States and sharing profits since 2002.

Under the terms of the agreement, Schering-Plough will pay to Millennium an upfront payment of $35.5 million and royalties over the U.S. lifespan of INTEGRILIN. In 2006 and 2007, minimum royalty payments for each year are set at $85 million, with some extraordinary conditions that could reduce these minimums. In addition, Schering-Plough will pay to Millennium approximately $45-50 million for the purchase of existing INTEGRILIN inventories. The agreement is subject to federal antitrust review under the Hart-Scott-Rodino Act and is expected to become effective September 1, 2005.

"Acquiring the balance of U.S. rights to INTEGRILIN will give us direct control of this important therapy in its largest market. This is yet another long-term action we are taking to increase our importance to health providers and patients and to become a global leader in the very important area of cardiac care," said Fred Hassan, Schering-Plough chairman and CEO. "We have said before that building strength in our cardiovascular portfolio would be a key driver of our Action Agenda to transform Schering-Plough into a high- performance company for the long term. Our announcement on INTEGRILIN today comes as we continue to see growth of the cholesterol-lowering agents VYTORIN and ZETIA, and as our innovative thrombin receptor antagonist continues in early-stage trials. We are moving steadily toward our goal."

"For Millennium, this new agreement allows the Company to focus its commercial infrastructure on oncology while providing a significant revenue stream from INTEGRILIN to support development of VELCADE and other molecules in the Company`s pipeline," said Mark Levin, retiring chief executive officer, Millennium. "This transaction demonstrates our continued commitment to making strategic business decisions in the best interest of patients and shareholders."

Strategic Impact for Schering-Plough

Schering-Plough said the near-term impact of the new agreement on its earnings is expected to be relatively neutral. Schering-Plough`s current expectations under the agreement include:

* A stronger foundation on which to build and expand Schering-Plough`s
cardiovascular portfolio, and to increase the company`s long-term
relevance to customers in this large sector;

* More effective and direct control over the management of the U.S.
INTEGRILIN® (eptifibatide) INJECTION franchise, allowing for greater
efficiencies;

* Increased flexibility to optimize sales force effectiveness for
INTEGRILIN and other cardiovascular products, and to gain additional
product promotion; and

* The potential for improved INTEGRILIN profitability over time, with the
product under the management of one company rather than under two.

In assuming these exclusive U.S. commercialization responsibilities, Schering-Plough also plans to integrate into its U.S. Acute Coronary Syndrome field force a significant number of Millennium U.S. sales representatives and managers currently assigned to INTEGRILIN® (eptifibatide) Injection. Schering-Plough will continue to be responsible for commercializing the product in Canada and other international markets excluding Europe. Schering- Plough has been co-promoting INTEGRILIN in the United States and sharing profits since 1998, initially with COR Therapeutics, Inc. and then with Millennium when COR merged with Millennium in 2002.

INTEGRILIN and Schering-Plough`s thrombin receptor antagonist (TRA) represent potentially complementary therapies in cardiovascular treatment. INTEGRILIN is most often used as an acute treatment in the hospital setting, in interventional cardiology, catheterization labs and emergency rooms for early use for patients with acute coronary syndrome. TRA, a potential oral agent for chronic therapy, is under development for use in the hospital and primary care setting as a once-daily anti-platelet agent to prevent thrombotic vascular events in patients with atherosclerosis that could be administered in combination with other anti-platelet or anti-thrombotic agents, such as INTEGRILIN, in treating acute coronary syndrome.

Schering-Plough reported INTEGRILIN sales of $325 million in 2004, of which $301 million were in the United States. In June 2004, Millennium reacquired European marketing rights to INTEGRILIN from Schering-Plough and licensed those rights to GlaxoSmithKline plc.

Strategic Impact for Millennium

INTEGRILIN has played an important role in the Company`s transition to a fully integrated R&D and commercial biopharmaceutical company. The product provided the capabilities and revenue that helped Millennium establish and grow the critical commercial infrastructure that ensured the successful launch of VELCADE® (bortzeomib) Injection in 2003.

Millennium expects the upfront payment and anticipated royalties from the restructured relationship, combined with the associated cost savings, will be at least equivalent to the value of the current profit share arrangement. Strategically, Millennium expects to:

* Continue to receive a substantial revenue stream while eliminating the
need to further invest its resources into INTEGRILIN sales and
marketing and development activities;

* Capture the opportunity for more efficient management of INTEGRILIN in
the U.S. by placing responsibility with one company; and

* Streamline and focus resources on VELCADE and its pipeline, which are
both critical to the continued success of Millennium.

Conference Call Advisory

In conjunction with this news release, Millennium will host a live webcast of its conference call today, Friday, July 22, 2005 at 4:30 PM ET. This webcast can be accessed by visiting the Investors section of the Company`s website, www.millennium.com. Following the webcast, an archived version of the call will be available at the same address for 30 days.

About INTEGRILIN® (eptifibatide) Injection

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment-elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including in patients undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN therapy. In the registration trials, the majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo.

Mfg
Snake3000

[Snake3000]

positiv

Das dürfte sich positiv auf den Kassenbestand auswirken.

1 Jahr: +80 Mio (35+45)
2 Jahr: +85 Mio
3 Jahr: +85 Mio

gesamt: ca. 250Mio Dollar + weitere noch nicht konkretisierte Zahlungen

Nach dieser Nachricht scheint die Gewinnerzielungsabsicht im Jahre 2006 keine Utopie mehr zu sein.

negativ

Der Umsatz wird drastisch fallen.

Snake 3000

[Snake3000]

Weiter gehts:

Millennium still sees 2005 loss of under $100 mln
Fri Jul 22, 2005 04:25 PM ET
LOS ANGELES, July 22 (Reuters) - Biotechnology company Millennium Pharmaceuticals Inc. (MLNM.O: Quote, Profile, Research) on Friday said it still expects a 2005 loss, excluding items, of under $100 million following a deal to sell marketing rights to anti-clotting drug Integrilin to Schering-Plough Corp. (SGP.N: Quote, Profile, Research)

In a regulatory filing, Millennium said that following the close of the deal its combined research and sales expenses will drop by about 15 percent, reflecting the loss of about 200 jobs.

Dieser Deal scheint kurzfristig sehr positiv aufgenommen zu werden. Der NB Kurs steht mittlerweilen auf 10,50.

Für das zukünftige Potenzial bedeutet die Abtretung der Rechte an Integriling einen Verlust. Sollten sich die Erwartungen rein auf Velcade stützen, frage ich mich wo die exorbitanten Umsätze herkommen sollen, die eine Markkapitalisierung von 3 Mrd Euro rechtfertigen.

Snake3000

[mmfriend]

Die Pipeline und kurzfristige Zulassungen sind ebenso notwendig wie eine nachhaltige erkennbare Strategie im Unternehmenskonzept, die ich zzt. nicht sehe. Der jetzige Deal könnte die Vorbereitung für eine baldige Übernahme von MLNM durch S-P o.a. sein, was mich nicht überraschen würde. Die Analysten werden die Aktie auf Verkauf stellen.
Die kurzfristige Entwicklung bleibt abzuwarten.

MfG

[aalerich]

Vielleicht war das ja auch der Grund für den pull back !
Da haben wohl Investoren schon vorher die Reissleine gezogen.....
Mal sehen wie der deal Montag betrachtet wird. Ich denke,
der deal hat auch positive Effekte. Schliesslich können
die sich jetzt ganz auf ihre pipeline focussieren.

[Koyo1]

wenn ich das richtig verstehe geht es um US Rechte ohne Europa dort hat die Rechte GlaxoSmithKline von Millenium
ändert das etwas


Schering-Plough To Buy Exclusive US Rights To Integrilin



KENILWORTH, N.J. -(Dow Jones)- Schering-Plough Corp. (SGP) agreed to acquire exclusive U.S. rights to develop and market Integrilin, a cardiovascular drug that it co-promotes with Millennium Pharmaceuticals Inc. (MLNM), for an upfront payment of $35.5 million, plus royalties.

In 2006 and 2007, minimum royalty payments are set at $85 million a year, with some "extraordinary conditions" that could reduce these minimum. In addition, Schering-Plough will pay Millennium about $45 million to $50 million to purchase existing inventories of the drug.

Schering-Plough said the near-term impact of the new agreement on its earnings is expected to be "relatively neutral."

Schering-Plough reported Integrilin sales of $325 million in 2004, of which $ 301 million were in the U.S. In June 2004, Millennium re-acquired European marketing rights to Integrilin from Schering-Plough and licensed those rights to GlaxoSmithKline PLC (GSK).

(MORE TO FOLLOW) Dow Jones Newswires

07-22-051642ET

Schering-Plough plans to hire a "significant number" of Millennium U.S. sales representatives and managers currently assigned to Integrilin. Schering-Plough will continue to market the product in Canada and other international markets, excluding Europe.

Schering-Plough has co-promoted Integrilin in the U.S. and shared profits since 1998, initially with COR Therapeutics Inc. and then with Millennium when COR merged with Millennium in 2002.

Besides cost efficiencies and more direct control over the management of the U.S. Integrilin franchise, Schering-Plough is also seeking to build and expand its cardiovascular portfolio, an area that the company sees as a key driver for its future growth.

Meanwhile, Millennium expects the upfront payment and anticipated royalties from Schering-Plough, combined with the associated cost savings, to be at least equivalent to the value of the current profit-share arrangement.

The deal is subject to federal antitrust review and is expected to take effect Sept. 1.

-Judy Lam; Dow Jones Newswires; 201-938-5400; [e-mail]

(END) Dow Jones Newswires

07-22-051647ET

[RAINBOWSIX]

...schlechte nachrichten!

[bonDiacomova]

Username: mmfriend

Registriert seit: 07.05.2004 [ seit 441 Tagen ]


Threads: 0

Postings: 2

zitat : Der jetzige Deal könnte die Vorbereitung
für eine baldige Übernahme von MLNM durch S-P o.a. sein,
was mich nicht überraschen würde.

Die Analysten werden die Aktie auf Verkauf stellen.

zitat ende


leute schickt das arbeitsamt


# 802 - begruendung moeglich
fuer den "inhalt" deines postings ¿?¿

[aalerich]

Die pipeline von Millenium könnte durchaus für Begehrlich-
keiten von Pharma`s in Frage kommen.Das sehe ich auch so.
Die Vermarktung des Medikaments von S P verschafft aber
auch Sicherheit auf der Ertragsseite für Jahre. Dies sollte man nicht ausser Acht lassen. Also nicht gleich den Kopf in den Sand stecken.
Montag sind wir alle schlauer......

[bonDiacomova]

Millennium deal worth as much as $255.5m

Cambridge firm sells rights to heart drug

By Ross Kerber, Globe Staff | July 23, 2005

Millennium Pharmaceuticals Inc. said it agreed to sell additional rights to its Integrilin heart drug to Schering-Plough Corp. in return for $35.5 million in cash and at least $170 million in royalties.

The deal, aimed at minimizing financial risk to Millennium, also lessens the Cambridge biotechnology company`s control over what has been one of its most important drugs and represents a major strategic move by its new chief executive.

Schering-Plough will also pay $45 million to $50 million to buy drug inventories, the companies said.

The deal drew criticism from some analysts frustrated by the lack of detail concerning future royalty payments, though others praised the strategy. Company executives said the move was in the works before Millennium`s founder and previous chief executive, Mark Levin, stepped down to be replaced by Deborah Dunsire recently.

Dunsire said the agreement will bring cash and guaranteed royalties that will help Millennium advance its Velcade cancer drug and other treatments still in development. ``It enables us to reduce our risk and have a steady revenue stream," she said. Also, Dunsire said, Schering-Plough is more focused on cardiovascular medicine.

The shift will eliminate 200 of Millennium`s 1,450 positions, mainly Integrilin`s 170-person sales force spread across the country. Many of those employees are likely to be hired by the larger New Jersey pharmaceutical company. The positions of about 30 marketing personnel, research scientists, and others at Millennium`s Cambridge headquarters will also be eliminated, and the company likely will take an undetermined charge to pay severance costs for those not placed in new jobs.

The move was disclosed after the close of stock trading yesterday. Millennium shares have fallen 17 percent this year as the company tries to achieve its target of becoming profitable in 2006, excepting certain costs.

Approved by the Food and Drug Administration in 1998, Integrilin is injected to prevent the grouping of blood platelets that could form clots and clog coronary arteries. It is used to treat patients with severe chest pain and those undergoing procedures such as angioplasty. It was first developed by COR Therapeutics Inc. of San Francisco, purchased in 2001 by Millennium in a $2 billion deal.

Like other biotechnology companies that need larger partners to sell their treatments, COR had already struck a deal with Schering-Plough under which the two would share profits from domestic sales of the drug. Millennium had continued that arrangement, though in 2004 it reacquired the right to market Integrilin in Europe and then resold the rights to GlaxoSmithKline PLC.

Schering-Plough reported $325 million in Integrilin sales in 2004, up from $306 million in 2003.

But Millennium hasn`t specified how much its Integrilin royalties have totaled to date. Yesterday it declined to talk about how much more money it might receive from Schering-Plough aside from minimum payments of $85 million annually in 2006 and 2007. Only ``extraordinary conditions" could reduce the payments -- for example, if Millennium reached a conflicting deal with another company or the supply of the drug was interrupted. Millennium will remain responsible for its manufacture.

Chief financial officer Marsha Fanucci said, ``We continue to believe in the upside potential of Integrilin."

[bonDiacomova]

Last Sale (After Hours) $10.35

% Change (After Hours) + 4.23%

ShareVolume (After Hours) 1292232

[mountainbiker]

Verdammt! Hätt doch verkaufen sollen heut morgen...

[covino02]

keine panik - mlnm fängt sich doch schon wieder!!

dabei bleiben - die läuft doch erst an...

[schakal23]

wann waren wir unter 10 $ wider?

[Snake3000]

Ruhig Blut - stehen wieder im Plus!

[Snake3000]

10$!!!!!!!!!!!!!!!!!

[FUNDAMENTAL7]

Ist diese Nachricht eigentlicht positiv oder negativ zu

bewerten ? Ich hoffe es heisst nicht dass MLNM nach 2007

keine Einnahmen von Intregin haben wird. Nähere

Infos ?

[covino02]

...weiter aufwärts...

[Snake3000]

Markt konsolidert! - Milli steigt!

So kanns weitergehen!

Snake

[Snake3000]

10,40!!!

Und hier die Begründung für den Kurssprung

Millennium Pharmaceuticals (MLNM: news, chart, profile) gained 5% to $10.32. Analysts at CFSB on Monday upped their price target of the stock to $13 from $11.

[blb]

ZIIIIIIEEEEEEH!!!!

[schakal23]

oh man das ist schöner plus heute

hoffentlich gehen wir nicht wider unter 10

[blb]

12$ könnten noch kommen, dann wirds schon schwerer...

[covino02]

...das gleiche spiel wie gestern - vorbörslich etwas schwächer - danach: auf zu neuen alten höhen!!



die 12usd fallen schneller,als wir annehmen...

[blb]

Zahlen sind nicht gut, v.a. wieder mal Integrilin enttäuscht...

Millennium Reports Second Quarter 2005 Financial Results
THURSDAY, JULY 28, 2005 7:01 AM
- PR Newswire

CAMBRIDGE, Mass., July 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (MLNM) today reported consolidated financial results for the quarter ended June 30, 2005 and provided an update to its financial guidance for 2005.

"Millennium continues to make steady progress toward its short- and long- term financial goals," said Marsha Fanucci, chief financial officer. "We are excited about the future with leadership under Dr. Deborah Dunsire, our new CEO and president, who has a track record of commercial successes. In addition, our newly restructured relationship with Schering-Plough Corporation for INTEGRILIN will provide us with substantial revenue and increased near- term certainty, allowing us to focus resources on VELCADE and the pipeline. Millennium will continue to aggressively pursue appropriate strategic moves such as these to achieve its goals."

2005 Second Quarter Results
-- Net loss on a GAAP basis for the second quarter of 2005 was $44.1
million, or $0.14 per share, compared to $53.9 million, or $0.18 per
share, for the second quarter of 2004. Non-GAAP net loss for the
second quarter of 2005 was $32.6 million, or $0.11 per share, compared
to $20.3 million, or $0.07 per share, for the second quarter of
2004.(1)
-- Total revenue for the second quarter of 2005 was $110.6 million
compared to $145.3 million in the second quarter of 2004. In the second
quarter of 2004, the Company recognized $50.0 million of revenue in
milestone payments received from the Company`s partner, Ortho Biotech
Products, L.P., a member of the Johnson & Johnson Family of Companies,
for VELCADE(R) (bortezomib) for Injection.
-- Net product sales of VELCADE in the second quarter of 2005 increased
26 percent to $43.9 million from $35.0 million in the second quarter
of 2004. As anticipated, during the second quarter of 2005,
inventories were drawn down by one week resulting in an inventory
level of approximately one week in the channel, based on our
consolidated distribution arrangement.
-- Co-promotion revenue for INTEGRILIN(R) (eptifibatide) Injection
decreased two percent to $47.7 million from $48.7 million in the
second quarter of 2004. The decline in co-promotion revenue is due
to a decrease in net expense reimbursement due from the Company`s
collaborator, Schering-Plough. While co-promotion revenue
decreased, U.S. ex-factory sales of INTEGRILIN for the second
quarter of 2005, as provided by Schering-Plough, increased nine
percent to $78.2 million from $71.6 million in the second quarter of
2004.
-- Strategic alliance revenue for the second quarter of 2005 decreased
to $19.1 million from $61.7 million in the same quarter a year
earlier due to revenue from the milestone payments recognized in the
second quarter of 2004, as previously mentioned.
-- Research and Development (R&D) expenses for the second quarter of 2005
decreased 17 percent to $86.9 million from $104.4 million in the second
quarter of 2004. This decrease reflects the impact from site closings
in Cambridge, Massachusetts and San Francisco, California, as well as
the continued focus of resources in key priority areas.
-- Selling, General and Administrative (SG&A) expenses for the second
quarter of 2005 increased 11 percent to $52.1 million from $46.8
million for the second quarter of 2004. This increase is primarily the
result of continued investment to improve the Company`s commercial
productivity and growth prospects.
-- Other income, net for the second quarter of 2005 increased to $12.4
million from $3.6 million in the second quarter of 2004. In the second
quarter of 2005, the Company recognized a realized gain of
approximately $10.5 million from the sale of its investment in
TransForm Pharmaceuticals.
-- As of June 30, 2005, the Company had approximately $589.6 million of
cash, cash equivalents and marketable securities and $105.5 million
outstanding principal amount of convertible debt.

2005 Financial Guidance


The Company is confirming the following full-year financial guidance for 2005 initially outlined in January 2005:

-- VELCADE U.S. net product sales are expected to be in the range of $185
million to $195 million.
-- Net loss on a non-GAAP basis is expected to be under $100 million.
-- Cash, cash equivalents, and marketable securities are expected to be
greater than $500 million at year end with approximately $105.5 million
outstanding principal amount of convertible debt.


As a result of the agreement reached with Schering-Plough on July 22, 2005 to transfer exclusive U.S. commercialization and development rights of INTEGRILIN(R) (eptifibatide) Injection to Schering-Plough, the Company will no longer provide guidance for INTEGRILIN U.S. ex-factory sales. As a result of this transaction, the Company announced an expected 15% reduction in combined R&D and SG&A expense from the current level starting in the fourth quarter of 2005. In addition, the Company has removed its 2005 guidance for net loss on a GAAP basis until the Company has determined the restructuring charges associated with this transaction. The Company expects to update guidance for 2005 GAAP net loss during its third quarter 2005 earnings announcement.

Second Quarter 2005 Highlights

"Millennium is full of opportunities. I will be focused in the near term on driving VELCADE sales and accelerating development of the pipeline," said Dr. Deborah Dunsire, chief executive officer and president. "VELCADE, already the market leader in relapsed multiple myeloma, continues to gain market share in the second-line setting and in the front-line setting, for which we do not promote the product. We`re advancing the development of VELCADE in indications that present larger market opportunities, such as non-Hodgkin`s lymphoma and non-small cell lung cancer, while also bringing forward pipeline assets such as MLN02 for ulcerative colitis, MLN1202 in inflammation, MLN518 for acute myelogenous leukemia, MLN2704 in prostate cancer and MLN8054 for solid tumors, as well as others, to facilitate long-term sustainable growth."

VELCADE(R) (bortezomib) for Injection Highlights

Millennium and its research collaborator, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced the initiation of a third registration-enabling trial of VELCADE in multiple myeloma (MM) patients in the front-line treatment setting. This 480-patient, phase III, multicenter study is being conducted by the Intergroupe Francophone du Myelome (IMF) and led by Professor Jean-Luc Harousseau of the Hospital Hotel-Dieu in France. This clinical trial compares VELCADE plus dexamethasone to standard front-line therapy, VAD (vincristine, adriamycin, dexamethasone), as induction treatment prior to autologous stem cell transplantation. Complete response rates post- induction therapy is the primary endpoint of the study.

Data from several clinical trials underscoring the important potential benefit of VELCADE in multiple myeloma patients in the front-line treatment setting were published in major scientific journals. The British Journal of Haematology published in its June 2005 issue results of two phase II studies of VELCADE in combination with standard therapies showing the highest reported response rates seen to date in the treatment of the disease, with overall response rates ranging from 88 to 95 percent and with complete and near complete responses ranging from 25 to 29 percent. Use of VELCADE allowed for successful stem cell transplants for these patients. Toxicities in these studies were similar to those observed in other studies with VELCADE.

In the June 16, 2005 issue of the New England Journal of Medicine (NEJM), results were published from the phase III APEX trial showing that VELCADE was superior in survival, time to disease progression and response rates compared to standard of care, high-dose dexamethasone in patients with relapsed multiple myeloma. Toxicities in these studies were similar to those observed in other studies with VELCADE.

At the 41st Annual Meeting of American Society of Clinical Oncology (ASCO) in May 2005, data were presented on VELCADE(R) (bortezomib) for Injection in multiple myeloma. Interim results were presented from a front-line multicenter phase II IFM cooperative group trial assessing the efficacy and safety of VELCADE in combination with standard therapy dexamethasone as an induction treatment prior to autologous stem cell transplant. The overall response rate was 67 percent, including complete and partial responses, with complete response and very good partial responses of 21 percent. Very good responses are defined as a 90 percent or better reduction in myeloma tumor burden. Toxicities in these studies were similar to those observed in other studies with VELCADE.

At ASCO, data were presented by Sundar Jagannath, M.D., from St. Vincent`s Comprehensive Care Center in New York, indicating a survival benefit of VELCADE in relapsed multiple myeloma patients despite the presence of a chromosomal 13 deletion, a poor prognostic factor associated with inferior outcomes. Adverse events were similar to those observed in other clinical trials with VELCADE.

In the area of indolent and mantle cell non-Hodgkin`s lymphomas, and Waldenstrom`s macroglubulinemia, VELCADE study results were presented at the ASCO meeting and the 9th International Conference of Malignant Lymphoma (ICML) in Lugano, Switzerland. At the ASCO meeting, interim results of a multicenter phase II study of single-agent VELCADE in relapsed mantle cell lymphoma patients showed median survival greater than 10.5 months and an overall response rate of 42 percent. Toxicities in these studies were similar to those observed in other studies with VELCADE.

At the ICML, data presented included interim results from a multicenter, phase II trial of weekly versus twice weekly dosing of VELCADE in combination with rituximab in patients with indolent non-Hodgkin`s lymphoma. Response rates were similar in both arms (35 and 41 percent), and the safety profile improved with the weekly VELCADE schedule. Data from a separate multicenter study of single-agent VELCADE indicated promising response rates of between 40 and 56 percent and progression-free survival in patients with follicular, marginal zone and mantle cell lymphomas. Results were also presented from a phase II clinical study of single-agent VELCADE in patients with relapsed or refractory Waldenstrom`s macroglubulinemia. Overall response rate from the 25 evaluable patients in this study was 80 percent. Toxicities in these studies were similar to those observed in other studies with VELCADE.

In the area of non-small cell lung cancer (NSCLC), Millennium and J&JPRD supported the presentation of data from their trial known as 048, a two arm randomized trial in relapsed patients testing VELCADE as a single agent in one arm and VELCADE in combination with docetaxel in the other arm. Results from this trial showed that VELCADE as a single agent was similar in terms of investigator assessed response rates and survival as other marketed therapies. Toxicities in these studies were similar to those observed in other studies with VELCADE. These results led to the design of two additional phase II trials of VELCADE in NSCLC which are expected to be initiated in the second half of 2005.

In the area of stroke, Millennium presented data at the International Symposium on Cerebral Blood Flow, Metabolism, and Function as well as at the International Stroke Conference. In an animal model of acute stroke, VELCADE was efficacious up to four hours after a stroke and safely extended the therapeutic window of the standard of care therapy to six hours. Millennium believes that VELCADE may interrupt several of the mechanisms by which brain cells die following a stroke, specifically reducing inflammation and increasing key enzymes responsible for improving blood flow. Working on multiple pathways, VELCADE may have the potential to reduce overall brain injury from severe ischemia and is an area for further study. Acute stroke is an area of great unmet medical need.

Millennium and J&JPRD continue to investigate VELCADE globally in phase I, II and III clinical trials in both hematologic and solid tumors including front-line MM, non-Hodgkin`s lymphoma and lung, prostate and ovarian cancers throughout the U.S., Europe, Latin America and Asia. VELCADE is currently available in more than 53 countries worldwide including the U.S., European Union, Latin America and South-East Asia.

INTEGRILIN(R) (eptifibatide) Injection Highlights

As announced on July 22, 2005, Millennium and Schering-Plough signed an agreement to restructure their relationship for the cardiovascular drug INTEGRILIN. Under the new relationship, Schering-Plough will acquire exclusive development and commercialization rights to INTEGRILIN in the U.S. and will pay to Millennium an upfront payment of $35.5 million and royalties over the U.S. lifespan of the product. Although the INTEGRILIN patents begin to expire in 2014, Millennium will continue to receive royalties on any sales beyond that time. In 2006 and 2007, minimum royalty payments for each year are set at $85 million, with some extraordinary conditions that could reduce these minimums. In addition, Schering-Plough will pay to Millennium approximately $45 to $50 million for the purchase of existing INTEGRILIN inventories, subject to adjustment at close.

This new arrangement, subject to federal antitrust review under the Hart- Scott-Rodino Act, is anticipated to become effective September 1, 2005. The combination of the revenue received under the new relationship and the associated expense savings are expected to make this new relationship at least financially equivalent to the current 50/50 profit share. Strategically, there are also important benefits to Millennium including:

-- Increasing the level of near-term certainty associated with INTEGRILIN
while preserving long-term upside potential and eliminating the need to
further invest the Company`s resources into INTEGRILIN sales and
marketing and development activities;
-- Capturing the opportunity for more efficient management of INTEGRILIN
in the U.S. by placing responsibility with one company; and
-- Streamlining and focusing the Company`s resources on VELCADE and the
pipeline -- both of which are critical to the continued success of
Millennium.

Research & Development Highlights


The NEJM published results from a double-blind, multicenter phase II trial of the Company`s investigational drug MLN02 in patients with ulcerative colitis (UC) in its June 16, 2005 issue. The study met the primary endpoint of a statistically significant improvement in the clinical remission rate as compared to placebo therapy. MLN02 appeared to be well tolerated at all doses tested. Millennium is currently formulating a commercially scalable cell line for MLN02 and intends to conduct a phase I normal healthy volunteer "bridging" study in 2006 after which the Company could initiate a pivotal program in UC.

Millennium announced the initiation of a multicenter phase II trial of MLN1202 in approximately 40 patients with relapsing-remitting multiple sclerosis (MS), the most common form of the disease. MLN1202, a novel humanized monoclonal antibody, is designed to block CCR2 chemokine receptors and prevent the infiltration of immune cells into inflammatory sites. The CCR2 chemokine pathway is believed to play a central role in a number of inflammatory conditions, including MS. This proof-of-concept study will assess the safety and tolerability of the molecule and determine the effect of MLN1202 on disease activity by magnetic resonance imaging. MLN1202 is also currently being investigated in a phase IIa multiple ascending dose trial in rheumatoid arthritis.

For MLN2704, a toxin conjugated deimmunized antibody to prostate specific membrane antigen, interim results were presented at the ASCO meeting from an ongoing multicenter, open label phase I/II study examining maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, safety and efficacy in prostate cancer. Results from the 26 evaluable patients showed:

-- Three patients achieved a decrease of PSA greater than 50 percent that
was sustained 10 weeks in one patient and greater than 31 weeks in
another patient; and
-- Of the seven patients with measurable disease, four achieved stable
disease by RECIST criteria, which measures tumor shrinkage as an
indicator of antitumor activity.


Toxicities observed at the interim analysis were generally low grade and manageable and included neutropenia, neuropathy, and fatigue. This trial has been expanded to explore different doses and schedules to increase the therapeutic window.

Organizational Highlights

Millennium announced the appointment of Deborah Dunsire, M.D. to the position of chief executive officer and president. She will also join the Millennium Board of Directors. Dr. Dunsire has extensive experience in the pharmaceutical industry. In particular, she built the Novartis U.S. Oncology Business in a competitive market to an industry leading position with $2 billion in revenues and more than 25 percent compounded annual growth rate over the past eight years. Dr. Dunsire succeeds Mark Levin, co-founder and CEO since the Company`s inception. He will remain an active member of the Board.

Kenneth Weg, a member of the Board since 2001, was appointed the Company`s new non-executive chairman. Additionally, Millennium appointed Robert Friel to the Company`s Board of Directors and the Audit Committee. Mr. Friel currently serves as executive vice president and chief financial officer of PerkinElmer, Inc. and currently serves as a member of the Board of Directors of Fairchild Semiconductor Corporation.

Conference Call Reminder

In conjunction with this news release, Millennium will host a live webcast of its conference call today, Thursday, July 28, 2005 at 8:30 AM ET. This webcast can be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address for 30 days.

About VELCADE(R) (bortezomib) for Injection

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE in a phase III study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%), anorexia and appetite decreased (34%), parasthesia (27%), dysesthesia (27%), anemia and headache (26%), and cough (21%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%), and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea, pneumonia (4%), and vomiting (3%).

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD). Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is also approved in the European Union as a second-line treatment. It is indicated as a monotherapy for use in patients with progressive MM who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About INTEGRILIN(R) (eptifibatide) Injection

INTEGRILIN is indicated for the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated in the United States for the treatment of patients at time of PCI, including patients undergoing intracoronary stenting.

INTEGRILIN is contraindicated in patients with a history of bleeding diathesis, or evidence of abnormal bleeding within the previous 30 days; severe hypertension (systolic blood pressure greater than 200 mm Hg or diastolic blood pressure greater than 110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product.

Bleeding is the most common complication encountered during INTEGRILIN therapy. In the registration trials, the majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal and retroperitoneal bleeding were also seen more commonly with INTEGRILIN compared to placebo.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortzeomib) Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in three therapeutic areas: oncology, inflammation, and cardiovascular. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products. The Company`s website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery, development of products and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE(R) (bortzeomib) Injection and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editor`s Note: This release is available under the Media section on the Company`s website at http://www.millennium.com.

Contacts:
Kyle Kuvalanka (investor) Lisa Adler (media)
[phone] [phone]


Millennium Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)


Three Months Ended Six Months Ended
June 30, June 30,
2005 2004 2005 2004

REVENUES:
Net product sales $43,892 $34,972 $88,687 $64,620
Co-promotion revenue 47,661 48,651 90,487 96,477
Revenue under strategic
alliances 19,092 61,697 55,182 76,788
Total revenues 110,645 145,320 234,356 237,885

COSTS AND EXPENSES:
Cost of sales 16,680 18,061 31,261 33,832
Research and development 86,939 104,382 173,093 200,660
Selling, general and
administrative 52,060 46,768 103,697 91,597
Total costs and expenses 155,679 169,211 308,051 326,089

OTHER INCOME (EXPENSE):
Investment income, net 14,737 6,147 19,179 12,535
Interest expense (2,315) (2,596) (4,903) (5,287)
Gain on sale of equity
interest in joint venture - - - 40,000
Total other income 12,422 3,551 14,276 47,248

NON - GAAP NET LOSS $(32,612) $(20,340) $(59,419) $(40,956)
(Note 1)

Amortization of intangibles (8,500) (8,378) (17,000) (16,756)
Restructuring charges (2,999) (25,191) (4,106) (36,784)

NET LOSS $(44,111) $(53,909) $(80,525) $(94,496)

NON-GAAP NET LOSS PER SHARE $(0.11) $(0.07) $(0.19) $(0.13)

Amortization of intangibles (0.03) (0.03) (0.06) (0.06)
Restructuring charges 0.00 (0.08) (0.01) (0.12)

BASIC AND DILUTED NET LOSS
PER SHARE $(0.14) $(0.18) $(0.26) $(0.31)

Weighted average shares,
basic and diluted 307,570 304,714 307,082 304,063

Note 1: Amortization of intangibles and restructuring charges are deducted
in accordance with generally accepted accounting principles in the
United States ("GAAP") to arrive at GAAP reported net loss for the
periods presented.



Condensed Consolidated Balance Sheets
(in thousands)

June 30, December 31,
2005 2004

Cash, cash equivalents and marketable
securities $589,626 $700,407
Other current assets 197,833 201,205
Property and equipment, net 203,387 220,115
Restricted cash and other assets 23,304 25,641
Goodwill and intangible assets, net 1,593,896 1,609,663
Total assets $2,608,046 $2,757,031

Current liabilities $178,076 $240,861
Other long term liabilities 43,952 57,263
Capital lease obligations, net of
current portion 77,618 80,452
Long term debt 105,461 105,461
Stockholders` equity 2,202,939 2,272,994
Total liabilities and
stockholders` equity $2,608,046 $2,757,031


(1) Non-GAAP net loss and non-GAAP profitability are non-GAAP financial measures. With respect to forward-looking information presented on a non-GAAP basis, other than amortization expenses of approximately $34.0 million in 2005 and 2006 and the remaining costs associated with the Company`s 2003 restructuring effort between $5.0 million and $20.0 million in 2005, the Company is unable to provide a quantitative reconciliation because the items that would be excluded (which include the types of items reflected in the reconciliation of historic results and starting in 2006, stock-based compensation expense) are difficult to predict and estimate and are primarily dependent on future events. Please see the Form 8-K furnished on July 28, 2005 by the Company to the Securities and Exchange Commission for a discussion of why the Company believes these non-GAAP measures are useful to investors and the additional purposes for which management uses these measures.

SOURCE Millennium Pharmaceuticals, Inc.

Kyle Kuvalanka (investor), [phone], or Lisa Adler (media), [phone],
both of Millennium Pharmaceuticals, Inc.


http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved. ********************************************************************** As of Sunday, 07-24-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 06-17-2005 for MLNM @ $9.43. (C) 2005 Comtex News Network, Inc. All rights reserved.

[Koyo1]

Deshalb der der Deal mit Schering-Plough
dieser Deal ist doch noch nicht eingerechnet.
Sehe ich das Falsch oder was meint ihr

[blb]

Ich hatte ja schon einmal geschrieben, dass die Entwicklung von Integrilin in der letzten Zeit enttäuschend war. Deshalb sehe ich den Deal auch positiv. Was mir nicht so gefällt ist, das momentan alles an Velcade hängt. Ich hoff, da kommt bald etwas nach...

Grüße
blb

[schakal23]

es sieht nicht gut aus heute

[blb]

Ach was, wird schon wieder hochgekauft. Das Ding läuft zur Zeit!

[schakal23]

es dreht

[Snake3000]

@kojo

Bitte lesen!

As a result of this transaction, the Company announced an expected 15% reduction in combined R&D and SG&A expense from the current level starting in the fourth quarter of 2005. In addition, the Company has removed its 2005 guidance for net loss on a GAAP basis until the Company has determined the restructuring charges associated with this transaction. The Company expects to update guidance for 2005 GAAP net loss during its third quarter 2005 earnings announcement.

[Snake3000]

#826 natürlich KOYO gemeint

[amorphis]

meiner meinung nach gehört das management von mlnm raus...der einstige börsenstar...der mal angekündigt hatte zu den größten bio-schmieden der welt zu gehören...rennt von einem verlust zum nächsten!sage nicht das mille scheisse ist... aber das zeug zum highflyer sehe ich erstmal nicht!

[Koyo1]

deshalb haben sie einen neuen CEO Dr. Deborah Dunsire

[amorphis]

das ist ein gutes argument..... sehe trotzdem bei vielen anderen werten das man gewinne schreibt...warum bekommt das mlnm nicht mal langsam auf die reihe...?wenn sie nicht zeigen das sie dazu in der lage sind dann wird das auch nichts mit einer entwicklung wie sie eine vphm oder eine lifc derzeit hinlegen...habe jedenfalls erstmal umgeschichtet...

[blb]

Die Neue wird den Laden schon aufmischen, da bin ich sicher. Und Cash ist erstmal genug vorhanden. Ich bleib da eher gelassen zur Zeit. Sicher gibts bessere Bios!

Grüße
blb

[schakal23]

hi ich bin gestern zu 8,76 raus ich werde mlnm im auge behakten und fals die tiefer fallen bin ich wider da um wider 850st zu sammeln

[Boersenkrieger]

immer dasselbe:
Celgene hui, Millennium pfui.
celgene 17 cents pro aktie statt 14 wie erwartet, über 140 Mio umsatz statt 131... immer besser als die schätzungen... millennium dagegen das gegenteil. hätte mal besser nur celgene kaufen sollen, denn warum sollte sich das plötzlich ändern

[Koyo1]

Durch die Entwicklungstechniken von Millennium würde die Entwicklungszeit eines Präparates nicht mehr zehn, sondern auf vier Jahre beschränkt. Dadurch könnten Kosten von 500 Mio. USD je Präparat eingespart werden. Für die größeren Pharmaunternehmen bestünde daher der Anreiz mit Millennium Pharmaceuticals zusammen zu arbeiten. Zur Zeit habe die Biotech-Firma 22 Kooperationen geschlossen, die noch weiter ausgebaut werden sollen.

Die Experten vom Anlegermagazin rechnen damit, dass die Marktkapitalisierung von derzeit 13,3 Mrd. USD auf 100 Mrd. USD gesteigert werden könne. Dies würde einem Kurszuwachs von 750 Prozent entsprechen. Gründe dafür seien die klinischen Tests, bei der Millennium neun Produkte laufen habe, die Technologie-Führerschaft, gute finanzielle Grundlagen und ein Top-Management.



Geschrieben im Jahre 2000???

sollte dann bald soweit sein.

[Boersenkrieger]

tja das war zu der zeit wo ich das erste mal mlnm gekauft habe... so tolle plattform wo man dann so richtig schnell wirkstoffe entwickeln kann ähnlich wie durch gute entwicklungsumgebungen in der software schneller anwendungen geliefert werden können...

problem an der sache: die analysten haben keine ahnung von biotechnologie und übernehmen dann solche aussagen einfach von den pressesprechern der unternehmer die selber auch nicht genau wissen was sie da reden

naja mal sehen lasse mich gerne eines besseren belehren

[jm78]

Die sollen einfach mal gute Zahlen oder neue Ideen oder Produkte auf den Markt bringen. Millennium ist doch mal ehrlich gesagt der Dauerverlierer der letzten 4 Jahre. Wir reden hier ganz klar von einer Scheißaktie.
Also geld rauß und in den Socken damit. wenigstens gibt es da kein Risiko und man verliert nicht ständig Geld.
Man wird doch nur belogen und betrogen von diesem scheiß Unternehmen.

Gruß JM 78

[Koyo1]

Multiple myeloma is an almost always-fatal blood cancer. But a
recent study in the New England Journal of Medicine showed the
prescription drug VELCADE increases patients` chances of survival,
especially when used earlier in treatment. Dr. Paul Richardson of the
Dana-Farber Cancer Institute comments.

Radio News Feature


You can reach the story directly by going to
http://www.newstream.com/home.aspx?story=30784" target="_blank" rel="nofollow ugc noopener">http://www.newstream.com/home.aspx?story=30784

This multimedia news story is for free and unrestricted use on
your news information site (and for print or broadcast too). Visit
http://www.newstream.com to download video, audio, text, graphics and
photos.

If you have any questions about the story, or about Newstream.com,
please write to us at [e-mail].



CONTACT: Newstream, New York
[e-mail]

SOURCE: Newstream and Millennium Pharmaceuticals

[Boersenkrieger]

Millennium ist doch mal ehrlich gesagt der Dauerverlierer der letzten 4 Jahre.

tja da hast du wohl recht... ich verfolge die (schwache) story schon seit 5 jahren... wunderschöne geschichten wurden geschrieben die auf einen giganten hinwiesen... wie´s geht zeigt derzeit Celgene... eisnt umstritten wegen ihres thalomid-wirkstoffes (kontergan) zur krebsbekämpfung... aber zahlen wie im wunderland... beide befinden sich schon lange in meinem depot und gehen getrennte wege (+100% und -52%)... hatte damals eigentlich ein besseres gefühl bei millennium. aber es kommt einfach kein kracher... man meinte ja einst mit irher tollen plattform und ihren vielen patenten würden sie neue wirkstoffe wie am fließband entwickeln können in kürzesten zeiten... oder kommen die goldenen zeiten noch ?

[amorphis]

tja...komme sie oder nicht?habe mille vor einigen wochen glatt gestellt...mag sein das sie noch kommen...aber bei anderen bios ist die story derzeit voll im gange, weshalb andere bios derzeit laufen und mille nicht

[bonDiacomova]

[posting]17.564.275 von amorphis am 16.08.05 03:12:30[/posting]amorphis

zitat : mag sein ...aber bei anderen bios
ist die story derzeit voll im gange,
weshalb andere bios derzeit laufen und mille nicht

diese empfehlungen von Dir :

medx 14,85$ akt.10,26
enzn 42,30$ akt. 7,40
mygn 32,90$ akt. 16,90

koennen ja nicht gemeint sein - also welche anderen meinst Du ¿?¿

[Boersenkrieger]

@bonDia...

Protein Design (PDLI)
Celgene (CELG)

...wird er meinen... habe ich auch noch im depot. cell genesys und mygn waren mal in meinem depot

[mountainbiker]

Was ist los? Keiner mehr investiert? Gehen ja geil ab heute...

[blb]

Klar bin ich noch dabei, sieht gut aus.

[jm78]

Lieber Mountainbiker,
ich garantiere dir, sobald wir wieder einen großen Sprung von 6-10 % machen tummeln sich hier wieder die " Experten"
und erzählen uns wie clever Sie sich in Zeiten der Dürre verhalten haben.
Also mein Freund, nur Geduld.

[Boersenkrieger]

[posting]17.819.693 von mountainbiker am 07.09.05 19:16:52[/posting]geil ab geht mal wieder Celgene mit fast +10%
die gleicht meine millenniumverluste so langsam aus.. nur dumm daß ich damals eingies mehr in millennium investiert hatte

[miristegal]

[posting]17.871.809 von Boersenkrieger am 12.09.05 23:57:56[/posting]@BK
Die liegen mir auch schwer im Magen.Meine mlnm.
30 Oiro für 200 - mein grösster Verlust.
Damals war ich noch Frotschi - anhänger

MFG

[miristegal]

UND ICH HAB SIE NOCH

[mountainbiker]

Was ist denn das für ein Scheiß-Kursverlauf heute???

[miristegal]

[posting]17.899.447 von mountainbiker am 14.09.05 20:04:59[/posting]NIX Ungewöhliches, so läuft es seit Jahren

MFG

PS. LEIDER

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


09/15/2005 (08:59 ET) Wall Street News Alert: Hot Stock to Watch for Thursday! September 15, 2005 - M2 Communications



09/14/2005 (12:15 ET) MLNM: Volume Spike; 22% > 20-adsv, Stock -0.30% - Knobias



09/13/2005 (16:09 ET) Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation - PR Newswire



09/12/2005 (13:32 ET) MLNM: To Present At Bear Stearns Conference @ 15:30 ET - Knobias



09/11/2005 (23:52 ET) FirstAlert: 3:30-4:45 P.M. Investrend / Bestcalls - Investrend



09/09/2005 (11:32 ET) MLNM: To Present At BioCentury NewsMaker Conference @ 13:20 ET - Knobias



09/08/2005 (13:02 ET) MLNM: To Present At Thomas Weisel Conference @ 14:40 ET - Knobias



09/08/2005 (00:06 ET) FirstAlert: 2 P.M. Investrend / Bestcalls - Investrend



09/06/2005 (16:22 ET) MLNM: Jumps +0.80%; Vol +75%; Last 90 Min of Trading - Knobias



09/06/2005 (16:01 ET) Bear Stearns 18th Annual Healthcare Conference to Webcast Millennium Presentation - PR Newswire



09/02/2005 (16:01 ET) NewsMakers in the Biotech Industry Conference to Webcast Millennium Presentation - PR Newswire



09/01/2005 (16:01 ET) Thomas Weisel Partners Healthcare Tailwinds Conference 2005 to Webcast Millennium Presentation - PR Newswire



09/01/2005 (13:49 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



08/25/2005 (06:49 ET) MLNM: mentioned in today`s Wall Street Journal - Knobias



08/24/2005 (16:20 ET) MLNM: Short Interest DN 8.2% to 19.9M in Aug 2005 - Knobias



08/23/2005 (13:00 ET) Millennium reports progress in lung cancer study - Datamonitor



08/23/2005 (08:38 ET) Wall Street News Alert: Aggressive Traders Alert! August 23, 2005 - M2 Communications



08/22/2005 (13:00 ET) Millennium begins new study of anti-inflammatory drug - Datamonitor



08/22/2005 (06:01 ET) MLNM: mentioned in latest Barron`s Publication - Knobias



08/19/2005 (16:21 ET) MLNM: Jumps +0.51%; Vol +61%; Last 90 Min of Trading - Knobias



08/18/2005 (08:01 ET) Millennium Initiates Phase II Clinical Trial to Evaluate MLN1202 in Cardiovascular Disease - PR Newswire



08/17/2005 (16:29 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



08/15/2005 (05:01 ET) More Options, More Hope - Business Wire



08/11/2005 (17:22 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



08/08/2005 (16:36 ET) MLNM: Filed New Form 10-Q, Quarterly Report - Edgar

[Fliese79]

Hallo,

ich habe auch Millennium-Aktien. Einstieg vor 5 Jahren mit 69,- Euro. Son Shit. Aber ich hoffe, dass die noch mal wieder kommen. Für einen Verkauf ist es sowieso zu spät. Stop-Loss-Strategie war mir damals noch ein Fremdwort und einen solch herben Absturz hätte ich auch nie für möglich gehalten.

Naja,

meine Fragen:

Wo kann ich Info´s über die Pipeline erhalten? Auf der Homepage ist alles nur in Englisch angegeben.

Diese Frage kann ich auch gleich in Zusammenhang mit Vertex Pharmaceuticals stellen. Die sind die letzte Zeit ja schon wieder gut gelaufen.

[blb]

@Fliese79: Keine Angst, ich bin selbst erst 2000 zu Bios gekommen und hab auch anfangs Lehrgeld bezahlt und von Stoppkursen aber sowas von Bull Ahnung gehabt. Kann dir nur raten nachzukaufen , um auf einen guten Mischkus zu kommen, wenn du an das Unternehmen glaubst. Ansonsten mach dir keine großen Hoffnungen, dass du dein Geld wieder bekommst, zumindest in den nächsten Jahren. MLNM ist nunmal keine kleine Firma mehr.

Zu deiner Frage über die Pipelines! Lies dir doch mal unsere Postings dazu in Ruhe durch oder benutze Übersetzungsprogramme. Grundsätzlich würde ich bei Sprachschwierigkeiten eher von einem Investment im Ausland abraten. V.a. im Biotechbereich sind die News teilweise sehr komplex.



Vertex

[blb]

So, jetzt bin ich aber wirklich weg! Machts gut und wählen am Sonntag nicht vergessen!

Grüße
blb

[mountainbiker]

Hallo!

Bin auch in MLNM investiert, allerdings momentan sogar im grünen Bereich. Hatte aber auch früher schon mal die Aktie...
Ich denke das Potential von VELCADE ist noch lange nicht ausgeschöpft. In der Pharnazeutischen Zeitung ist diese Woche erst ein Artikel der besagt, dass VELCADE zukünftig eventuell als FIRST Line Therapie bei der Behandlung des Multiplen Myeloms eingesetzt wird. Allerding werden auch die hohen Behandlugskosten des Medikamentes erwähnt. Dennoch denke ich dass es noch positive Überraschungen durch VELCADE geben wird.

[amorphis]

[posting]17.923.767 von Fliese79 am 16.09.05 14:05:22[/posting]kann dir nur als tip geben...dich damit vertraut zu machen...auch die angaben in englisch studieren zu können!das ist bei diesen werten mit das wichtigste...denn...die besten und meißten infos zu den ganzen nasdaq werten...findest du immer noch im englischsprachigen raum...bzw auf us-sites!

[jm78]

Hallo Leidensgenossen,
in dieser Woche gibt es Zahlen. Womit müssen wir rechnen und vor allem wie geht es weiter? Schwarze Zahlen in 06 ???? Wagt euch ( unter uns ) mal einen hoffnungsvollen Ausblick für die nächsten 5 Jahre. Wo stehen wir 2010???
Muß ich dann noch arbeiten??? Ernsthaft, wie tief geht es noch herunter und wie schätzt Ihr die Aussichten langfristig ein?
Gruß
JM78

[blb]

Solange die 8$ halten ist alles im Lot, MLNM ist natürlich weiterhin eine Enttöäuschung, aber ich setz mal auf den Managementwechsel. Wenn das wieder nichts ist, kann ich immer noch verkaufen.
Billig sind sie aktuell nicht, teuer auch nicht, immerhin 500 Millionen $ Umsatz...

Grüße
blb

[Snake3000]

Millennium Reports Strong Third Quarter 2005 Financial Results
Wednesday October 26, 4:01 pm ET
-- VELCADE(R) (bortezomib) for Injection sales up --
-- Company announces strategy refinement and restructuring; narrows 2005 non- GAAP net loss guidance(1) --

CAMBRIDGE, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today reported strong financial results for the third quarter ended September 30, 2005, with VELCADE sales up 35 percent and combined research and development (R&D) and sales, general and administration (SG&A) expenses down 16 percent over the third quarter of 2004. The Company also announced a refined strategy focused on advancing key growth assets, including VELCADE, its clinical pipeline of seven novel oncology and inflammation molecules and its oncology-focused discovery organization. As a result, the Company is substantially reducing inflammation discovery programs and resources and increasing the proportion of R&D investment dedicated to its clinical pipeline. Based on this announcement and a number of other actions taken over the course of the year, the Company expects to reduce total R&D and SG&A expenses by approximately 30 percent in 2006 from 2004, including headcount reductions from 1,500 at the end of 2004 to approximately 1,100 by year end 2005.

ADVERTISEMENT
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"By refining our strategy and focusing investment on areas with the highest growth potential, we are well-positioned to grow revenue, support R&D innovation and achieve our long-term goal of delivering products that change outcomes for patients with cancer and inflammatory diseases while creating value for our shareholders," said Deborah Dunsire, M.D., president and chief executive officer. "The steps that we have taken firmly enable us to achieve non-GAAP profitability in 2006."

2005 Third Quarter Results
* Total revenue for the third quarter of 2005 was $201.7 million compared
to $110.0 million in the third quarter of 2004.
-- Net product sales of VELCADE in the U.S. for the quarter increased by
35 percent to $50.9 million from $37.7 million in the third quarter
of 2004.
-- As a result of the restructured relationship with Schering-Plough for
INTEGRILIN® (eptifibatide) Injection, as of September 1, 2005,
Millennium no longer reports co-promotion revenue for INTEGRILIN and
began recording royalties as a separate line item on the statement
of operations.
* For the first two months of the third quarter of 2005, co-promotion
revenue for INTEGRILIN was $33.0 million.
* Royalty revenue for September 2005 was $12.5 million and primarily
included royalties from Schering-Plough for product sales of
INTEGRILIN in the U.S. and other territories around the world and
from Ortho Biotech Products, L.P., a member of the Johnson &
Johnson Family of Companies, for sales of VELCADE outside the U.S.

* Revenue under strategic alliances was $105.2 million. This result
included the one-time sale of INTEGRILIN inventory on September 1,
2005, per the transfer of U.S. commercialization rights of INTEGRILIN
to Schering-Plough, of $71.4 million, which was offset largely by a
corresponding increase in cost of sales.
* R&D expenses for the third quarter of 2005 decreased by 19 percent to
$80.6 million from $99.0 million in the third quarter of 2004. The
decrease was driven by reduced spending in discovery and a decrease in
development costs for VELCADE compared to the higher level of spending
in 2004 associated with the preparation of the sNDA filing for VELCADE
in the multiple myeloma second-line treatment setting.
* SG&A expenses for the third quarter of 2005 decreased by 12 percent to
$40.6 million from $45.9 million for the third quarter of 2004. This
decrease is primarily attributable to reduced sales and marketing
expenses resulting from the transfer of U.S. commercialization rights
of INTEGRILIN to Schering-Plough.
* Net loss on a GAAP basis for the third quarter of 2005 was $73.8
million, or $0.24 per share, compared to $63.1 million, or $0.21 per
share, for the third quarter of 2004.
* Excluding restructuring and amortization, non-GAAP net loss for the
third quarter of 2005 was $6.5 million, or $0.02 per share, compared to
$55.1 million, or $0.18 per share, for the third quarter of 2004. This
decrease was primarily the result of increased revenue from U.S. net
product sales of VELCADE and from the Company`s strategic alliances,
including several one-time payments from collaborators, and reductions
in R&D expense, as detailed previously.
* The Company recorded restructuring charges of $58.8 million in the third
quarter of 2005. The charges consisted of $30.6 million associated
with the Company`s 2003 restructuring reflecting revised sublease
estimates. Also included in the charges this quarter were $28.2
million from the Company`s 2005 strategy refinement including
consolidation of Cambridge, Mass. facilities and employee termination
benefits relating to the transfer of U.S. commercialization rights of
INTEGRILIN to Schering-Plough.
* As of September 30, 2005, the Company had $655.2 million of cash, cash
equivalents and marketable securities and $105.5 million outstanding
principal amount of convertible debt, of which $5.9 million is
classified as short term.

"Millennium had a strong quarter with VELCADE U.S. net product sales up over the previous quarter and a substantial narrowing in our non-GAAP net loss due to revenue growth and aggressive expense management," said Marsha Fanucci, senior vice president and chief financial officer. "These results, coupled with our refined strategy to focus investment on the Company`s key growth areas, position Millennium to narrow its original 2005 non-GAAP net loss guidance."

2005 Strategy Refinement and Restructuring

Throughout 2005, Millennium has taken and continues to take a series of actions, which in the aggregate are projected to reduce operating expenses by approximately 30 percent for the full year 2006 compared to the full year results of 2004. Steps include:

* Substantially reducing the Company`s effort in inflammation discovery;
* Reducing the workforce from 1,500 at the end of 2004 to approximately
1,100 by the end of 2005, by managing attrition, eliminating INTEGRILIN
sales and marketing positions, reducing the number of positions in
inflammation discovery and reducing the number of positions in business
support groups;
* Consolidating further the Company`s Cambridge-based facilities; and
* Realizing operating efficiencies and continuing to manage expenses.

The Company`s priorities are:
* Expanding the commercial organization in order to maximize the revenue
potential of VELCADE;
* Strengthening development investment to advance molecules in the
oncology and inflammation clinical pipeline; and
* Building a leading oncology-focused discovery organization.

This announcement builds on the restructured relationship with Schering- Plough for INTEGRILIN, effective September 1, 2005, and the natural conclusion of the successful small molecule inflammation research collaboration with sanofi-aventis, which is expected to end October 31, 2005. Millennium and sanofi-aventis will continue to co-develop several molecules as part of the development and commercialization collaboration. These molecules include MLN3897, MLN3701 and MLN0415 (pre-clinical). The Company will also continue to develop its proprietary molecules in inflammation (MLN02 and MLN1202) and in oncology (MLN518, MLN2704 and MLN8054).

Millennium currently expects to incur total restructuring charges of between $75 million to $85 million related to this 2005 strategy refinement, consisting primarily of facilities costs and employee termination benefits. The majority of these charges will be spread over 2005 and 2006. The Company recorded $28.2 million of restructuring charges for this effort in the third quarter of 2005.

2005 Financial Guidance

Millennium is updating its full-year financial guidance for 2005, initially outlined in January 2005:

* VELCADE U.S. net product sales guidance is narrowing to the range of
$190 million to $195 million from the range of $185 million to $195
million;
* Non-GAAP net loss guidance is narrowing to between $85 million to $95
million from less than $100 million;
* GAAP net loss is increasing to between $200 million to $215 million from
less than $155 million. The Company now expects to record
restructuring charges in the range of $80 million to $85 million in
2005 from the 2003 restructuring and the 2005 strategy refinement. The
difference between GAAP and non-GAAP net loss is attributable to
restructuring and amortization charges; and
* Cash, cash equivalents, and marketable securities guidance is increasing
to greater than $600 million at year end. The original cash guidance
was set at greater than $500 million.

As a result of the agreement with Schering-Plough effective September 1, 2005, the Company will no longer provide guidance for INTEGRILIN U.S. ex- factory sales.

Third Quarter Conference Call and Analyst & Investor Day 2005 Reminder

In conjunction with this news release, Millennium will host a live webcast of its conference call tomorrow, Thursday, October 27, 2005 at 8:30 AM ET. In addition, Millennium management will discuss the Company`s refined strategy at its Analyst & Investor Day beginning at 9:00 AM on Wednesday, November 2, 2005 from Le Parker Meridien Hotel in New York City. Webcasts of both the third quarter conference call and the Company`s Analyst Day can be accessed by visiting the Investors section of http://www.millennium.com. The webcasts will be archived for 30 days.

About VELCADE

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE in a phase III study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%), anorexia and appetite decreased (34%), parasthesia (27%), dysesthesia (27%), anemia and headache (26%), and cough (21%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%), and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea, pneumonia (4%), and vomiting (3%).

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is also approved in the European Union as a second-line treatment. It is indicated as a monotherapy for use in patients with progressive multiple myeloma who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products. The Company`s website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery, development of products and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Editor`s Note: This release is available under the Media section on the Company`s website at http://www.millennium.com.

Contacts:
Kyle Kuvalanka (investor) Theresa McNeely (media)
[phone] [phone]

(1) Non-GAAP net loss and non-GAAP profitability are non-GAAP financial
measures. With respect to forward-looking information presented on a
non-GAAP basis, other than amortization expenses of approximately $34
million in each of 2005 and 2006, restructuring charges of between
$80 million to $85 million in 2005 and between $35 million and $45
million in 2006, the Company is unable to provide a quantitative
reconciliation because the items that would be excluded (which
include the types of items reflected in the reconciliation of
historic results and starting in 2006, stock-based compensation
expense) are difficult to predict and estimate and are primarily
dependent on future events. Please see the Form 8-K furnished on
October 26, 2005 by the Company to the Securities and Exchange
Commission for a discussion of why the Company believes these non-
GAAP measures are useful to investors and the additional purposes for
which management uses these measures.



Millennium Pharmaceuticals, Inc.
Condensed Consolidated Statements of
Operations
(unaudited)

(in thousands, except per share amounts)

Three Months Ended Nine Months Ended
September 30, September 30,
2005 2004 2005 2004

REVENUES:
Net product sales $50,942 $37,668 $139,629 $102,288
Co-promotion revenue 33,037 62,557 123,524 159,034
Revenue under strategic
alliances 105,186 9,749 160,368 86,537
Royalties (Note 1) 12,514 - 12,514 -
Total revenues 201,679 109,974 436,035 347,859

COSTS AND EXPENSES:
Cost of sales 89,020 18,630 120,281 52,462
Research and development 80,632 98,961 253,725 299,621
Selling, general and
administrative 40,623 45,903 144,320 137,500
Total costs and expenses 210,275 163,494 518,326 489,583

OTHER INCOME (EXPENSE):
Investment income, net 4,902 1,115 24,081 13,650
Interest expense (2,820) (2,725) (7,723) (8,012)
Gain on sale of equity interest
in joint venture - - - 40,000
Total other income (loss) 2,082 (1,610) 16,358 45,638

NON-GAAP NET LOSS (Note 2) $(6,514) $(55,130) $(65,933) $(96,086)

Amortization of intangibles (8,500) (8,378) (25,500) (25,134)
Restructuring (58,791) 414 (62,897) (36,370)

NET LOSS $(73,805) $(63,094) $(154,330) $(157,590)

NON-GAAP NET LOSS PER SHARE $(0.02) $(0.18) $(0.21) $(0.32)

Amortization of intangibles (0.03) (0.03) (0.08) (0.08)
Restructuring (0.19) 0.00 (0.21) (0.12)

BASIC AND DILUTED NET LOSS PER
SHARE $(0.24) $(0.21) $(0.50) $(0.52)

Weighted average shares, basic
and diluted 308,848 305,202 307,675 304,445

Note 1: Beginning September 1, 2005, in connection with the closing of the
Company`s transaction with Schering-Plough for INTEGRILIN, the Company now
reports royalty revenue. Royalty revenue may include royalties earned
upon sales of INTEGRILIN in the United States and other territories around
the world as provided by Schering-Plough, royalties earned upon sales of
INTEGRILIN in Europe as provided by GlaxoSmithKline, distribution fees
earned upon sales outside of the United States of VELCADE as provided by
Ortho Biotech and any royalties earned under certain of its early
discovery alliances.

Note 2: Amortization of intangibles and restructuring charges are deducted
in accordance with generally accepted accounting principles in the United
States ("GAAP") to arrive at GAAP reported net loss for the periods
presented.



Condensed Consolidated Balance Sheets
(in thousands)

September 30, December 31,
2005 2004
(unaudited) (audited)

Cash, cash equivalents and marketable
securities $655,154 $700,407
Other current assets 112,804 201,205
Property and equipment, net 194,447 220,115
Restricted cash and other assets 24,036 25,641
Goodwill and intangible assets, net 1,586,054 1,609,663
Total assets $2,572,495 $2,757,031

Current liabilities $162,947 $240,861
Other long term liabilities 96,597 57,263
Capital lease obligations, net of
current portion 76,521 80,452
Long term debt, net of current
portion 99,571 105,461
Stockholders` equity 2,136,859 2,272,994
Total liabilities and
stockholders` equity $2,572,495 $2,757,031

[Snake3000]

Starke Zahlen!

Am Ende sollten 600 Mio Umsatz locker erreichbar sein.

2,5 Mrd Mk. nicht zu teuer.

vergeleiche bitte mit:
PDLI: 3Mrd
VRTX: 2,2 Mrd

Gruß
Snake3000

[jm78]

Hallo Snake3000, ich bin sicher,dass die Mehrzahl der Leser mit deinem Beitrag nichts anfangen kann, da er in Englisch verfasst ist. Es wäre daher schön wenn du die Essenz mit ein bis zwei Sätzen erklähren könntest.

Gruß
JM78

[js200]

2005 Credit Suisse First Boston Health Care Conference to Webcast Millennium Presentation

Thursday , November 10, 2005 16:01 ET

CAMBRIDGE, Mass., Nov 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the 2005 Credit Suisse First Boston Health Care Conference will be webcast live and may be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The presentation will include an overview of the Company, marketing plans for VELCADE(R) (bortezomib) Injection, R&D activities and other upcoming corporate events. The presentation will be delivered at 4:00 PM ET on Thursday, November 17, 2005 from the Arizona Biltmore Resort in Phoenix, Arizona.

The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, its understanding of disease mechanisms and its industrialized drug discovery platform, Millennium is seeking to develop breakthrough products. The Company`s website is http://www.millennium.com.

Editors` Note: This press release is also available under the Media section of the Company`s website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

[phone]

SOURCE Millennium Pharmaceuticals, Inc.

Kyle Kuvalanka of Millennium Pharmaceuticals, Inc., [phone]

http://www.prnewswire.com

Copyright (C) 2005 PR Newswire. All rights reserved.

**********************************************************************

As of Sunday, 11-06-2005 23:59, the latest Comtex SmarTrend(SM) Alert,
an automated pattern recognition system, indicated an UPTREND on
11-03-2005 for MLNM @ $9.30.

(C) 2005 Comtex News Network, Inc. All rights reserved.

[Wastl 1]

hei,

bin seit jahren, bereits vor dem grossen crash in ihren glanzzeiten grosser fan dieser aktie, aber was da seit längerem abgeht, macht mich schon bedenklich - da geht überhaupt nichts.
hatte grosse hoffnung, als es über 10 an der nasdaq ging, aber das geht ja auch schon wieder ganz rasant nach unten, und hier im forum interessiert sich ja anscheinend auch keiner mehr für diese ehemalige "perle".
7 jahre kann man nicht so streichen, aber hat millennium überhaupt noch ne zukunft? da scheint es im ganzen laden nicht mehr zu stimmen.
mal abwarten, was noch kommt - schätze mal, es geht noch weiter runter !!

[amorphis]

fand die letzten zahlen eigtl recht gut...bin zwar nicht mehr in mlnm investiert...aber...abwarten...das kann noch gut enden...

[miristegal]

[posting]19.208.995 von Wastl 1 am 08.12.05 23:02:31[/posting]bin seit 6 jahren dabei. SCH....aktie.
habe eine depotleiche mit 80% - .
lohnt nicht mehr zu verkaufen.
sie haben es geschaft 7 mlr. in 5 jahren auf eine halbe mln.
zu verpulvern.
die einzige hoffnung - velcade heilt auch die meisten
und häufigsten krebsarten.
daran arbeiten sie schon meines wiessen 2 jahre und
die anderen laufen dennen davon.

MFG

[Snake3000]

Frohe Weihnacht!

[Fliese79]

Hey...weiß jemand was 2006 von Millennium zu erwarten ist?

Bringen die eventuell neue News raus? Ist was in der Pipeline?

Wo steht eurer Meinung nach das Unternehmen in vier bis fünf Jahren? Wie voll ist die Pipeline?

Danke für die News und euch allen ein gutes Börsenjahr 2006!

[amorphis]

[posting]19.473.546 von Fliese79 am 31.12.05 13:45:20[/posting]die pipe...

http://www.mlnm.com/rd/pipeline/index.asp

hab vor mehreren monaten bei mille nen schnitt gemacht...solange der kurs "klebt" ist dein geld woanders besser aufgehoben...alles steigt und erholt sich von den 2000er tiefs...nur mille nicht...daran hab ich mich gewöhnt...würd die position also besser nochmal überdenken...

[amorphis]

05.01.2006 - 23:32
Millennium Pharma sieht hohe Verluste



Millennium Pharmaceuticals rechnet im Jahr 2006 mit einem Nettoverlust zwischen 95 und 115 Millionen Dollar. Ohne Sondereffekte soll ein Gewinn von etwa 5 Millionen Dollar erwirtschaftet werden. Daneben geht das Biotech-Unternehmen davon aus, mit seinem Krebsmedikament „Velcade“ Umsätze zwischen 225 und 250 Millionen Dollar zu erzielen, was einem Anstieg zwischen 17 und 30 Prozent entspräche. Daneben sollen 115 bis 125 Millionen Dollar an sonstigen Vergütungen vereinnahmt werden.

Die Analysten waren laut Reuters Estimates von einem Nettoverlust von 68,5 Millionen Dollar und einem Pro-Forma-Verlust von 9,8 Millionen Dollar ausgegangen.

In den USA rutschten Millennium Pharmaceuticals nachbörslich um 3,38 Prozent auf 9,71 Dollar ab.

[blb]

Langsam nervt mich diese Bude wirklich gewaltig...

[jm78]

Also Leidensgenossen,
sagen wir mal Millennium ist eine Scheißbude, eine dreckige.
Jetzt habe ich aber leider sehr viel Geld und Hoffnung in diese Scheißdrecksbude gesteckt. Ich stecke leider in der Falle der Börsenpsychologie und komme nicht da rauß. Ich kann meinen Verlust nicht eingestehen und endlich verkaufen. Scheiße.
Ich frage mich ob es Alternativen gibt oder ob es noch Hoffnung für Millennium sagen wir mal in den nächsten 5-6 Jahren gibt wieder mal die 50€ zu sehen gibt???????????
Also haut rein und versprüht mal Optimismus.

Gruß JM78

[blb]

Heute kommen die Zahlen...

[blb]

Millennium Achieves 2005 Financial Guidance
THURSDAY, JANUARY 26, 2006 7:01 AM
- PR Newswire

Jan 26, 2006 /PRNewswire-FirstCall via COMTEX/ -- Millennium Pharmaceuticals, Inc. (MLNM) today reported financial results for the year ended December 31, 2005 and reiterated financial guidance for 2006 including achieving non-GAAP profitability.(1)


"For the third consecutive year, we achieved our financial guidance while continuing to build a solid foundation for profitable growth long term," said Marsha Fanucci, senior vice president and chief financial officer. "Entering 2006, we are executing on our refined strategy announced in October with operating expenses expected to be approximately 30 percent lower than 2004 results and approximately 19 percent lower than 2005 results. We are confident we can become profitable while continuing to invest in VELCADE and the pipeline for long-term sustainable growth."

2005 Financial Results

* Non-GAAP net loss for 2005 narrowed 52 percent to $87.2 million, or $0.28 per share, from $180.8 million, or $0.59 per share, in 2004. Net loss on a GAAP basis for 2005, including restructuring and amortization of intangibles, narrowed 21 percent to $198.2 million, or $0.64 per share, from $252.3 million, or $0.83 per share, in 2004.

* Total revenue in 2005 increased to $558.3 million from $448.2 million in 2004.

-- U.S. net product sales for VELCADE in 2005 increased to $192.1 million from $143.1 million in 2004. This 34 percent increase was driven primarily by growth in the multiple myeloma second-line treatment setting, corresponding with the drug`s full approval in March 2005, and in the multiple myeloma front-line treatment setting, although Millennium only promotes the product for its approved indication.

-- For the first eight months of 2005, the Company reported co-promotion revenue of $123.5 million associated with the original collaboration agreement with Schering-Plough Corporation for INTEGRILIN(R) (eptifibatide) Injection.

-- Effective September 1, 2005, the Company modified the relationship with Schering-Plough for INTEGRILIN from a co-promotion arrangement to a royalty-stream arrangement. As a result, the Company began reporting royalties in a separate line item. Royalties for the last four months of 2005 were $38.2 million and primarily included royalties from Schering-Plough for product sales of INTEGRILIN in the U.S. and in other territories and from Ortho Biotech Products, L.P., a member of the Johnson & Johnson Family of Companies, for sales of VELCADE outside the U.S.

-- Strategic alliance revenue in 2005 increased to $204.5 million from $98.9 million in 2004, which included the $71.4 million one-time sale of INTEGRILIN inventory to Schering-Plough on September 1, 2005 as well as reimbursements and payments upon the achievement of milestones from the Company`s collaborations.

* Research and development (R&D) expenses in 2005 decreased to $342.2 million from $402.6 million in 2004 primarily as a result of cost reductions associated with the Company`s strategy refinement and restructuring efforts.

* Selling, general and administrative (SG&A) expenses in 2005 decreased to $180.6 million from $196.6 million in 2004 primarily as a result of cost savings associated with the restructured relationship with Schering-Plough for INTEGRILIN.

* As of December 31, 2005, the Company had $645.6 million in cash, cash equivalents and marketable securities and $105.5 million outstanding principal amount of convertible debt, of which $5.9 million is classified as short term.

2006 Financial Guidance

The Company is reiterating guidance for 2006, as originally provided on January 5, 2006:

* VELCADE U.S. net product sales are expected to be in the range of $225 million to $250 million, a 17 percent to 30 percent increase over 2005.

* Royalties are expected to be in the range of $115 million to $125 million.

* Operating expenses, consisting of R&D and SG&A expenses, are anticipated to be approximately $425 million, a reduction of approximately 30 percent compared to 2004 expenses and approximately 19 percent compared to 2005 expenses.

* Non-GAAP net income is projected to be up to $5 million.

* GAAP net loss is expected to be in the range of $95 million to $115 million with the difference between the GAAP net loss and non-GAAP net income attributable to stock-based compensation, amortization of intangibles and restructuring.

-- Stock-based compensation expense for 2006, related to stock options, the Company`s employee stock purchase plan and restricted stock, is expected to be in the range of $40 million to $50 million. This estimate is dependent upon market price, assumptions used in estimating the fair value and the levels of share-based payments in 2006.

-- Amortization of intangibles is expected to be approximately $34 million.

-- Restructuring charges are expected to be in the range of $25 million to $30 million.

* Cash, cash equivalents and marketable securities are anticipated to be greater than $500 million on December 31, 2006.

"Millennium made significant strategic moves in 2005 to solidify our foundation for continually delivering new medicines to the marketplace in areas of high unmet medical need," commented Deborah Dunsire, M.D., president and chief executive officer. "In the coming year, our priorities are to grow VELCADE sales through our expanded sales force and new marketing strategy, aggressively advance the pipeline by meeting key development milestones and progress new molecules from discovery to the development pipeline. We will also continue to look outside the Company for complementary assets that could add value to the Company in 2007 and beyond."

Recent Pipeline Developments

Millennium continues to advance a pipeline of seven clinical and late preclinical molecules in oncology and inflammation including two high-priority molecules which have shown meaningful clinical activity with manageable safety profiles: MLN02, an antibody to alpha 4 beta 7, and MLN518, a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases. In a phase II trial, MLN02 has demonstrated statistically significant improvements in remission rates compared to placebo in ulcerative colitis patients. In a phase I/II trial, MLN518 has demonstrated single-agent anti-leukemic activity in patients with acute myelogenous leukemia (AML) in the relapsed treatment setting. Recent developments include:

* MLN518: Based on data of MLN518 as a single agent in the relapsed treatment setting, the Company initiated a phase I/II, open-label, multi- center study of MLN518 in combination with standard induction chemotherapy in patients with newly diagnosed acute myelogenous leukemia. Millennium also entered into a multi-year research agreement with the Cancer Therapy Evaluation Program, a branch of the National Cancer Institute and the National Institutes of Health, to explore the potential of MLN518 in a variety of tumor types.

The Company announced several additional pipeline advances in the fourth quarter 2005:

* MLN3701: In December, the Company initiated a phase I trial in healthy volunteers with MLN3701, an oral CCR1 inhibitor, to test safety, tolerability, as well as pharmacokinetics/pharmacodynamics of the molecule.

* MLN8054: In November, the Company initiated a phase I trial in advanced malignancies with MLN8054, an oral, selective Aurora A kinase inhibitor discovered by Millennium. This trial will examine the safety and activity of MLN8054 in a range of solid and hematological tumors.

* MLN0415: The Company also brought forward a new small molecule, MLN0415, an oral inhibitor of IKK beta, from its discovery organization to development candidate status. MLN0415 is the fourth Millennium discovered molecule to reach the Company`s development pipeline in two years.

As part of the Company`s ongoing portfolio management process and based on the evaluation of recent clinical data in the context of additional opportunities in the pipeline, the Company has decided not to continue the development of MLN1202, a novel anti-CCR2 antibody, in rheumatoid arthritis (RA), one of the four indications being evaluated with this molecule, or MLN2704, a novel anti-PSMA antibody conjugated to the toxin DM1.

* MLN1202 in RA: While the Company has been encouraged by the activity seen with MLN1202, Millennium does not believe the data from the phase IIa trial in RA warrant moving forward at this time. Millennium will continue to explore MLN1202 in phase IIa studies in multiple sclerosis, atherosclerosis and scleroderma.

* MLN2704: Based on data from a phase I/II trial, the Company does not believe that a sufficient therapeutic window is achievable with MLN2704. The Company is evaluating whether to continue development of the anti-PSMA antibody with other conjugated toxins including other maytansanoid.

Recent VELCADE Developments

VELCADE is the market leader in the multiple myeloma relapsed treatment setting. To build on this leadership position in 2006, the Company has expanded its sales force by 50 percent with the goal of approximately doubling the number of calls to physicians per day. The expanded sales force was deployed January 1, 2006.

At the 47th Annual Meeting of the American Society of Hematology (ASH), VELCADE was included in 117 abstracts further demonstrating significant interest in the product from the hematology community.

* VELCADE continued to show a significant single-agent survival advantage in the multiple myeloma relapsed treatment setting. At ASH, the Company presented an update on the phase III APEX trial, which continued to show that single-agent VELCADE is superior to high-dose dexamethasone with a median overall survival of 30 months in the VELCADE arm versus 24 months in the dexamethasone arm, even though 62 percent of patients in the dexamethasone arm crossed over to VELCADE at some point. VELCADE is the only therapy to show a single-agent survival advantage in the multiple myeloma relapsed treatment setting. The most common adverse events in this trial were asthenic conditions, diarrhea, nausea and constipation.

* Other ASH abstracts featuring VELCADE showed some of the highest recorded response rates seen in the multiple myeloma front-line treatment setting with overall response rates as high as 92 percent and complete and near-complete response rates as high as 43 percent. The most common adverse events reported in these abstracts were gastrointestinal events, hematologic events, fatigue and peripheral neuropathy.

* VELCADE in combination with melphalan and prednisone in the multiple myeloma front-line treatment setting showed response rates comparable to those typically seen only in transplant. In a phase I/II study with patients 65 years and older, presented by J. San Miguel, M.D., of the Hematology Department at the University of Salamanca in Spain, VELCADE with melphalan and prednisone showed an 86 percent overall response rate and a complete response rate of 30 percent, with molecular remission achieved in half of the patients who received a complete response. The most common adverse events were gastrointestinal events, hematologic events, fatigue and peripheral neuropathy.

* A phase II study of VELCADE in combination with rituximab demonstrated encouraging results in the relapsed and refractory treatment setting of indolent B-cell lymphomas, including a large percentage of patients who had previously been treated with rituximab alone and in combination with chemotherapy. The results of the study, presented at ASH with 74 evaluable patients, showed response rates greater than 50 percent with improved efficacy, safety and dosing convenience in a once-weekly VELCADE regimen. The most common adverse events in this trial were gastrointestinal events, neutropenia, thrombocytopenia and peripheral neuropathy.

Millennium and Johnson & Johnson Pharmaceutical Research and Development, L.L.C. are investigating VELCADE in both hematologic and solid tumors in trials throughout the U.S. and Europe. VELCADE is currently approved in more than 60 countries worldwide including the U.S., most of Europe, and a number of countries within Latin America and South-East Asia such as Argentina, China, Korea, Singapore and Thailand.

Recent Organizational Developments and 2006 Strategic Goals

The Company continues to build on a strong foundation of leadership. Christophe Bianchi, M.D. has been appointed executive vice president of commercial and a member of the executive team. Dr. Bianchi has over 17 years of pharmaceutical-marketing experience, most recently with sanofi-synthelabo USA, where he served as vice president, business unit head of oncology. Mark Kost has been appointed vice president of finance. Mr. Kost has over 20 years of experience in a variety of accounting and financial roles and was most recently a vice president of finance at the Gillette Company.

The Company also announced the promotions of Grant Bogle to senior vice president of sales and marketing for VELCADE, and Elizabeth Lewis to vice president, commercial law. In addition, Anna Protopapas, senior vice president of corporate development, joined the Company`s executive team.

The Company outlined 2006 goals relating to three key strategic drivers of the business: VELCADE, the pipeline and strategic business relationships.

VELCADE:

* Grow U.S. net product sales to be in the range of $225 million to $250 million.

* Support publications for compendia listing in the multiple myeloma front-line treatment setting while continuing with the registration strategy of three phase III trials exploring VELCADE in combination with standard front-line therapies.

* File an sNDA in the mantle cell non-Hodgkin`s lymphoma relapsed treatment setting.

* Initiate a phase III trial of VELCADE and rituximab versus rituximab alone in relapsed follicular and marginal zone non-Hodgkin`s lymphoma relapsed treatment setting.

Pipeline:

* Advance highest priority clinical programs, MLN518 and MLN02.

* Progress at least two molecules to critical decision points in order to advance the pipeline and enable focus of resources on key programs.

* Advance two new molecular entities from discovery to development candidate status.

Strategic Business Relationships:

* Continue to evaluate and pursue opportunities that support long-term growth.

Conference Call Reminder

In conjunction with this news release, Millennium will host a live webcast of its conference call today, Thursday, January 26, 2006 at 8:30 AM ET. This webcast can be accessed by visiting the Investors section of the Company`s website, http://www.millennium.com. Following the webcast, an archived version of the call will be available at the same address for 30 days.

About VELCADE

VELCADE is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac disorders, gastrointestinal adverse events, thrombocytopenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.

In 331 patients who were treated with VELCADE in a phase III study, the most commonly reported adverse events were asthenic conditions (61%), diarrhea (57%), nausea (57%), constipation (42%), peripheral neuropathy (36%), vomiting (35%), pyrexia (35%), thrombocytopenia (35%), psychiatric disorders (35%), anorexia and appetite decreased (34%), parasthesia (27%), dysesthesia (27%), anemia and headache (26%) and cough (21%). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4%), neutropenia (2%) and hypercalcemia (2%). A total of 144 patients on VELCADE (44%) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6%), diarrhea (5%), dyspnea, pneumonia (4%) and vomiting (3%).

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. Outside the United States, VELCADE is approved as a second-line treatment. Johnson & Johnson Research & Development, L.L.C., Ortho Biotech Products, L.P., Janssen- Cilag and Janssen Pharmaceuticals K.K. are all members of the Johnson & Johnson Family Of Companies.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical Company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company`s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative candidate products. The Company`s website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company`s growth, future operating results, discovery, development of products and strategic alliances. Various important risks may cause the Company`s actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company`s dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company`s products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(1) Non-GAAP net loss, non-GAAP net income and non-GAAP profitability are non-GAAP financial measures. With respect to forward-looking information presented on a non-GAAP basis, other than amortization of intangibles of approximately $34 million in 2006, restructuring charges between $25 million and $30 million in 2006 and stock-based compensation expense of between $40 million and $50 million in 2006, the Company is unable to provide a quantitative reconciliation because the items that would be excluded are difficult to predict and estimate and are primarily dependent on future events. Please see the Form 8-K furnished on January 26, 2006, by the Company to the Securities and Exchange Commission for a discussion of why the Company believes these non-GAAP measures are useful to investors and the additional purposes for which management uses these measures.

Contacts:
Kyle Kuvalanka (investors) Theresa McNeely (media)
[phone] [phone]


Editor`s Note: This press release is also available under the Media section of the Company`s website at: www.millennium.com.

Millennium Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)

Three Months Ended Year Ended
December 31, December 31,
2005 2004 2005 2004

REVENUES:
Net product sales $ 52,444 $ 40,764 $ 192,073 $ 143,052
Co-promotion revenue - 47,230 123,524 206,264
Revenue under strategic
alliances 44,151 12,353 204,519 98,890
Royalties (Note 1) 25,678 - 38,192 -
Total revenues 122,273 100,347 558,308 448,206

COSTS AND EXPENSES:
Cost of sales 21,046 17,824 141,327 70,286
Research and development 88,459 102,937 342,184 402,558
Selling, general and
administrative 36,279 59,144 180,599 196,644
Total costs and expenses 145,784 179,905 664,110 669,488

OTHER INCOME (EXPENSE):
Investment income, net 5,002 (2,429) 29,083 11,221
Interest expense (2,710) (2,679) (10,433) (10,691)
Gain on sale of equity interest
in joint venture - - - 40,000
Total other income (loss) 2,292 (5,108) 18,650 40,530

NON-GAAP NET LOSS (Note 2) $(21,219) $(84,666) $ (87,152) $(180,752)

Amortization of intangibles (8,487) (8,378) (33,987) (33,512)
Restructuring (14,213) (1,663) (77,110) (38,033)

NET LOSS $(43,919) $(94,707) $(198,249) $(252,297)

NON-GAAP NET LOSS PER SHARE $ (0.07) $ (0.28) $ (0.28) $ (0.59)

Amortization of intangibles (0.03) (0.02) (0.11) (0.11)
Restructuring (0.04) (0.01) (0.25) (0.13)

BASIC AND DILUTED NET LOSS PER
SHARE $ (0.14) $ (0.31) $(0.64) $(0.83)

Weighted average shares, basic
and diluted 310,096 305,977 308,284 304,830

Note 1: Beginning September 1, 2005, in connection with the closing of the
Company`s transaction with Schering-Plough for INTEGRILIN, the Company now
reports royalty revenue. Royalty revenue may include royalties earned
upon sales of INTEGRILIN in the United States and other territories around
the world as provided by Schering-Plough, royalties earned upon sales of
INTEGRILIN in Europe as provided by GlaxoSmithKline, distribution fees
earned upon sales outside of the United States of VELCADE as provided by
Ortho Biotech and any royalties earned under certain of our early
discovery alliances.

Note 2: Amortization of intangibles and restructuring charges are deducted
in accordance with generally accepted accounting principles in the United
States ("GAAP") to arrive at GAAP reported net loss for the periods
presented.


Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)

December 31, December 31,
2005 2004

Cash, cash equivalents and marketable
securities $ 645,588 $ 700,407
Other current assets 95,508 201,205
Property and equipment, net 183,059 220,115
Restricted cash and other assets 25,202 25,641
Goodwill and intangible assets, net 1,578,275 1,609,663
Total assets $2,527,632 $2,757,031

Current liabilities $ 164,595 $ 240,861
Other long-term liabilities 85,562 57,263
Capital lease obligations, net of
current portion 76,226 80,452
Long-term debt, net of current
portion 99,571 105,461
Stockholders` equity 2,101,678 2,272,994
Total liabilities and
stockholders` equity $2,527,632 $2,757,031


SOURCE Millennium Pharmaceuticals, Inc.

Kyle Kuvalanka, investors, [phone], or Theresa McNeely, media,
[phone], both of Millennium


http://www.prnewswire.com


Copyright (C) 2006 PR Newswire. All rights reserved.

[Sharp2000]

was ist hier los warum gehn die in deutschland runter,hat jemand info

[blb]

Gab eine Abstufung und das gerade nach dem schönen Ausbruch gestern, manchmal könnte ich diese Analysten echt killen...

[crivit]

Millennium prescht mit Krebs-Test vor!!!!

Millennium Pharmaceuticals hat heute mitgeteilt, schneller als erwartet eine klinische Phase-III-Studie mit dem Krebspräparat „Velcade“ aufzulegen. Dabei soll das Präparat in Kombination mit einem anderen Wirkstoff zur Behandlung einer Abart des Non-Hodgkin´s-Lymphoms eingesetzt werden.

Als Grund für das schnelle Vorpreschen führte Millennium Pharma die erfolgreichen vorklinischen Versuchsreihen an. Diese hätten objektiv eine Vielzahl positiver Reaktionen erbracht. In der neuen Studie werde Velcade an 670 Patienten erprobt. Kooperationspartner sei Johnson and Johnson.

Velcade ist bereits zur Behandlung des multiplen Myeloms, einer Form von Blutkrebs, zugelassen.

[schakal23]

hi leute ich bin wider dabei ab heute gut das ich damals raus gegangen bin

und jetzt hoffe wider auf die 10€

[liasis]

Antwort auf Beitrag Nr.: 21.314.632 von schakal23 am 25.04.06 16:57:31

Was ist denn jetzt los? Fett im Minus!

[schakal23]

Antwort auf Beitrag Nr.: 21.364.314 von liasis am 28.04.06 15:03:16

ja wie immer die haben wider so ein scheis verlust gemacht

ich habe gedacht sie haben nach ein jahr seid ich hier raus bin langsam das im griff anscheinend nicht

bin so früh eingestiegen

[liasis]

Antwort auf Beitrag Nr.: 21.367.381 von schakal23 am 28.04.06 17:34:01

Die zahlen waren gestern und die waren okay. heute ist Mlnm von einem Analystenheini auf "sell" gestuft worden. Deshalb die Verluste heute!

[schakal23]

Antwort auf Beitrag Nr.: 21.368.267 von liasis am 28.04.06 18:19:17

oh man hier geht richtig den bach runter und ich habe gedacht es ist zeit das die was vernuftiges rüber bringen

[liasis]

Antwort auf Beitrag Nr.: 21.607.829 von schakal23 am 16.05.06 16:47:34

Geht gerade überall den Bach runter!1

[schappi64]

hier ist wohl keiner mehr in diesen thread.war mal eine sehr schöne aktie die mann berechnen konnte und verlass war.

[tschicki]

Antwort auf Beitrag Nr.: 21.995.313 von schappi64 am 07.06.06 21:31:50

Nee.. Nee.. bin schon noch da

halte es nur etwas mit kostolany...

die leute muß man Arbeiten lassen - manchmal gehts etwas schneller - manchmal etwas langsamer - aber gute firmen kommen wieder... hier dauerts halt etwas länger.....

Gruß tschicki

[schappi64]

hoffe es auch habe mit dieser aktie immer geld gemacht.hatte einen sehr guten chart.sie wird sich wieder duchsetzen????.

[schakal23]

was war den los heute?

[schappi64]

heute sieht es ja mal wieder besser aus.es wird ja mal zeit

[schappi64]

heute sieht es ja mal wieder besser aus.es wird ja mal zeit

[Posthornschnecke]

Wahnsinn!

Riesige Blöcke gehandelt.Sprung über 11$.

Da ist was im Busch!!!

[schakal23]

was ist los heute haben die was neues entdeckt??????????
habe nicht gedacht das ich so schnell wider im plus bin

[Posthornschnecke]

Es können auch technische Kaufprogramme sein.
Der Sprung über 10$ löst ein technisches Kaufsignal aus.

siehe Chart...

[schakal23]

Antwort auf Beitrag Nr.: 22.134.899 von Posthornschnecke am 15.06.06 20:46:40

hoffe das wir auch den 10 schafen

[schakal23]

Antwort auf Beitrag Nr.: 22.134.899 von Posthornschnecke am 15.06.06 20:46:40

das ist der grund und nicht chartteschnick aber es könnte auch dazu beigertagen



CAMBRIDGE, Mass., June 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) issued today the following statement in response to a market report:

As a result of an offer to acquire Millennium initiated by a third party, the Company had engaged in a time-limited process to explore a strategic sale relative to the Company's stated strategy of building a sustainable biopharmaceutical company. The Company has ended this process and will continue to focus on its stated strategy by growing sales of its market-leading cancer product VELCADE(R) (bortezomib) for Injection, progressing a pipeline of seven novel product candidates and achieving profitable growth long-term.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

[schakal23]

es sind schon 24 millionen st bis jetzt gehandelt worden aber scheisse der kurs kommt zurück

[schakal23]

also ich hoffe das es stimmt und millennium zum verkauf steht und wir kurse um die 14€ wider sehen

[schakal23]

wo ist der meinung die experten hier

da wollte jemand mlnm kaufen und keiner sagt hier was

über eine million gestern nach börsen schluss schluss kurs 10,25

[schappi64]

ist totale schei....... das sie sich nicht übernehmen lassen.

[schakal23]

Antwort auf Beitrag Nr.: 22.151.315 von schappi64 am 16.06.06 16:40:59

ja die wollen noch die restlichen gelder von den 2 milliarden einsacken

[schakal23]

und wider einen verkauf empfehlung

ich denke ich steige hier wider raus mit plus minus ausser die bank gebühren nichts gewesen

[jm78]

Antwort auf Beitrag Nr.: 22.304.209 von schakal23 am 27.06.06 20:20:00

Ich besitze Mille seit 2000,
keine Hoffnung, keine Rendite, keine Perspecktive aber dafür Mafiose Machenschaften. Ich habe so viel geld verloren und frage mich wer kauft diese Müllaktie noch? "FINGER WEG" von diesem Dreck.
Viele Worte um absolut nichts. Die brauchen 100 Jahre um die selbst gesteckten Ziele zu erreichen. Schließt dieses Forum und vergesst euer Geld für immer und ewig.
Grüße aus dem Pott
Jm78

[schakal23]

Antwort auf Beitrag Nr.: 22.413.636 von jm78 am 05.07.06 01:44:38

ach kuck an die haben ja welche selber gekauft da hat jeder von die einen monat gehalt in mlnm investiert damit die witer gross kassieren können

[TeamPirnok]

Ich kaufe Millennium!
Langzeitanlage
www.bio-tech-depot.com

Grüße aus dem schönen Sauerland

TeamPirnok

[schakal23]

HEIDRICH, A. GRANT III DIR 08/10/2006 Form 4 S D (7,000) $9.870 295,864

HEIDRICH, A. GRANT III DIR 08/09/2006 Form 4 S D (1,700) $9.870 302,864

TEPPER, ROBERT I. PR 08/09/2006 Form 4 S D (1,700) $9.870 200,675


die verkaufen aber eine ganze menge und der kurs steigt trotzdem

[crivit]

Das sieht gguuutt aus!

[crivit]

Antwort auf Beitrag Nr.: 23.323.679 von TeamPirnok am 04.08.06 21:55:48

Dann nehme Dir noch Celgene, Medimmune und Alkermes mit ins Depot!

Grüße auch aus dem Sauerland
Crivit

[TeamPirnok]

ICOS, CELGENE und BIOPHAN eingekauft!
www.bio-tech-depot.com
Gruß TeamPirnok

[crivit]

Antwort auf Beitrag Nr.: 23.832.304 von TeamPirnok am 08.09.06 20:39:31

Es geht los!
Immune Response!

Meine Millennium gefällt mir immer besser!

[schakal23]

anscheinend kommen die vorran endlich nach 5jahren

[js200]

11/06/2006 (13:02 ET) MLNM: To Present At CIBC World Markets Healthcare Conference @ 14:40 ET - Knobias



11/03/2006 (10:26 ET) MLNM: Filed New Form 8-K, Material Event Disclosure - Edgar



11/02/2006 (16:16 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



11/02/2006 (16:01 ET) CIBC World Markets 17th Annual Healthcare Conference to Webcast Millennium Presentation - PR Newswire



11/02/2006 (13:02 ET) MLNM: To Present At Mass Opportunities Conference @ 14:50 ET - Knobias



11/02/2006 (09:32 ET) MLNM: To Present At Mass Opportunities Conference @ 11:30 ET - Knobias



10/31/2006 (16:55 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



10/31/2006 (16:18 ET) MLNM: Filed New Form 10-Q, Quarterly Report - Edgar



10/30/2006 (16:27 ET) MLNM: New Form 4 Filed, Change in Beneficial Ownership - Edgar



10/30/2006 (16:01 ET) MassOpps Investment Conference to Webcast Millennium Presentation - PR Newswire



10/30/2006 (14:50 ET) Schaeffer's Daily Market Blog Features: Wal-Mart Stores, Verizon Communications, Yahoo!, Millennium Pharmaceutical, McDonald's - Business Wire



10/30/2006 (14:10 ET) MLNM: New 52-Wk High @ $11.940 up 1.27% - Knobias



10/30/2006 (14:10 ET) MLNM: Filed New Form 8-K, Material Event Disclosure - Edgar



10/27/2006 (18:58 ET) Corporate Announcement: Millennium Pharmaceuticals - Wall Street Horizon



10/27/2006 (17:58 ET) Corporate Announcement: Millennium Pharmaceuticals - Wall Street Horizon



10/27/2006 (13:45 ET) MLNM: Volume Spike; 43% > 20-adsv, Stock +5.54% - Knobias



10/27/2006 (10:11 ET) MLNM: New 52-Wk High @ $11.491 up 2.69% - Knobias



10/27/2006 (04:16 ET) www.streetinvesting.com: Global Market Perspective - Progressive Review on Millennium Pharmaceuticals Inc. - M2 Communications



10/26/2006 (18:54 ET) Corporate Announcement: Millennium Pharmaceuticals - Wall Street Horizon



10/26/2006 (17:50 ET) Corporate Announcement: Millennium Pharmaceuticals - Wall Street Horizon



10/26/2006 (16:02 ET) Millennium shares rise after 3Q report - Xinhua News Agency - Financial Network



10/26/2006 (15:30 ET) MLNM: Volume Spike; 63% > 20-adsv, Stock +6.69% - Knobias



10/26/2006 (14:29 ET) Millennium shares rise after 3Q report - Xinhua News Agency - Financial Network



10/26/2006 (09:56 ET) MLNM: Q3 Adj EPS (4c) vs (2c) Misses 0c Est - Knobias



10/26/2006 (07:34 ET) MLNM: Filed New Form 8-K, Material Event Disclosure - Edgar

[TerrySam]

Antwort auf Beitrag Nr.: 25.229.303 von js200 am 08.11.06 22:09:48

Hoffe Du kannst gut schlafen?

Oder haste die Leichen schon vergessen,die Deinen Weg pflastern?

TerrySam

[schakal23]

Antwort auf Beitrag Nr.: 25.870.766 von TerrySam am 01.12.06 21:05:49

glaube schon er hat das mit links gemacht

[TerrySam]

Antwort auf Beitrag Nr.: 25.914.076 von schakal23 am 03.12.06 22:36:03

Ich versteh es bis Heute nicht,er hat wirklich alle verraten und verkauft,das alles unter dem Deckmantel der Freundschaft,wie erbärmlich,wenn das sien Mutter noch erleben könnte,

TerrySam

[schakal23]

Antwort auf Beitrag Nr.: 25.917.377 von TerrySam am 04.12.06 06:40:36

du denkst so einer interesiert ihn der meinung seiner mutter

[TerrySam]

Auf seine Mutter hat er viel gehalten,oder war dies auch gelogen,wie alles andere??????????????????????????????????

ich versteh es bis heute nicht,

TerrySam

[moneygone]

Antwort auf Beitrag Nr.: 25.870.766 von TerrySam am 01.12.06 21:05:49

Der Mr. Slechta kann gut schlafen

Nach Aussage des Herrn Schweizer hat er nämlich die ewige Ruhe gefunden, angeblich

[moneygone]

Antwort auf Beitrag Nr.: 25.917.377 von TerrySam am 04.12.06 06:40:36

Ein solches Verhalten nennt man wohl
abgebrüht, kaltschnäuzig, hinterlistig, abgeklärt, gewissenlos.......

[moneygone]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Frank888]

bin heute eingestiegen zu 8,73

[Knocky]

neues jahr neues glück josefneues jahr neuneues jahr neues glück josefneues jahr neues glück josefes glück josef

[schakal23]

Antwort auf Beitrag Nr.: 27.245.047 von Knocky am 28.01.07 11:44:06

was ist los ?????????????????

[gerdass]

Antwort auf Beitrag Nr.: 7.922.403 von js200 am 22.11.02 20:30:11

[ballard1]

jemand noch in dem Wert investiert?
Performance ist ja unterirdisch. Hab noch welche im Bestand, aktuell zum Einstandspreis.
Lohnt sich halten?
Hab den Wert zuletzt ziemlich vernachlässigt;-)

[schakal23]

Antwort auf Beitrag Nr.: 28.855.214 von ballard1 am 17.04.07 12:11:37

ich bin immer noch mit 700st drinn

bis 2010

[ballard1]

Antwort auf Beitrag Nr.: 28.874.393 von schakal23 am 18.04.07 10:35:35

und ich bin gestern raus, mit meinne 150

[schakal23]

Antwort auf Beitrag Nr.: 28.874.803 von ballard1 am 18.04.07 10:54:26

hast du gut gemacht hier werd von denn ceos nur abverkauft keine wüder das der kurs nicht steigt


LEVIN MARK J DIR 05/02/2007 Form 4 AS D (10,000) $10.970 2,954,224

PROTOPAPAS ANNA OFF 05/01/2007 Form 4 AS D (1,929) $11.070 127,389

LEVIN MARK J DIR 04/18/2007 Form 4 AS D (10,000) $11.880 2,964,224

LEVIN MARK J DIR 04/11/2007 Form 4 AS D (10,000) $11.340 2,974,224

PROTOPAPAS ANNA OFF 04/09/2007 Form 4 AS D (4,250) $11.560 127,389

PROTOPAPAS ANNA OFF 04/09/2007 Form 4 Option OE D 4,250 $6.880 131,639

LEVIN MARK J DIR 04/04/2007 Form 4 AS D (10,000) $11.330 2,984,224

PROTOPAPAS ANNA OFF 04/02/2007 Form 4 AS D (4,250) $11.400 127,389

PROTOPAPAS ANNA OFF 04/02/2007 Form 4 Option OE D 4,250 $6.880 131,639

LEVIN MARK J DIR 03/28/2007 Form 4 AS D (10,000) $11.260 2,994,224

PROTOPAPAS ANNA OFF 03/26/2007 Form 4 AS D (4,250) $11.380 127,389

PROTOPAPAS ANNA OFF 03/26/2007 Form 4 Option OE D 4,250 $6.880 131,639

LEVIN MARK J DIR 03/21/2007 Form 4 AS D (10,000) $10.800 3,004,224

KEATING LAURIE B. OFF 03/20/2007 Form 4 AS D (12,400) $11.000 105,162

KEATING LAURIE B. OFF 03/20/2007 Form 4 Option OE D 12,400 $8.410 117,562

PROTOPAPAS ANNA OFF 03/19/2007 Form 4 AS D (4,088) $10.730 127,389

PROTOPAPAS ANNA OFF 03/19/2007 Form 4 Option OE D 4,088 $7.990 131,477

LEVIN MARK J DIR 03/14/2007 Form 4 AS D (10,000) $10.560 3,014,224

KEATING LAURIE B. OFF 03/13/2007 Form 4 AS D (25,568) $10.640 105,162

KEATING LAURIE B. OFF 03/13/2007 Form 4 Option OE D
FANUCCI MARSHA OFF 03/12/2007 Form 4 AS D (4,245) $10.640 92,982

PROTOPAPAS ANNA OFF 03/12/2007 Form 4 AS D (1,970) $10.640 127,389

PROTOPAPAS ANNA OFF 03/09/2007 Form 4 Option OE D 3,833 $0.065 133,192

PROTOPAPAS ANNA OFF 03/09/2007 Form 4 S D (3,833) $10.570 129,359

DUNSIRE DEBORAH OFF 03/08/2007 Form 4 AS D (10,771) $10.410 733,764

FANUCCI MARSHA OFF 03/08/2007 Form 4 AS D (6,173) $10.410 97,227

LEVIN MARK J DIR 03/07/2007 Form 4 AS D (10,000) $10.380 3,024,224

LEVIN MARK J DIR 02/28/2007 Form 4 AS D (9,700) $10.720 3,034,224

BIANCHI CHRISTOPHE OFF 02/27/2007 Form 4

[schakal23]

Antwort auf Beitrag Nr.: 29.169.483 von schakal23 am 06.05.07 15:43:12

der LEVIN verkauft wie welt meister


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940




1. Name and Address of Reporting Person *

LEVIN MARK J 2. Issuer Name and Ticker or Trading Symbol

MILLENNIUM PHARMACEUTICALS INC [ MLNM ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Last) (First) (Middle)

MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET 3. Date of Earliest Transaction (MM/DD/YYYY)

5/16/2007
(Street)

CAMBRIDGE,, MA 02139
(City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 5/16/2007 S (1) 1100 D $10.87 2943124 D

Common stock 5/16/2007 S (1) 900 D $10.91 2942224 D

Common stock 5/16/2007 S (1) 500 D $10.93 2941724 D

Common stock 5/16/2007 S (1) 400 D $10.94 2941324 D

Common stock 5/16/2007 S (1) 300 D $10.90 2941024 D

Common stock 5/16/2007 S (1) 300 D $10.92 2940724 D

Common stock 5/16/2007 S (1) 100 D $10.96 2940624 D

Common stock 5/16/2007 S (1) 900 D $10.89 2939724 D

Common stock 5/16/2007 S (1) 1200 D $10.88 2938524 D

Common stock 5/16/2007 S (1) 700 D $10.84 2937824 D

Common stock 5/16/2007 S (1) 700 D $10.86 2937124 D

Common stock 5/16/2007 S (1) 300 D $10.85 2936824 D

Common stock 5/16/2007 S (1) 200 D $10.95 2936624 D

Common stock 5/16/2007 S (1) 500 D $10.97 2936124 D

Common stock 5/16/2007 S (1) 800 D $11.00 2935324 D

Common stock 5/16/2007 S (1) 300 D $10.99 2935024 D

Common stock 5/16/2007 S (1) 100 D $10.98 2934924 D

Common stock 5/16/2007 S (1) 600 D $11.01 2934324 D

Common stock 5/16/2007 S (1) 100 D $11.03 2934224 D

Common stock 5957 I by 401(k) plan account

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1) The sales reported on this Form 4 were effected under a trading plan previously established by the reporting person under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
LEVIN MARK J
MILLENNIUM PHARMACEUTICALS, INC.
40 LANDSDOWNE STREET
CAMBRIDGE,, MA 02139 X




Signatures

Joel S. Goldberg, Attorney-In-Fact 5/17/2007
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

[schakal23]

der arsch geige verkauft ohne ende


MILLENNIUM PHARMACEUTICALS INC DIR 05/30/2007 Form 4 AS D 10,000 $10.700 2,914,224

MILLENNIUM PHARMACEUTICALS INC DIR 05/23/2007 Form 4 AS D 10,000 $10.750 2,924,224

MILLENNIUM PHARMACEUTICALS INC DIR 05/16/2007 Form 4 AS D 10,000 $10.840 2,934,224

MILLENNIUM PHARMACEUTICALS INC DIR 05/09/2007 Form 4 AS D 10,000 $11.010 2,944,224

MILLENNIUM PHARMACEUTICALS INC DIR 05/02/2007 Form 4 AS D 10,000 $10.970 2,954,224

MILLENNIUM PHARMACEUTICALS INC DIR 04/18/2007 Form 4 AS D 10,000 $11.880 2,964,224

MILLENNIUM PHARMACEUTICALS INC DIR 04/11/2007 Form 4 AS D 10,000 $11.340 2,974,224

MILLENNIUM PHARMACEUTICALS INC DIR 04/04/2007 Form 4 AS D 10,000 $11.330 2,984,224

MILLENNIUM PHARMACEUTICALS INC DIR 03/28/2007 Form 4 AS D 10,000 $11.260 2,994,224

MILLENNIUM PHARMACEUTICALS INC DIR 03/21/2007 Form 4 AS D 10,000 $10.800 3,004,224

MILLENNIUM PHARMACEUTICALS INC DIR 03/14/2007 Form 4 AS D 10,000 $10.560 3,014,224

MILLENNIUM PHARMACEUTICALS INC DIR 03/07/2007 Form 4 AS D 10,000 $10.380 3,024,224

MILLENNIUM PHARMACEUTICALS INC DIR 02/28/2007 Form 4 AS D 9,700 $10.720 3,034,224

MILLENNIUM PHARMACEUTICALS INC DIR 02/21/2007 Form 4 AS D 10,000 $11.030 3,044,224

MILLENNIUM PHARMACEUTICALS INC DIR 02/14/2007 Form 4 AS D 10,000 $11.070 3,054,224

MILLENNIUM PHARMACEUTICALS INC DIR 02/08/2007 Form 4 AS D 300 $10.760 3,041,024

[asics01]

Antwort auf Beitrag Nr.: 29.611.812 von schakal23 am 03.06.07 16:01:41

der wird wohl seine gründe haben

[schakal23]

Antwort auf Beitrag Nr.: 29.617.278 von asics01 am 03.06.07 19:33:49

ich denke aus diesen aktie werd nie was

[schakal23]

Millennium Pharma Presents Positive Results For Velcade - Update



(RTTNews) - On Monday, Millennium Pharmaceuticals Inc. (MLNM) presented positive results for Velcade in Phase II trial for patients with multiple myeloma or MM, who have received at least one prior therapy. The company also reported results for the Phase III trial of Velcade in combination with Doxil.

The Phase II trial enrolled up to 24 patients. This trial evaluated the pharmacokinetics/pharmacodynamics (PK/PD), toxicity and response rate of Velcade in patients treated with either an SC or intravenous (IV) administration option.

In the Phase III study, 646 patients were involved. This trial evaluated the efficacy and safety of Velcade in combination with Doxil.

Nancy Simonian, Chief Medical Officer, Millennium, said, "These data demonstrate that VELCADE in combination with another active agent can further strengthen the unparalleled impact of VELCADE. We are aggressively pursuing development of a subcutaneous delivery form to broaden alternatives for patients who prefer to receive VELCADE treatment at home." Velcade is being co-developed by Millennium Pharmaceuticals Inc. and Johnson & Johnson Pharmaceutical Research & Development L.L.C. Velcade is approved in more than 80 countries worldwide. In the U.S., Velcade is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. In the European Union, Velcade is approved for patients with multiple myeloma after first relapse.



das ding ist in europa anerkannt

3% in minus das wegen schmeist der arsch

[Mister NO]

leute, die aktie ist schon seit längere zeit tot!!!
wenn ich positiv denke dann werden unsere enkelkinder ev in 20-30 jahren ein höhers kurs als 10 € sehen.
verkaufen was an den aktien hat von m schrott unternehmen und woanders anglegen.
seit jahren ist die aktie im 1 stelligen bereich! leider.

so viel zu "mille"

[Frank888]

sind gestern ausgebrochen. Noch jemand investiert?

[Frank888]

Antwort auf Beitrag Nr.: 32.264.529 von Frank888 am 03.11.07 11:56:44

bin anscheinend der Einzige, der heute gekauft hat.

[Frank888]

1. Kursziel $ 15

[curacanne]

Antwort auf Beitrag Nr.: 32.264.529 von Frank888 am 03.11.07 11:56:44

ja, seit kurzem

[jm78]

Antwort auf Beitrag Nr.: 32.572.271 von curacanne am 26.11.07 17:45:51

Kursziel 20 $ von heute!

[curacanne]

Antwort auf Beitrag Nr.: 32.264.529 von Frank888 am 03.11.07 11:56:44

ja, eine pos. am 12.11. gekauft
mein Kz ist 15 euro
cura

[Frank888]

Antwort auf Beitrag Nr.: 32.603.977 von curacanne am 28.11.07 19:52:10

2. KZ 20$ = 13,50 Euro.
Wer Zeit hat, spekuliert auf den großen Turn-arround, vielleicht in einigen Jahren wieder das alte Hoch und dann von Anfang an dabei gewesen zu sein, das wär doch mal was .....

[Frank888]

Antwort auf Beitrag Nr.: 32.603.977 von curacanne am 28.11.07 19:52:10

na bitte, geht doch !!

Gib es news?

[Frank888]

Antwort auf Beitrag Nr.: 32.604.322 von Frank888 am 28.11.07 20:10:26

das Jahr fängt gut an und das 2. KZ kommt näher !!!!

Ist überhaupt noch jemand dabei?

[Fruehrentner]

10.04.2008 09:33:00

Takeda übernimmt Millennium Pharmaceuticals für 8,8 Mrd. Dollar

Osaka (aktiencheck.de AG) - Die Takeda Pharmaceutical Co. Ltd. (ISIN JP3463000004 / WKN 853849), der größte Pharmakonzern in Japan, übernimmt den amerikanischen Biotechnologiekonzern Millennium Pharmaceuticals Inc. (ISIN US5999021034 / WKN 900625) für rund 8,8 Mrd. Dollar.

Wie aus einer gemeinsamen Pressemitteilung vom Donnerstag hervorgeht, erhalten die Aktionäre von Millennium Pharmaceuticals im Rahmen der Offerte 25,00 Dollar in bar für jeden Anteilsschein. Dies entspricht einer Prämie von 53 Prozent auf den Schlusskurs der Aktie vom Mittwoch. Die Boards beider Unternehmen haben der Transaktion bereits zugestimmt.

Im Geschäftsjahr 2007 beliefen sich die Erlöse von Millennium Pharmaceuticals auf rund 528 Mio. Dollar.

Die Aktie von Takeda Pharmaceutical schloss heute in Tokio bei 5.410 Japanischen Yen (-2,52 Prozent), die von Millennium Pharmaceuticals gestern in New York bei 16,35 Dollar. (10.04.2008/ac/n/a)

Quelle: Finanzen.net / Aktiencheck.de AG

© Aktiencheck.de AG


Quelle: AKTIENCHECK.DE

[blb]

Antwort auf Beitrag Nr.: 33.853.897 von Fruehrentner am 10.04.08 09:47:21

Tja, Glückwunsch allen Investierten, ich hoffe es ist trotz Dollarschwäche noch ein schöner Gewinn für den ein oder anderen hängen geblieben. Find das Übernahmeangebot einen Hammer, knapp 9 Milliarden Dollar für die Bude..

Naja, fragt nicht, wann ich damals ausgestiegen bin! Schwamm drüber!

[schappi64]

ich bin einer von den glücklichen.aber schon viele jahre investiert.und nun eine kleine belohnung für die zeit.

[kiefernberg]

Antwort auf Beitrag Nr.: 33.854.731 von schappi64 am 10.04.08 10:48:57

ach ja, Millenium ... nun auch weggekauft ...

ich abe noch als Biotechhype-Rest die Firmen

Medarex
PDL (ex-Protein Design)

anzubieten

wann werden die bitte aufgekauft??

[schappi64]

Antwort auf Beitrag Nr.: 33.858.942 von kiefernberg am 10.04.08 17:24:51

habe auch noch eine leiche (genta)200st wenn du sie haben möchtest.

[crivit]

Na toll nach Medimmune nun auch MLNM!

[chivas999]

JUHUUUUU!!!! Bin mit USD 8,09 eingestiegen. Super!

So, jetzt geh ich auf ein Bier, habe ich mir (oder doch MLNM)verdient.

Lg

chivas999

[turbogustl]

Antwort auf Beitrag Nr.: 33.858.942 von kiefernberg am 10.04.08 17:24:51

...genau, die alten Favoriten : Medarex, Icos, Vertex und wie sie alle hießen. Das waren noch Zeiten, da war die Euphorie am größten ? Heute musst Du zusehen, wie die "Perlen von einst" (für die du Unsummen bezahlt hast) für kleines Geld über den Tisch gehen. Was macht man mit 100 Aktien in solch schlechten und ungehörigen Zeiten ?! Verkaufen, Halten, gibt´s noch nen Schnaps drauf ??!

[Frank888]

Antwort auf Beitrag Nr.: 32.604.322 von Frank888 am 28.11.07 20:10:26

das war ne gute Spekulation. Schade, ich hätte gerne auf den großen Turn-arround spekuliert. Was machen wir mit der Kohle? Hat jemand eine Alternative?

[super66]

Soll man sie an der Börse verkaufen , oder auf das Angebot warten!

[crivit]

Antwort auf Beitrag Nr.: 33.868.852 von Frank888 am 11.04.08 17:54:41

SQNM!

[crivit]

Antwort auf Beitrag Nr.: 33.869.436 von super66 am 11.04.08 18:50:24

Hoffe der Dollar wird stärker!

[Frank888]

Antwort auf Beitrag Nr.: 33.871.393 von crivit am 11.04.08 22:56:51

das könnte klappen. Ich habe mal mit minimalen Kapital AFFX probiert.

[Dabbeljubush]

Wer kann mir weiterhelfen?: Ich bekam heute ein Übernahmeangebot von Takeda bzw. Mahogany Acquisitions, die das für Takeda machen.
Pro Aktie von Millennium würden mir 25 $ gezahlt. Was würde aber passieren, wenn ich bis zum Ende der Frist nicht auf dieses Angebot eingehe? Lösen sich meine Millennium Aktien in Nichts auf?

Aus dem Terminanschreiben ging leider nichts genaues hervor. Es wär super, wenn mir jemand weiterhelfen könnte!

[drefnox7b]

Keine Angst, es kann nix passieren. Erst wenn die 95% besitzen, kann der Handel eingestellt und die Restaktionäre zur Abgabe verdonnert werden. Jedoch zu einem zur dieser Zeit angemessenen Kurs. Es kann natürlich sein, dass es nach dem Deal abwärts geht, dann würde ich sagen: verzockt! Für mich steht das Problem nicht, bin seit vielen Jahren drin und habe bei 29,... gekauft. Also, schlimmere Zeiten durch gemacht und trotzdem auf die Entwicklungen gehofft.

[gispri]

He Leute, heute ist die letzte Gelegenheit das Angebot der Mahogany Corp. anzunehmen oder auszuschlagen. Ist es ratsam es anzunehmen, oder ..? Was ist eigentlich das oder? Werden meine Stücke ansonsten automatisch "umgestellt"? Ist in diesem Fall eine Wertsteigerung zu erwarten?

[rythm]

Hallo,

kann mir bitte jemand was zum Stand der Übernahme/squeez out sagen.

Ein Broker spricht von laufendem zwangsverfahren zu 25 us$
während der andere noch von gar nichts gehört haben will

Auch würde mich eine Bewertung der Aussage interessieren, wonach
es im Rahmen des Angebotes von Takeda zu einer Quellensteuer bei Zahlung an Ausländer bis zu 30% kommen kann.

Besten Dank

Grüße
rythm

[rythm]

Antwort auf Beitrag Nr.: 34.177.932 von rythm am 27.05.08 11:58:49

Weiss denn niemand hier Bescheid?

[rythm]

Antwort auf Beitrag Nr.: 34.177.932 von rythm am 27.05.08 11:58:49